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The word “technology” has its origins in the Greek language, where the term “techne” refers
to “skill”, “craft” or “art”, whereas “logos” means “word” or “to speak of”. Thus, if we are to
consider it literally, “technology” means expressing in words the way things are created,
built, developed or gained. Although Merriam-Webster provides two simple and tidy defi‐
nitions of “technology”: (1) “the use of science in industry, engineering, etc., to invent useful things
or to solve problems” and (2) “a machine, piece of equipment, method, etc., that is created by technol‐
ogy”, pinning down a definition of the word that would please everyone is not as easy as it
seems. Technology may refer to a technological process, a technological object, a technologi‐
cal system, technological knowledge or to a set of technological items. This complicates
things in terms of providing a brief and objective answer to the question “What is technolo‐
gy?” What is, however, clear and certain is that technologies are inseparable to human na‐
ture and that the modern society in which we live in today would not be where it is now
without them.
In the title of this book, three terms based on the word “technology” can be found: “micro‐
technologies”, “nanotechnologies” and “biotechnology”. While at first this repetition may seem
to be not too harmonious, if we give it more thought, we come to observe that these three
words nicely blend and fit in next to each other. This is because over the past decades cut‐
ting-edge micro- and nanostructured materials, systems or devices have been successfully
transferred to innovative applications oriented towards the “Bio” realm, which practically
consists in everything that has to do with life. Such developments would not have been pos‐
sible without the advent of a wide range of investigation techniques, methods and protocols
that allow today the in-depth characterization of micro- and nanoscaled items and processes
at sufficient resolutions to precisely understand their properties and characteristics; these
tools are now considered to be of the utmost importance for biomedical research and prac‐
tice. Moreover, countless healthcare and biomedical solutions with high impact in terms of
timely diagnostics, therapeutic success, patient comfort or financial sustainability of health‐
care systems around the world rely on micro- and nanotechnologies. Thus, it is not at all
exaggerating to claim that such technologies play in current days a tremendous role with
respect to improving the quality of our life, health and well-being, which are the main prior‐
ities of modern science. Taking a look at what has been happening in the biotechnology field
in recent years, we can well figure that the number of applications and solutions based on
micro- and nanotechnologies will exponentially rise in the forthcoming years, resulting in
next-generation applications that will take critical areas such as medicine or biology by
storm. The six chapters of this book represent, in my view, illustrative examples for these
statements, addressing highly significant scientific subjects from diverse areas of micro- and
nanotechnologies for biotechnology. Authoritative voices in their fields present in this vol‐
ume their work, or review recent trends, concepts and applications, in a manner that is ac‐
cessible to quite a broad readership audience from both within and outside their specialist
area. I am confident that this volume will be of great value not only to those actively in‐
volved in the addressed fields but also to those with passive but constant interest in these
scientific areas and to those who will have their first encounter with micro- and nanotech‐
nologies for biotechnology when reading the contained chapters. In the end, I like to express
my deepest thanks to each of the authors for their fine contributions to this project.
Stefan G. Stanciu, PhD
Center for Microscopy-Microanalysis and Information Processing
University Politehnica of Bucharest,
Bucharest, Romania
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Abstract
In  the development  of  a  nanodevice  for  biomedical  applications,  the  study of  the
interactions with the biomolecules is essential. Proteins, in particular, are known to
be easily adsorbed on the surface of the nanoparticles and the resulting complex is
the one that will be effectively internalized by the target cells. Owing to the versatility
of  the  preparation  methods  available  and  the  unique  optical  properties,  gold
nanomaterials represent an excellent choice to study this interaction. This chapter will
initially describe the synthesis of gold nanorods and nanoshells that are able to absorb
light in the near-infrared (NIR) region. Then, the methods available for the function‐
alization of their surface will be discussed. The surface plasmon absorption will be
used as an optical tool to monitor the process of preparation and surface modifica‐
tion. In the last section of the chapter, fluorescence and microscopy techniques will
be used to follow the formation and characterize the protein-nanoparticle complex.
The  modifications  of  the  emission  spectra  of  two  model  proteins,  bovine  serum
albumin  (BSA)  and  myoglobin  (Mb),  will  be  analyzed  in  detail.  The  data  will
demonstrate that structural rearrangements following the adsorption on the surface
of  the  nanoparticles  are  responsible  for  the  changes  in  the  fluorescence  of  the
tryptophan residues of the protein. The data will be discussed in terms of static and
dynamic quenching, proving the formation of a protein-nanoparticle complex. Atomic
force  microscopy  (AFM)  measurements  will  allow  the  direct  visualization  of  this
complex.
Keywords: gold nanostructures, protein adsorption, localized surface plasmon reso‐
nance, fluorescence, atomic force microscopy
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
1. Introduction
In the last few decades, the use of nanotechnology in the biomedical field has grown exponen‐
tially. This interest is originated from the fact that materials at the nanometer scale have
completely different properties than their bulk counterparts and these properties are depend‐
ent on the particle size [1, 2]. Also, nanoparticles are ideal systems for application in bioimag‐
ing and therapy because they are small enough to interact with the biomolecules and to be
efficiently internalized by the cells.
The first and most important process that occurs when a nanoparticle comes in contact with a
biological fluid is the association with proteins. In the design of engineered nanostructures,
this process has to be taken into account, because it may determine the fate of these species
inside the living cells, their clearance rate and cytotoxicity. In fact, the systems that will be
eventually delivered to the final biological target are protein-coated nanoparticles and their
surface properties will affect their ability to cross the cell membrane barrier. Also, the adsorp‐
tion of proteins on the surface of the particles may lead to conformational changes, unfolding
and eventually to their irreversible denaturation [3–5]. These processes could alter the normal
protein functions and cause unwanted side-effects for the organism. For all these reasons, it is
clear that a full comprehension of the nature and the mechanism of this process of association
can be of support in the development of optimized nanostructures for biomedical applications.
Gold-based nanomaterials (GNMs) are among the most studied systems to be employed as
diagnostic and therapeutic tools for biomedical applications. This success comes from their
unique properties. They are highly biocompatible and the preparation method can be easily
adjusted to control their morphology and optical properties. They also have easy processable
surfaces, which allow the conjugation with different ligands for the specific targeting to the
cells of interest. Most importantly, when gold is reduced to the nanometric size, the interaction
with light under certain experimental conditions produces a strong absorption in the visible
region caused by the collective oscillation of the electron cloud on the surface of the metal. This
effect, known as localized surface plasmon resonance (LSPR), is extensively used in biological
sensing and imaging [6–10]. In fact, the frequency at which LSPR occurs and its intensity are
dependent on size and shape of the nanoparticles, interparticle distance and the dielectric
function of the surrounding Medium. All these physical parameters can change upon inter‐
action of the GNMs with the biological species. The adsorption of protein on GNMs drastically
modifies the surface properties of gold colloids and may eventually lead to their aggregation.
These effects result in changes in the LSPR optical response that can be measured by ultraviolet-
visible (UV-Vis) spectroscopy.
Many other techniques are currently employed to study the interaction between proteins and
nanoparticles, such as Fourier transform infrared spectroscopy (FTIR) [11, 12], nuclear
magnetic resonance (NMR) [13], circular dichroism spectroscopy [12, 14], size-exclusion
chromatography [15]. Among them, fluorescence is a powerful tool for probing the adsorption
of proteins on the surface of nanoparticles because of its high sensibility in detecting even small
changes in the microenvironment surrounding the emitting species. Additionally, the use of
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the intrinsic fluorescence of the proteins to monitor the association process makes unnecessary
the attachment of an imaging probe that may perturb the system under investigation.
In this chapter, the interaction of GNMs with different model proteins in vitro is analyzed by
UV-Vis spectroscopy and microscopy techniques. The first section describes the most common
methods of preparation of GNMs with the focus on those systems whose morphology
promotes a shift of the LSPR in the NIR region. An efficient absorption of the system in this
portion of the electromagnetic spectrum is desirable because the light at these energies has the
maximum penetration in the biological tissues. This section also illustrates the synthetic steps
able to functionalize the GNMs surface in order to tune the interaction with the proteins. In
the second section, the detailed study of the adsorption of the model proteins on the surface
of the GNMs is reported. The modifications of the protein structure and the formation of a
complex with the GNMs are demonstrated by UV-Vis absorption and static and time-resolved
fluorescence data. Atomic force microscopy (AFM) is used as complementary tool to charac‐
terize the protein-GNM complex.
2. Design of plasmonic GNMs
2.1. Nanorods
A class of GNMs, which has attracted much attention because of their potential as therapeutic
agents in biomedicine, is gold nanorods (NRDs). They present two LSPR extinction bands,
which correspond to the oscillation of the plasmons in the transversal and the longitudinal
direction. The transversal mode is not strongly affected by the NRD morphology and the
relative absorption occurs at about 520 nm. On the contrary, the position of the longitudinal
LSPR can shift from the visible region to the NIR depending on the aspect ratio (length-to-
width ratio). Higher is the aspect ratio, lower is the frequency at which the plasmon absorbs.
In order to design NRDs with the desired optical properties, several computational methods
have been developed to correlate the morphology of the NRDs with their absorption and
scattering efficiencies [16–18] obtaining in most cases an excellent agreement between the
simulations and the experimental data.
The first report of the synthesis of gold NRDs is from the group of Jana et al. in 2001 [19]. This
experimental procedure is known as the seed-mediated growth method and it is still the most
common preparation for this type of GNM. In this synthesis, gold nanoparticles of 1–3 nm
(seeds) are obtained by reduction of a Au3+ salt by NaBH4 in the presence of a surfactant, usually
sodium citrate or cetyltrimethylammonium bromide (CTAB), as stabilizer. These seeds are
then quickly added to an aqueous growth solution containing AgNO3, CTAB and Au+ ions
formed by partial reduction of Au3+ with ascorbic acid. The seeds act as nucleation centers for
the reduction of Au+ to atomic gold and CTAB, which has a strong affinity for specific facets
of the metal, promotes the anisotropic growth of the rod. Through this method, it is possible
to obtain NRDs of about 15 nm wide and up to 100 nm long depending on the amount of
AgNO3 and the seed to gold molar ratio in the growth solution. NRDs with higher aspect ratio
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presenting the longitudinal LSPR region can be still produced with this procedure by an
additional growth step in the presence of a mixture of two surfactants [20].
The extinction spectra and the corresponding transmission electron microscopy (TEM) images
of two samples of NRDs synthesized by our group using the seed-mediated growth method
are shown in Figure 1. The sample (a), having an aspect ratio of 2.3 ± 0.2 as determined by the
analysis of the TEM images, presents an intense longitudinal LSPR absorption band centered
at 652 nm. The use of a larger amount of silver ions in the growth solution increases the NRDs
aspect ratio to 4.8 ± 0.2, which shifts the longitudinal band to 775 nm (Figure 1, sample b).
Figure 1. Extinction spectra of NRDs with an aspect ratio of 2.3 (a) and 4.8 (b) and the corresponding TEM images
(scale bar = 50 nm). An increase in the amount of silver ions added in solution allows the formation of nanorods with a
higher aspect ratio and with an extinction spectra shifted at longer wavelengths.
2.2. Nanoshells
An interesting approach to shift the LSPR absorption in the NIR region is the synthesis of gold
nanoshells (NSHs) that are hybrid nanostructures formed by a dielectric core (such as silicon
dioxide) covered by a thin and uniform layer of gold. Their optical properties have been
rationalized in terms of the coupling between the plasmons of the internal and the external
metal surface; the plasmon hybridization model, which can be seen as the analog of the
molecular orbital theory for molecules, demonstrates that the extent of the coupling, and thus
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the shift toward longer wavelengths of the LSPR, depends on the shell/core size ratio [21, 22].
These calculations are in good agreement with the experimental data.
Brinson et al. [23] in 2008 first developed a reliable multistep approach to prepare the gold
NHSs. The synthesis starts from SiO2 nanoparticles formed through the sol-gel method [24]
and whose surface is functionalized with amino groups. Separately, gold seeds of 2–5 nm in
diameter are prepared by reduction of a gold salt with an organophosphorus compound in
water and then adsorbed on the amino-functionalized silica nanoparticles. With a process
similar to the one described earlier for the NRDs, the further reduction of Au3+ by formaldehyde
on the seed attached to the SiO2 surface allows the growth of a complete gold shell. The
thickness of the metal layer and thus the position of the LSPR absorption band can be controlled
by changing the amount of gold salt in the growth solution. In Figure 2, the extinction spectra
of NSHs synthesized in our laboratory together with the corresponding TEM images are
shown. Amino-functionalized SiO2 nanoparticles of 120 nm were used as template for the
formation of the shells. From the analysis of the TEM images, a thickness of the gold layer of
11 ± 1 nm has been measured for sample (b), which corresponded to a LSPR absorption band
centered at 805 nm. When a higher concentration of gold salt was present in the growth
solution, the shell thickness was increased to 20 ± 1 nm, which resulted in a surface plasmon
band blue shifted to 550–600 nm (Figure 2a). This is explained by the increase in the distance
between the inner and the outer metal layer that causes uncoupling of the two surfaces and
the extinction spectrum resembles one of the clustered gold nanoparticles on silica [25]. This
example illustrates the importance to achieve a strict control of the synthesis parameters in
order to obtain nanoparticles with the desired properties.
Figure 2. Extinction spectra of NSHs prepared with a [Au3+] concentration in solution of (a) 39.2 μM and (b) 32.4 μM
and the corresponding TEM images (scale bar = 100 nm). The amount of gold ions in solution determines the metal
shell thickness and hence the position of the SPR band of the NSHs.
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Recently, this multistep approach has been adapted by our group to obtain NSHs with a
fluorescent core for biomedical applications [26].
2.3. Strategies for the surface functionalization of GNMs
The functionalization of the GNMs surface is often required for the following reasons:
replacing stabilizers used for the synthesis that are toxic for the cells [27, 28], enhancing their
stability in biological environments [29, 30] and introducing species (e.g., antibodies) to
promote site-specific delivery of the system in the body [31, 32]. When the stabilization of the
GNMs has an electrostatic nature (as for example for citrate-stabilized gold nanoparticles
prepared by the common Turkevitch method [33]), the ligands can be easily substituted by
stronger thiolated stabilizers under mild conditions. Using the suitable thiol linker, it is
possible to functionalize the GNMs with a wide range of different species such as polymers
[34, 35], fluorophores [36], deoxyribonucleic acid (DNA) [37], and antibodies [38, 39]. The
ligand exchange is generally carried out at room temperature and it can also involve the use
of a biphasic system [40]. However, this method has also some drawbacks. For example, the
replacement of the stabilizer could be incomplete making difficult to determine the exact
amount of the ligand exchanged. Also, the exchange process could lead to irreversible
aggregation.
It has been shown that CTAB is toxic to the cells [41] and CTAB-coated NRDs are unstable in
basic conditions [42]. However, its replacement from the surface of the gold nanorods is
particularly tricky. The use of thiolate ligands usually brings to a partial exchange on the ends
of the NRDs because of the preferential binding of these species on the Au {111} facets [43]. In
recent years, various methods have been developed to obtain a complete CTAB removal
avoiding aggregation. One of the approaches that can be used is the layer-by-layer deposition
of polyelectrolytes on the CTAB-coated NRDs, which assures the control of the polymeric shell
and the final surface charge of the rods. This method has been used with good results by several
groups [42, 44, 45]. However, the main disadvantage is that the further functionalization of the
surface with site-specific ligands is not easy to obtain. The growth of a silica shell around the
nanorods is another strategy that can be adopted to remove the surfactant from the metal
surface. SiO2 is a good choice because it is a biocompatible material, it can be prepared with
low cost and reliable methods and it can be easily functionalizable with other specific ligands.
The silica coating can be carried out in a simple single-step process following the procedure
first reported by Gorelikov et al. [46]. Briefly, CTAB-capped NRDs are diluted in water and
NaOH is added to raise the pH to ~10. Then, the sequential addition of tetraethylorthosilicate
(TEOS) as silica precursor to this solution allows the hydrolysis and condensation of the shell
on the NRD surface. After mixing overnight, the silica-coated NRDs are separated from CTAB
by centrifugation, removal of the supernatant and redispersion in the fresh solvent. The careful
control of the TEOS-to-NRDs molar ratio in the reaction mixture and the amount of TEOS
chosen for each addition determines the success of the procedure and the thickness of the
coating. To demonstrate this with an example, Figure 3 shows the extinction spectra and the
TEM images of two samples of silica-coated NRDs with an aspect ratio of 2.3 prepared by our
group in different experimental conditions.
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Figure 3. Extinction spectra of silica-coated NRDs prepared with a TEOS concentration in the solution of (a) 10.0 mM
and (b) 2.3 mM together with the corresponding TEM images (scale bar = 50 nm). The growth of a homogenous silica
shell is obtained by choosing the appropriate TEOS-to-NRDs molar ratio in the reaction mixture. An increase in TEOS
content in solution leads to irreversible aggregation of the NRDS.
For sample (a), the coating process resulted in the aggregation of the nanorods. This aggrega‐
tion is also confirmed by the extinction spectrum, which shows a broad and unstructured band
with a maximum at about 900 nm that is red shifted with respect to the one of the initial CTAB-
coated NRDs. For sample (b), the fine control of the experiment allowed us to obtain a
homogeneous coating of the nanorods with a silica shell of 16 ± 1 nm. In this case, the extinction
spectrum resembles that of the NRDs before the exchange of the stabilizer. This example also
proves that the optical properties of the plasmonic nanoparticles can be successfully used to
monitor the stability of the system in a fast and reliable manner during postsynthesis treat‐
ments.
3. Interaction of GNMs with proteins
Myoglobin (Mb) and bovine serum albumin (BSA) are used as model proteins to study the
interaction with GNMs. The structure of Mb consists of a single polypeptide chain of 153 amino
acids, which is arranged in eight α-helices for about the 75% of its length. The fluorescence of
Mb is dominated by the emission of its two Trp residues with one of them located at the protein
surface (Trp-7) and the other one buried inside the hydrophobic pocket of protein (Trp-14).
However, this emission is partially quenched by energy or electron transfer to the heme group
in the protein [47] and this explains the low fluorescence quantum yield of Mb in the native
form. BSA is a relatively bigger protein (583 amino acids) that has numerous biochemical
functions and the most important function is the transport of drugs and fatty acids inside the
body [48–50]. In analogy with Mb, it contains two Trp residues, one on the surface (Trp-134)
and the other in a hydrophobic domain (Trp-212), which are responsible for the intrinsic
fluorescence of the protein [51]. Modifications of the fluorescence properties of the proteins
offer useful information on structural changes, rearrangements and eventually denaturation
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processes occurring upon interaction with different types of chemical species [52–56]. In the
following section, the same techniques have been applied to the study of GNMs-protein
association.
3.1. Interaction of Mb with GNMs
NSHs with a silica diameter of 120 nm and a gold shell thickness of 11 nm (for morphological
and optical properties refer to Figure 2) were gradually added to a 10−5 M aqueous solution of
Mb. As shown in Figure 4a, the fluorescence spectrum of the protein drastically changed by
interaction with the NSHs. A decrease of the band at 320 nm associated with the Trp fluores‐
cence and the appearance of two additional emission bands centered at 390 and 440 nm were
observed. Different excitation spectra were recorded at 330 and 440 nm (Figure 4b), demon‐
strating that upon interaction with NSHs two distinct emitting species become responsible of
the Mb fluorescence. Time-resolved data reported in Table 1 further supported this hypoth‐
esis. The fluorescence decay curve recorded at 330 nm for the native protein was successfully
fitted with a monoexponential function giving a lifetime value of 2.6 ns. When NSHs were
added to the solution of Mb, this value was reduced of about 20%.
Figure 4. (a) Fluorescence emission spectra of Mb (λexc = 290 nm) in the presence of increasing concentration of NSHs;
(b) fluorescence excitation spectra of Mb in the presence of 2.5 × 10−12 M NSHs recorded at two emission wavelengths.
The fluorescence data indicate that a protein-nanoparticle complex is formed upon interaction of Mb with the NSHs.
The fluorescence decay signal at 390 and 440 nm showed a more complex behavior, and from
the analysis of the data, we obtained two decay components of about 4.5 and 1.0–1.5 ns. These
values and their relative statistical weight on the lifetime were not affected by the concentration
of nanoshells in solution. All the fluorescence data suggested that the interaction of Mb with
the NSHs brings to the formation of a fluorescent protein-nanoparticle complex in which the
protein is in a different conformational arrangement or is partially denaturated. The value of
the longer and principal component (4.5 ns) of the decay of the new species was close to the
value of Trp lifetime in water [57], which would indicate that in the rearranged configuration
the two Trp are more exposed to the external medium. However, the decrease in the lifetime
value at 330 nm suggests that static quenching due to the formation of the Mb-NSH complex
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alone cannot explain the mechanism of interaction, and energy/electron transfer processes
between the Trp residues and the gold are not excluded.
[NSHs] (M) λem (nm) τ (ns) Percentage (%)
0 330 2.6 100










Table 1. Fluorescence decay time parameters of Mb (λexc = 295 nm) in the presence of increasing concentration of
NSHs.
The same experiment has been carried out by using CTAB-capped gold nanorods with an
aspect ratio of 2.3 (Figure 1a for the optical and microscopy data of the sample). The addition
of NRDs to a 10−5 M solution of Mb in water efficiently quenched the protein emission, but in
this case, no additional bands at longer wavelengths were detected (Figure 5a).
Figure 5. (a) Fluorescence emission spectra of Mb (λexc = 290 nm) in the presence of increasing concentration of NRDs;
(b) Stern-Volmer plot from the emission intensity values at 322 nm. The efficient quenching of the fluorescence ob‐
served upon addition of NRDs to the Mb solution demonstrates that a protein-nanoparticle complex in the ground
state is formed.
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One of the most used models to analyze fluorescence data is through the Stern-Volmer
equation, which can give indications about the occurrence of both static and dynamic quench‐
ing processes:
[ ] [ ]0 01 1SV q
I K Q k Q
I
t= + = +
where Io and I are the fluorescence intensities in the absence and in the presence of the
quencher, KSV is the Stern-Volmer quenching constant, kq is the bimolecular quenching rate
constant, τ0 is the average lifetime of the fluorophore in the absence of the quencher and [Q]
is the concentration of the quencher in solution. The Stern-Volmer plot of fluorescence data
(Figure 5b) showed a linear relationship and a KSV value of 1.9 × 109 M−1 was obtained from
the linear fit. Using 2.6 ns for the lifetime of the myoglobin (Table 1), we estimated a kq of 7.3
× 1017 M−1 s−1 that is several orders of magnitude greater than the maximum dynamic collisional
quenching constants of various types of quenchers with biomolecules [58]. This demonstrates
that the quenching has an important static component and that a nonfluorescent Mb-NRD
complex in the ground state is formed. The fluorescence measurements clearly indicate that
the interaction between GNMs and the myoglobin occurs in any case through the adsorption
of the proteins on the surface of the nanoparticle although with a different structural rear‐
rangement. Different surface properties of the GNMs tuned by their size and by the nature of
the stabilizers could explain these differences.
The role of the surface properties of the plasmonic NPs in the interaction with the proteins has
been further investigated by using NRDs with the same aspect ratio of 2.3 in which the
surfactant CTAB has been replaced by a uniform silica shell of 16 ± 1 nm (Figure 3b for the
optical and morphological data of these nanoparticles).
The addition of silica-coated NRD to a 10−5 M solution of Mb brought to drastic changes in the
fluorescence spectrum of the protein (Figure 6). The complete quenching of the emission of
the native protein and the appearance of a new broad band at 365 nm was detected right after
the addition of the nanoparticles. This new emission can be attributed to Trp residues that are
completely exposed to a polar environment [49, 59]. The data indicate that the interaction of
Mb with the NRD surface is followed by the denaturation of the protein that brings the Trp-14
to be in contact with the water solvent. The adsorption of Mb on the silica-coated nanorods
has been also demonstrated by AFM microscopy. A drop of the solution containing the protein
and the silica coated NRD at concentrations of 10−5 M and 5 × 10−12 M, respectively, was
deposited on freshly cleaved mica. After complete evaporation of the solvent, the sample was
scanned with an AFM in tapping mode. The topographic image in Figure 7a shows objects of
about 200–250 nm that can be associated with aggregates of 2–3 nanoparticles. The irregular
surface of these particles and the presence of regions at different phase contrast (Figure 7b)
indicate that these species are covered by Mb molecules as previously observed with micro‐
scopy techniques for other protein-silica systems studied by our group. The presence of protein
molecules on the surface of the silica-coated NRDs could also assist and promote the aggre‐
gation process [60].
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Figure 6. Fluorescence emission spectra of Mb (λexc = 290 nm) in the presence of increasing concentration of silica-coat‐
ed NRDs (from 0 to 6.8 × 10−12 M). The appearance of a new emission band at 365 nm is attributed to the exposure of
Trp residues of Mb to the aqueous environment following the protein denaturation.
Figure 7. (a) Topographic and (b) phase-contrast AFM image of myoglobin and silica-coated NRDs after deposition on
mica substrate. Aggregates of nanoparticles covered by myoglobin molecules are clearly observed from the images.
3.2. Interaction of BSA with GNMs
NRDs with different surface properties have been employed to study the interactions of
plasmonic nanoparticles with BSA. The fluorescence spectra of the protein upon gradual
addition of increasing amount of nanorods with an aspect ratio of 2.3 are reported in Figure 8.
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Figure 8. Fluorescence emission spectra of BSA (λexc = 290 nm) in the presence of increasing concentration of NRDs;
(inset) Stern-Volmer plot from the emission intensity values at 340 nm. The strong quenching of the BSA emission
demonstrates the formation of nonfluorescent protein-NRD complexes.
Analogous to Mb, an efficient quenching of fluorescence was observed without any modifi‐
cation in the shape of the emission band. The intensity values treated with the Stern-Volmer
equation showed a linear correlation of the quenching with the concentration of the NRDs
added. The analysis allowed to calculate a KSV value of 3.9 × 109 M−1 and a kq of 8.1 × 1017 M−1
cm−1 using a calculated average lifetime of 4.8 ns for BSA. These values demonstrate once again
that the interaction is dominated by static quenching, and thus, a nonfluorescent GNM-protein
complex at the ground state is formed.
When a silica shell of 16 nm was grown on the NRDs replacing the surfactant, the interaction
with the BSA molecules changed dramatically. In fact, as shown in Figure 9a, a quenching
much more efficient was detected even at lower concentrations of silica-coated NRDs in
solution (~10−11−10−12 M). Interestingly, the resulting Stern-Volmer plot (Figure 9b) of the data
Figure 9. Fluorescence emission spectra of BSA (λexc = 290 nm) in the presence of increasing concentration of silica-
coated NRDs; (inset) Stern-Volmer plot from the emission intensity values at 340 nm. A more complex mechanism of
interaction occurs when a silica shell is grown around the nanorods interacting with the BSA molecules. This results in
a more efficient quenching and an upward curvature of the Stern-Volmer plot.
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showed an upward curvature which indicates that the decrease in the fluorescence intensity
might be due to a bimodal mechanism of interaction. A small red shift of 2–3 of the emission
maximum also suggests that a certain rearrangement of BSA follows the adsorption of the
protein on the silica surface of the nanorods.
4. Conclusion
Nowadays, several nanodevice families are available as biomedical tools. Among them, gold-
based nanomaterials have a prominent role to play because of their excellent properties. In this
chapter, we demonstrated that it is possible to obtain GNMs through simple and reliable
chemical methods and their optical properties can be tuned by changing the synthetic
conditions. Nanorods capped with CTAB can be prepared by a seed-mediated growth method
in aqueous solution and the final aspect ratio strongly affects the position of the longitudinal
plasmon band of the extinction spectrum. The removal of the toxic CTAB from the metal
surface of the rods is necessary in order to use these them for in vivo applications and we
showed that different approaches can be used to exchange this surfactant with other stabilizers.
By a fine control of the preparation conditions, it is possible to grow a silica shell of variable
thickness on the nanorods, which can be further functionalized with site-specific ligands.
Another interesting system showing plasmonic properties is gold nanoshell made of a silica
core covered by a thin layer of gold. Depending on the ratio between the size of the core and
the shell thickness, the surface plasmon absorption can be shifted from the visible to the NIR
region of the spectrum which is desirable for biomedical applications.
In the second section, we described in detail the interaction of model proteins with these two
types of gold-based nanomaterials through fluorescence and microscopy techniques. In all
cases, quenching of the protein emission was detected. The data analyzed by the Stern-Volmer
equation indicate that protein-nanoparticles complexes are formed at the ground state. The
appearance of new red-shifted emission bands in the fluorescence spectra and the AFM images
confirmed the presence of these species. The comparison between the data collected for the
nanorods before and after growth of a silica shell demonstrated that the surface properties of
the nanoparticles have an important role in regulating the process of protein adsorption.
The use of GNMs as biomedical devices requires the in-depth study of their therapeutic efficacy
along with their potential toxicity. In this context, a deep comprehension on how the biological
molecules interact with the nanoparticles is desirable. Several recent studies have been focused
on the biological effects of GNMs, but a detailed description of the mechanism of interaction
between proteins and nanoparticles and a comprehensive study of the factors affecting this
interaction is still lacking. This knowledge would bring enormous advantages in the design of
nanomaterials with controllable properties. The development of methods sensitive enough for
the detailed study of NP-proteins interaction is also a challenge. For this purpose, single-
molecule techniques and ultrafast spectroscopy may play a fundamental role in elucidating
the mechanism of interaction between a protein and a metal surface with high spatial resolu‐
tion. Moreover, a multimethod approach would allow describing in detail the process of
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protein adsorption onto GNMs from different points of view. The big question that remains
open is how to obtain the interaction information with a similar sensitivity in a living organism.
By addressing these issues, it will be possible to create gold-based nanostructures with
engineered surfaces that could interact predictably with proteins opening up the possibility
to obtain more efficient therapeutic agents and nanoprobes for biomedical applications.
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Abstract
Two types of micro‐ and nanocarriers for immobilization of enzymes for biotechno‐
logical and biomedical applications are described: magnetic nanoparticles and cross‐
linked enzyme aggregates (CLEAs). Nanosized structures with their large surface and
smaller size volume ratio, which is dependent on their strong magnetic dipole, give
key features that make magnetic nanoparticles useful in many biotechnological and
biomedical applications. They are therefore used as carriers to which different active
substances can bind. The preparation of the magnetic nanoparticles, possible surface
coating  methods,  and  functionalization  with  different  materials  are  described.
Enzyme immobilization methods, such as adsorption, affinity binding, chelation, or
metal  binding  or  covalent  binding,  enable  the  preparation  of  efficient  and  stable
enzyme  bound  to  magnetic  nanoparticles.  Such  a  product  may  be  used  among
bioreactor applications for targeted drug delivery in biosensors or bioimaging and
magnetic  resonance  imaging.  Preparation  of  CLEAs,  the  microsized  enzyme
structures without a carrier, is described as well. Their main advantage is very simple
preparation,  where  two  steps,  precipitation  of  the  enzyme  and  cross‐linking,  are
joined. A broad spectrum of enzymes for CLEA preparation has been used and many
biotechnological reactions are catalyzed. The improvement in CLEA preparation to
enhance their stability and operability is also shown.
Keywords: Biotechnology, Biomedicine, Enzymes, immobilization, carriers, nanotech‐
nology.
1. Introduction
Thirty years ago, the first chemical immobilization of proteins and enzymes was performed.
Immobilized proteins are currently used for processing of several products in different areas:
from food industry to environment and medicine. Their use is also in many bioanalytical and
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
biomedical applications,  which include the use of immobilized antibodies or antigens in
bioaffinity chromatography, of immobilized receptors or ligands, and of immobilized cells in
biosensors.
Because free enzymes show poor stability towards heat and pH, they offer limited possibilities
of its reusability and recovery. To improve those main characteristics, new approaches are
constantly producing new ways of improvement in enzyme stability and reusability with
growing tools, such as immobilization techniques. New immobilization techniques offer new
improved materials, which provide high‐performance biocatalysts and favorable environ‐
ments in which immobilized enzymes can work. These environments include much wider pH
and temperature range and give more activity and stability than free enzymes [1–5]. Numerous
applications of magnetic micro‐ and nanoparticles in biotechnology and biomedicine have
been expanding and growing over the last decade due to their tremendous potential in
targeting and delivery systems and due to their advantages in biosubstance binding. The
development and synthesis of such materials have contributed immensely to several research
disciplines, such as pharmaceutical, biomedical, and biotechnological to physics and electron‐
ics, to advanced materials, and to chemical science in general in a form of imaging agents,
sensors, drug delivery targets/vehicles, and diagnostic tools. A great contribution was made
to improve engineering skills in surgical diagnosis, therapy, and treatment [6–9]. The advan‐
tages and applicability of nanoparticles has opened up a large scope of studies. The main
advantages of nanoparticles, compared to larger‐sized particles, are their high surface‐to‐
volume ratio and hence higher surface energy and excellent magnetic properties and, of course,
their small size (approximately 1–100 nm). Their inorganic magnetic core is usually surround‐
ed by layers of functional coatings. Their large surface and smaller size volume ratio, which is
dependent on their strong magnetic dipole, gives key features that make them useful in many
biotechnological and biomedical applications. Magnetic nanoparticles are therefore used as
carriers to which different active substances can bind. They also have high coercivity and high
magnetic susceptibility and are often bound together in aggregates, which give them many
new possibilities in properties and functionalization. High surface area of magnetic nanopar‐
ticles allows the improvement of its bioapplicability and bioavailability, which allows larger
dosage of bulk drugs and its pharmacokinetic properties and increase of vascular circulation.
In nanoparticle applications, their properties are mainly used to develop drugs for targeted
delivery systems and for diagnostic purposes, as they are a good contrast device for magnetic
resonance imaging (MRI). Magnetic nanoparticles are able to concentrate in a specific tissue
or anatomical location. The results of clinical studies may help us determine the key substances
for immobilization on magnetic nanoparticles with the aim to gain better control of four healing
processes: migration and proliferation of fibroblasts, deposition of extracellular matrix,
angiogenesis, and transformation (scarring). At the same time, the optical properties of
magnetic nanoparticles are used as alternatives to organic dyes for imaging purposes and also
provide enhanced target specificity, which makes them an attractive drug delivery vehicle
with an advantage and possibility of monitored drug release. Magnetic nanoparticles coated
with different materials give more advantages in biological applications and provides an
improvement in properties. Those properties can provide less cytotoxicity, improve biocom‐
patibility, and provide better conjugation with other biologically active substances. Because
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magnetic nanoparticles are generally toxic to a living system, when they penetrate through
membranes and interfere with basal metabolic reactions within the cell, a form of a coating on
top of the core particle can make the magnetic nanoparticle less toxic and more biocompatible.
The conjugation of biologically active substances and other suitable proteins onto its surface
can improve many bioapplications. Magnetic nanoparticles modified with different surface
substances are able to improve the surface chemistry of the nanoparticles to increase its affinity
to bind different biologically active substances, proteins, DNA complexes, drugs, receptors,
etc. All these modifications have led to improvements in the synthesis and preparations of
magnetic nanoparticles that have to be in sync with a certain biological system. Therefore,
biocompatibility and cytocompatibility are the most important aspects to increase the thera‐
peutic value in using magnetic nanoparticles as drug delivery vehicles and furthermore in
controlling drug release [10–14].
Another interesting area are micro‐ and nanosized enzyme cross‐linked aggregates without
additional carrier. Due to their extremely high activity, they are welcome in biotechnology and
in biomedicine applications as biosensors.
1.1. Immobilized enzymes in biotechnology
Over the past decades, immobilized enzymes have affected numerous technologies in
industrial processes. The ability of the enzymes to catalyze the reaction has made them
indispensable to science for many years. Because one of the most important roles of enzymes
as natural biocatalysts is their ability to enhance the rate of all chemical reactions, they increase
the rates of chemical reactions without their altering or being consumed by the reaction and
without changing the equilibrium between reactants and products. The most valuable
properties of immobilized enzymes are their ability of easy reusability, lower degradation,
higher control over the reaction rate, and ability to prevent contamination of the substrate with
enzyme or protein. Also, the immobilization of the enzymes has been shown to improve the
stability of the enzymes and to lengthen their half‐life. It offers the enzymes to work in a larger
range of environments, which improves enzyme stability against temperature, solvents, pH,
contaminants, and impurities. The immobilization of the enzymes increases the productivity
of biocatalysts and enhances their features, which makes them more attractive and highly
applicable in all kinds of evolving biotechnologies.
The enzyme, the matrix, and the mode of attachment are the main components of an enzyme
immobilization, where the main advantages are the improvement of enzyme stability, increase
of volume‐specific enzyme loading, and simplification of biocatalyst recycling [1,3].
Immobilized enzymes have been employed in reactions in either a batch or a continuous flow
reactor. Batch reactors are applicable for smaller productions. They are suitable for expensive
enzymes, as they can be used in small amounts and are not wasteful. Continuous reactors are
suitable for increasing the time of reactions as well as the efficiency of a reaction using
biocatalysts.
With recent advances and improvements in biotechnology, immobilized enzymes have been
used in a wide range of applications. The advances include the improvements of immobiliza‐
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tion techniques, new methods for the production or breakdown of compounds using biocata‐
lytic reactions, methods of targeted drug delivery and tumor identification, and advances in
using immobilized enzymes in biosensors. The most frequent enzyme immobilization is used
for the synthesis of chemicals, where the industrial applications are straightforward. Through
biocatalyzed reactions, they provide a reusable method for the production of chemicals and
can break down harmful or undesired compounds. To develop stable and recoverable enzymes
for multipurpose biotechnological applications and to increase their utilization as industrial
biocatalysts, biocatalysts must be obtained from enzymes isolated from microbes, which
naturally exist in extreme environments. Another way of obtaining stable enzymes is genetic
engineering, which involves isolation. The most common and best way of obtaining stable
enzymes is achieved by immobilization, protein engineering, and chemical modifications.
Protein engineering has been able to produce enzymes that differ from their native forms in
only several or one amino acids. This approach is offering many possibilities of stabilizing
enzymes by changes in amino acid sequences [15–25].
1.2. Immobilized enzymes in biomedicine
Currently, the routine use of immobilized proteins or enzymes in medical field is in the
diagnosis and treatment of various diseases. Immobilized antibodies, receptors, and enzymes
are used as biosensors for the detection of different bioactive compounds in diagnosis.
Encapsulated enzymes are used in different types of bioreactors for the separation of metab‐
olites from body fluids or for the improvement of metabolic deficiency in the human body.
Artificial cells and the development of controlled drug delivery systems for dosing of proteins
or enzymes is also an application of immobilized enzymes in biomedicine. One of the appli‐
cations of immobilized enzymes in medicine are also enzyme‐based electrodes. High specif‐
icity and reactivity of an enzyme towards its substrate is used in biosensors, which have high
reliability, sensitivity, accuracy, and ease of handling and are relatively low cost compared to
conventional analytical methods. These biosensors are currently used in the clinical diagnosis
of glucose [26–30], exalate [31,32], urea [33,34], glutamate [35,36], theophylline [37], creatine
and creatinine [38,39], cholesterol [40,41], and bilirubin [42,43].
The application of immobilized enzymes in bioreactions is in the convection of inborn errors
of metabolism, cancer treatment, and separation of waste products from body fluids. Enzyme
or enzymes could be immobilized on solid support, encapsulated in sol‐gel support, or
alternatively cross‐linked without a support to form the bioreactor.
Some applications of bioreactors used in human medicine are in areas of
a. Degradation of organophosphate in organophosphate poisoning by the use of phospho‐
triesterases [44,45],
b. Conversion of alcohol to acetate in alcohol poisoning by the use of alcohol dehydrogenase
(ADH) and acetaldehyde dehydrogenase [46,47],
c. DNA damage repair in skin aging and cancer by DNA repair enzyme (liposome) [48,49],
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only several or one amino acids. This approach is offering many possibilities of stabilizing
enzymes by changes in amino acid sequences [15–25].
1.2. Immobilized enzymes in biomedicine
Currently, the routine use of immobilized proteins or enzymes in medical field is in the
diagnosis and treatment of various diseases. Immobilized antibodies, receptors, and enzymes
are used as biosensors for the detection of different bioactive compounds in diagnosis.
Encapsulated enzymes are used in different types of bioreactors for the separation of metab‐
olites from body fluids or for the improvement of metabolic deficiency in the human body.
Artificial cells and the development of controlled drug delivery systems for dosing of proteins
or enzymes is also an application of immobilized enzymes in biomedicine. One of the appli‐
cations of immobilized enzymes in medicine are also enzyme‐based electrodes. High specif‐
icity and reactivity of an enzyme towards its substrate is used in biosensors, which have high
reliability, sensitivity, accuracy, and ease of handling and are relatively low cost compared to
conventional analytical methods. These biosensors are currently used in the clinical diagnosis
of glucose [26–30], exalate [31,32], urea [33,34], glutamate [35,36], theophylline [37], creatine
and creatinine [38,39], cholesterol [40,41], and bilirubin [42,43].
The application of immobilized enzymes in bioreactions is in the convection of inborn errors
of metabolism, cancer treatment, and separation of waste products from body fluids. Enzyme
or enzymes could be immobilized on solid support, encapsulated in sol‐gel support, or
alternatively cross‐linked without a support to form the bioreactor.
Some applications of bioreactors used in human medicine are in areas of
a. Degradation of organophosphate in organophosphate poisoning by the use of phospho‐
triesterases [44,45],
b. Conversion of alcohol to acetate in alcohol poisoning by the use of alcohol dehydrogenase
(ADH) and acetaldehyde dehydrogenase [46,47],
c. DNA damage repair in skin aging and cancer by DNA repair enzyme (liposome) [48,49],
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d. Hydrolysis of phospholipids in hypercholesterolemia by the use of phospholipase A2
(liposome) [50], and
e. Conversion of ifosfamide or oxazaphosphorine to tumoridical metabolites in tumors by
the use of cytochrome P450 (cells encapsulated in cellulose sulfate formation) [9,51,52].
2. Magnetic nanoparticles as nanocarriers
Recent developments in life sciences in the last decade have produced numerous applications
of magnetic nanoparticles in different fields of science and technology (biomedicine, biotech‐
nology, biochemistry, etc.) and offer exciting new possibilities for applying new methods in
an ever‐growing and developing field of nanomedicine.
Superparamagnetic iron oxide (magnetite and maghemite) nanoparticles are the most used
particles in several research disciplines due to their advantages in biosubstance binding and
their tremendous potential in targeting and delivery systems. The main advantages of
nanoparticles, compared to larger‐sized particles, are their high surface‐to‐volume ratio and
hence higher surface energy and excellent magnetic properties. Magnetic nanoparticles have
been widely used in enzyme immobilization because of their unique properties, which among
others include superparamagnetism and easy separation [29–31]. Together with the bound
enzymes, they are interesting for the use in bioreactors. Among other advantages of magnetic
nanoparticles, such as biocompatibility, small size, low toxicity, and, especially, superpara‐
magnetism, a significant reduction of the biocatalyst amount used in a reaction was achieved
at nicotinamide adenine dinucleotide hydrate (NADH) oxidation in a microreactor using
ADH‐loaded magnetic nanoparticles. In a reactor system with an oscillating magnetic field
and an actively moving ADH‐loaded magnetic nanoparticles, 100% NADH conversion was
achieved for residence time of just 2 min [53].
Figure 1. Magnetic nanoparticle surrounded by layers of functional coatings.
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Magnetic nanoparticles are typically crystals of inorganic elements for which the largest
characteristic dimension is approximately 1 to 100 nm. Their inorganic magnetic core is usually
surrounded by layers of functional coatings (Figure 1).
Frequently used magnetic nanoparticles are also cobalt and nickel magnetic nanoparticles.
Cobalt is a ferromagnetic element commonly used as an alloying element in permanent
magnets. Nickel magnetic nanoparticles are of great interest due to their superparamagnetic
and optical properties. There have been many protocols for the synthesis of cobalt or nickel
magnetic nanoparticles, which include thermal decomposition, reverse micelles, chemical
reduction, and polyol reduction, and for cobalt magnetic nanoparticles also sonochemical
synthesis [54–62]. There are also many alloy‐bimetallic magnetic nanoparticles that include
various systems, such as iron‐cobalt, nickel‐cobalt, iron‐platinum, and cobalt‐platinum.
However, because of their low toxicity and biocompatibility, the most used magnetic nano‐
particles are iron oxide nanoparticles [10,13,63,64]. Iron, being a ferromagnetic element, has
the highest saturation magnetization at room temperature; therefore, iron magnetic nanopar‐
ticles exhibit superparamagnetic behavior in the size range below 20 nm. In general, naked
iron oxide magnetic nanoparticles are often highly reactive and can easily undergo degrada‐
tion and oxidation, which leads to poor stability in strong acidic solutions and results in an
iron oxide shell. Also, leaching can occur, which limits the reusability and lifetime of such
materials [12,65–68]. The aggregation of the particles is also one problem, which is a result of
large surface‐to‐volume ratio that presents another limitation. This limitation results in low
surface energy that can occur due to strong magnetic attractions between particles and would
result in the loss of activity or certain decrease of it.
To prevent and overcome such limitations, many various approaches can be used to modify
the surface of magnetic nanoparticles. These approaches and techniques can improve and
optimize their biocompatibility and biodegradability and, more importantly, can transfer a
hydrophobic system into a hydrophilic one. To prevent oxidation and avoid instability in
ambient conditions, iron magnetic nanoparticles must be protected by applying suitable
coatings with materials that are chemically stable and biocompatible, such as gold (Au). Au
shell makes a versatile surface for biofunctionalization due to its strong affinity towards thiols
that are often present in biological molecules. Many versatile materials have been used in the
application of these improvements. Surfactants, such as oleic acid, citric acid, lauric acid,
alkylsulfonic acids, and alkylphosphonic acids, are commonly used. Also used as coatings are
different polymers, such as polyethylene glycol (PEG), polyvinylpyrroline (PVP), and poly‐
vinyl alcohol (PVA). More importantly, also natural materials, such as chitin, dextran, alginate,
albumin, gelatin, starch, liposomes, and ethyl cellulose, are widely used and applied as
coatings onto iron oxide magnetic nanoparticles, which are bound chemically or by multiple
hydrogen bonds and therefore develop hydrophilic system [69–75]. Coatings on iron magnetic
nanoparticles do not only influence the colloidal stability but also the biological functionality
of nanoparticles. Good colloidal stability and the prevention of particle aggregation in a pH
area of approximately 7.4 are the most important requirements for biomedical applications.
Molecules on the surface of nanoparticles can interact in different ways.
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“Encapsulation” of nanoparticles in polymers can apply through polymerization in a suspen‐
sion of nanoparticles or magnetic nanoparticle synthesis occurs in a polymeric media or
polymer molecules are grafted at the surface of nanoparticles [76].
“Coating through hydrophobic interactions” is a strategy also named bilayer functionalization.
Magnetic nanoparticles that are synthesized by thermal decomposition are capped by
hydrophobic surfactants that are coated with amphiphilic molecules [77].
“Interactions using coupling agents or covalently binding” present an alternative to physi‐
sorption, as physisorbed molecules are easily desorbed when nanoparticles are introduced to
physiological media and nanoparticles coated with adsorbed molecules tend to aggregate in
phosphate‐buffered saline (PBS), which is caused by the displacement of carboxylic acid
groups from the nanoparticle surface by phosphate salts [78–80].
To improve coating stability, other high‐affinity surface‐capping agents are being explored
(silane group, carboxylate, carboxylate and OH groups, catechol, hydroxamic acid, phospho‐
nate groups, and inorganic coatings, which include silica, Au, and other metals and metal
oxides). A silica shell is mostly used for the modification and protection of magnetic core,
where it can prevent unwanted interactions, such as acidic corrosion. Silica coating has many
advantages and can provide better stability under aqueous conditions and better biocompat‐
ibility [72,81,82].
Surface silanization is a commonly used method to introduce functional groups onto magnetic
nanoparticles. The silanization process can widely improve and help forward to low cytotox‐
icity and high stability under acidic conditions and can ease the surface chemical modification.
Reactions of silanization can be carried out in aqueous media or organic solvents at moderate
temperatures. In the reaction mechanism, silane‐based molecules such as 3‐aminopropyl
trimethoxysilane (APTMS) are covalently bound to the surface of nanoparticles to where other
bioactive molecules can be further bound. The main advantage of a silane agent is its biocom‐
patibility and a high density of surface functional end groups (alcohol, amine, thiol) to which
other biocompatible components can bind and be functionalized [76,80,83].
Another agent used for the modification of nanoparticle surface is carboxylic acid group, which
can be employed with oleic acid used as a surfactant. Carboxylic groups are reportedly more
active than hydroxyl groups. However, when the hydroxyl group is ortho‐positioned regarding
the carboxyl group, both groups will coordinate to the iron atom, forming a chelating structure.
Hydroxamic acid derivates are mainly used in ligand exchange process to coat nanoparticles
in situ with fatty acids during synthesis. Using bifunctional phosphonic acid groups with polar
end groups (‐COOH, ‐NH2, ‐OH) provides functionality on the surface and a hydrophilic and
stable system.
The size of the magnetic carriers can be engineered by their preparation technique. Chitosan‐
coated magnetic nanoparticles were prepared using three different methods: microemulsion
process, suspension cross‐linking technique, and covalent binding method [84]. The size of the
particles varied with the preparation method and was increased by the increase in the
concentration of chitosan and decreased by the increase of the cross‐linker concentration.
Particles coated with chitosan had a spherical shape and a size range of 40 to 350 μm using the
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microemulsion process, 10 to 50 μm using the suspension cross‐linking technique, and 50 to
100 nm using the covalent binding method. Magnetic nanoparticles coated with chitosan with
the covalent binding method were the most suitable for practical applications due to their
sufficiently high values of amino groups (2.48 mmol/g), which is important for protein
immobilization [85].
Immobilization methods developed for enzyme/protein binding onto iron magnetic nanopar‐




Physical immobilization, including physical adsorption, is considered as the simplest method
for protein or enzyme immobilization. This method is based on the adsorption of enzyme or
protein on the surface of water‐insoluble carriers, which include porous carbon, ion‐exchange
matrices, or polymeric aromatic resins (Figure 2). Furthermore, the method can easily be
carried out without any additional coupling agents, surface treatment, or enzyme/protein
modification. Also, it makes no conformation changes to the enzyme and is simple and cheap.
It can simply be performed by dipping the material into a certain solution containing our target
bioactive substances [86–88]. In recent years, many physically immobilized enzymes based on
iron magnetic nanoparticles were developed. For example, hybrid magnetic Fe3O4‐SiO2‐
poly(ethylene oxide)‐maltose nanoparticles were used as affinity adsorption carriers for the
direct separation of maltose binding protein‐fused heparinase I. The results demonstrated that
the mentioned nanoparticles were suitable carriers for affinity purification and immobilization
in a single step, showing high adsorption capacity [89]. Also, glucose oxidase was immobilized
by employing tannic acid‐modified CoFe2O4 magnetic nanoparticles. Using strong protein and
tannic acid binding, glucose oxidase immobilization was carried out via physical adsorption,
where it showed excellent reusability and where immobilized glucose oxidase maintained at
60% of its initial activity [90]. Feruloyl esterases (FAE) were also successfully immobilized on
magnetic iron nanoparticles via physical adsorption. Optimal immobilization conditions were
significantly influenced by pH 6, where the maximum activity of immobilized FAEs were
observed [91]. Because physical adsorption is a simple and mild method, it involves weak
interactions, where enzymes are attached to the matrix through hydrogen bonds [92], van der
Waals forces [93,94], and hydrophobic interactions [95]. Thermomyces lanuginosa lipase (TLL)
was immobilized via physical adsorption onto the polyethyleneimine‐coated iron magnetic
nanoparticles that were prepared for the chelation of three metal ions. The immobilized lipase
obtained more than 60% of initial activity after 10 cycles and retained about 80% of initial
activity after 14 days of storage [96].
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Figure 2. Adsorption of the enzyme on the surface of a carrier.
Forces involved in noncovalent immobilization result in a process that can be reversed by
changing the environmental conditions, such as pH, temperature, ionic strength, polarity of
the solvent, and concentration of bioactive molecules. Immobilization by adsorption usually
preserves the catalytic activity of the enzyme, which makes them economically attractive.
However, because these interactions in physical adsorption are relatively weak, they often
result in breaking away from the support or in enzyme leakage from matrix, which can lead
to the loss of activity and denaturation of the protein or enzyme.
2.1.2. Affinity binding
Affinity binding has well been applied to enzyme immobilization, where the most important
advantage is the selectivity of the interactions. The method often requires covalent binding of
an expensive ligand to the matrix. For example, an oriented immobilization of chloroperoxi‐
dase on iron magnetic nanoparticles was achieved by layer‐by‐layer controlled assembly
through specific interactions of avidin‐biotin affinity binding [97].
2.1.3. Chelation or metal binding
Another method of reversible immobilization is also presented in chelation or metal binding,
where metal salts or hydroxides on the surface of organic carriers are bound by coordination
with nucleophilic groups on the matrix. The metal salt or hydroxide is precipitated on the
support (chitin, alginate, silica‐based carriers) by heating or neutralization. Some of the
positions on the metal remain free, as it is impossible for the matrix to occupy all positions on
the metal. This occurs because of the steric factors. The method is simple and can obtain
relatively high remaining specific activities of the enzyme (30–80%). For example, β‐D‐
glucosidase was immobilized on iron magnetic nanoparticles coupled with agarose via metal
ion affinity between alkaline amino groups located on the surface of the β‐D‐glucosidase and
the Co2+ chelated on the carrier [98]. Another example shows that metal chelate ions (Co2+,
Cu2+, Pd2+) increase the capacity of enzyme immobilization, where polyethyleneimine‐coated
iron magnetic nanoparticles were prepared via chelation [96].




Covalent immobilization is the most widely used immobilization method and an attractive
one, as it can be regulated with specific functional groups to bind enzymes or proteins. The
main advantage of covalent immobilization is that the bonds formed between the enzyme and
the matrix are of stable nature, so the enzyme cannot be released into the solution and the
enzyme leakage is absent or limited. There are several immobilization protocols that are being
researched using covalent binding and applying it in enzyme immobilization [1,99–101]. For
improving enzyme activity, a coupling reaction can be applied using coupling agents, such as
glutaraldehyde (GA) [72,99,102–105] or 1‐ethyl‐3‐(3‐dimethylaminopropyl) carbodiimide
hydrochloride (EDC) [106,107]. GA and EDC are because of their functional group (aldehyde
group) mostly covalently cross‐linked to magnetic nanoparticles and enzymes/proteins due
to their interaction with both functional groups (Figure 3). However, in some cases, the
presence of a coupling agent can also cause conformational changes in proteins, which can
result in a decrease of enzyme activity.
Figure 3. Covalent immobilization of the enzyme.
There are many researches performed, where enzymes were covalently immobilized onto iron
magnetic nanoparticles. For example, recombinant trehalose synthase was immobilized onto
glutaraldehyde‐activated silanized iron magnetic nanoparticles by covalent binding, where it
retained 82% of its initial activity after successive 12 repeated cycles of reaction [108]. Another
research reports the covalent coupling of lipase using EDC onto chitosan magnetic nanopar‐
ticles, where the immobilization of lipase was performed by the formation of an amide bond
between the carboxy group of lipase and the primary amino group of the nanoparticle. Lipase
immobilized onto the magnetic support demonstrated high catalytic activity and retained 78%
of its initial activity [109]. Also, superparamagnetic nanoparticles were surface modified with
a mixture of two polymers for lipase immobilization, where the lipase was covalently bound
to the surface of nanoparticles via EDC/N‐hydroxysulfosuccinimide sodium salt (sulfo‐NHS)
activation and retained 82% of its initial activity [73]. Another study reports recombinant acetyl
xylan esterase (rAXE) being covalently immobilized with chitosan magnetic nanoparticles
using glutaraldehyde and demonstrating better stability at thermal and pH ranges than soluble
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free rAXE. The immobilized rAXE was stable for about 90% of activity in aqueous phase and
retained only 60% of its initial activity after 10 cycles of reuse [105]. Furthermore, serraptio‐
peptidase enzyme was immobilized by covalent binding through glutaraldehyde after
aminofunctionalization of magnetic nanoparticles. The immobilized enzyme showed 67% of
residual activity and good storage stability [110]. α‐Acetolactate decarboxylase (α‐ALDC) was
covalently immobilized to paramagnetic Fe3O4‐Si‐NH2 nanoparticles using 1'‐carbonyldiimi‐
dazole (CDI). Such immobilized α‐ALDC retained almost 65.35% of its initial activity and
31.05% of its initial activity after five times of reusing [111]. Another study reports of cholesterol
oxidase (COX) immobilization to magnetic fluorescent core‐shell structured nanoparticles,
where immobilization consisted of silanization, linker molecule deposition, and enzyme
coupling of GA and 3‐aminopropyltriethoxysilane (APTES). Therefore, immobilized COX
maintained 80% of its initial activity and 71% of its initial activity after seven consecutive
operations [103]. AiiA, which is a 28‐kDa lactonase, was covalently immobilized onto magnetic
nanoparticles, where immobilized recombinant AiiA (r‐AiiA) was evaluated for its ability to
hydrolyze and inhibit bacterial quorum sensing [112]. An interesting research was presented
where pullulanase was immobilized onto magnetic chitosan activated nanoparticles prepared
by in situ mineralization, showing that, although the immobilization by electrostatic adsorp‐
tion can preserve higher activity of the enzyme (87%), the poor stability of the immobilized
pullulanase cannot be avoided. Covalent immobilization by cross‐linking maintained 70% of
initial activity but gave smaller activity losses and more improvement between enzyme and
substrate affinity and gave more stability, as the covalent attachment formed between amino
groups of the enzyme and support showed more catalytic activity than between the carboxy
groups of the enzyme and support [113]. Another study describes COX covalently immobilized
onto magnetic nanoparticles of maghemite further functionalized with silica and amino‐silane
molecules. Therefore, prepared nanoparticles immobilized with COX maintained up to 60%
of initial activity [114], where another study shows how Aspergillus niger xylanase A (XylA)
was covalently immobilized onto chitosan‐coated magnetic nanoparticles by forming covalent
bonds between the aldehyde group of glutaraldehyde and the amino group of the enzyme.
The retained activity of immobilized XylA was 56.5% of its initial activity [115]. The immobi‐
lization of yeast ADH (YADH) from Saccharomyces cerevisiae onto chitosan‐coated magnetic
nanoparticles was performed by covalent binding, where different preparation conditions
were taken into account, such as immobilization time, pH, and enzyme concentration. Finally,
the optimum reaction temperature was 30°C with pH of 7.4 and the retained activity of
immobilized YADH was 65% of its original initial activity [71]. Another work presents α‐
amylase being covalently immobilized using glutaraldehyde onto magnetic nanoparticles
using gum acacia as the steric stabilizer. GA magnetic nanoparticles have been demonstrated
to be capable of being reused for at least six cycles while retaining about 70% of the initial
activity [116]. Another lipase immobilization was performed by both physical adsorption and
covalent binding onto magnetic nanoparticles, of which the surface was grafted by block
copolymer of 2‐dimethylaminoethyl methacrylate (DMAEMA) and glycidyl methacrylate
(GMA). The activity recovery of the immobilization lipase reaches 43.1% at the protein loading
of 0.5 mg (per mg of support) and retains 73% of its initial activity at 65°C for 8 h and its residual
activity is reportedly more than 55% after six consecutive cycles [117].
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On the contrary, a biosorbent was successfully prepared by the immobilization of Phanerochaete
chrysosporium with iron oxide magnetic nanoparticles and calcium alginate, which is capable
of removing Pb(II) ions from solutions, as P. chrysosporium was reported for the biosorption of
heavy metals, taking advantages of favorable heavy metal affinity. In this case, the immobili‐
zation assists native microbes in improving their biosorption capacity. The biosorption
efficiency was reportedly highly time and pH dependent and affected by initial Pb(II) con‐
centration [118].
2.3. Targeted drug delivery using magnetic nanoparticles
There are many advantages when talking about targeted drug delivery systems based on
magnetic nanoparticles. Compared to other conventional drug carriers, magnetic nanoparti‐
cles have a better retention ability and are therefore promising simulative carriers that can
transport a drug to the desired place in the body. Nanotechnology in biomedicine is mostly
used for intravenous delivery, especially to cancer tissues. Another advantage of magnetic
nanoparticles for targeted drug delivery is that nanoparticles as carriers can also be coated
with different biodegradable organic polymers to enable interaction by binding with active
molecules and to achieve a sufficient drug load. Thus, such system allows biodegradability,
biocompatibility, nontoxicity, and prolonged circulation of a specific therapeutic or drug
agent. Once the drug carrier is concentrated at our desired tissue location, the drug can be
released either by enzymatic activity or by changes in physiological conditions, such as
temperature, pH or osmolality, as can be seen in Figure 4.
Figure 4. Targeted drug delivery: targeting of a nanoparticle includes targeting ligands, such as antibodies or peptides
that specifically bind to receptors expressed on target side.
An extensive research has been made regarding targeted drug delivery systems using
magnetic nanoparticles. For example, magnetic molecularly imprinted polymer was synthe‐
sized using polydopamine, which was used for controlled 5‐fluorouracil delivery in a spon‐
taneous model of breast adenocarcinoma in BALB/c mice in the presence of an external
magnetic field [119]. Another study investigates magnetic nanoparticles functionalized with
thiol‐terminated polyethylene glycol, loaded with anticancer drug doxorubicin (DOX) used as
a biodegradable system for targeted delivery [120], whereas another research explores the
same drug DOX delivered with β‐cyclodextrin assembled magnetic nanoparticles, which were
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fabricated with layer‐by‐layer method to develop a versatile biocompatible platform for
selective loading, targeted delivery, and pH‐responsive release of mentioned drug [8].
2.4. Magnetic nanoparticles in biosensors
Iron magnetic nanoparticles can also be coated with fluorescent materials or with silica, metal,
or a polymer. Magnetic nanoparticles coated with such materials are used as bioanalytical
sensors. In developing new biosensors, Au nanoparticles show good mechanical resistance
and electrical properties as well as good biocompatibility. As all magnetic nanoparticles, they
have large surface area for enzyme or protein immobilization. Biosensors contain layers that
are bioselective, which can react with a target biomolecule that transforms the biologic
interaction into physical signal (optical, chemical, electrical, thermal, etc.). The principle of
biosensors is represented in Figure 5.
Figure 5. Principle of biosensors: transforming biological interaction into electrical signal.
A study proposes a biosensor using glassy carbon electrode modified with Au nanoparticles
and tyrosinase, which is covalently immobilized in a dihexadecylphosphate film. Therefore,
modified electrode is used to determine catechol concentrations by amperometry in natural
water samples [121].
Biosensors are also applied to the determination of hepatitis B virus (HBV) DNA in urine and
blood plasma samples. As described in a recent study, a magnetite and Au nanoparticle‐
modified paste electrode was prepared for the immobilization of thiol‐modified HBV probe
DNA. Therefore, developed biosensor could measure target HBV DNA virus concentration
with low concentrations [122]. Later on, an ultrasensitive electrochemical DNA biosensor
based on in situ labeling Au nanoparticles on the free terminal of hairpin DNA was developed,
with good regeneration, stability, and hybridization selectivity [123]. Another paper describes
Au nanoparticles being used to enhance electrochemical DNA biosensor, where the goal was
to improve the sensitivity of biosensor by detecting small sequences in large amounts of
double‐stranded DNA [124]. Magnetic fluorescent core‐shell nanoparticles immobilized with
COX were prepared to be used as a sensing material with application in multiparameter fiber‐
optic biosensor based on enzyme catalysis and oxygen consumption [125].
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2.5. Bioimaging and MRI using magnetic nanoparticles
MRI is a commonly used medical imaging technique that is a powerful and noninvasive tool
used for the visualization of structures and functions in tissue. MRI is based on the detection
of proton relaxation and an external magnetic field. Different enzymes and proteins immobi‐
lized on magnetic nanoparticles are largely applied in MRI imaging mostly because of their
biocompatibility, superparamagnetism, low toxicity, colloidal stability at physiological
conditions (37°C, pH 7.4, PBS buffer), and well‐controlled surface charges. For example,
magnetite nanoparticles were functionalized with mebrofenin, as it is known as a liver
targeting function. Therefore, functionalized nanoparticles coated with silica were prepared
as liver targeting contrast agents in MRI [126]. In another study, magnetic nanoparticles were
used as drug carriers, aiming to form a magnetically controlled nanoplatform [127].
3. Cross‐linked enzyme aggregates (CLEAs) as microcarriers
Many biotechnological approaches for production cover the synthesis of drugs. A lot of these
enantiopure compounds, such as anticancer, antiviral, anti‐infective, antipsychotic, antiar‐
rhythmic, cholesterol‐lowering agents, calcium channel blockers, ACE inhibitors, and many
others, may be synthesized enzymatically.
Via immobilization of enzymes, stabilization occurs. Intermolecular interactions are prevented
[100] and the enzyme structure becomes more rigid due to multipoint covalent attachment [1].
In multimeric enzymes, the dissociation of the subunits is prevented [128] and inhibition is
reduced [100]. However, structural properties such as size, specific area, and porosity that
dictate the resistance to mechanical stress are also important.
The most used cross‐linking agent for enzyme immobilization is glutaraldehyde, as it is
available in commercial quantity and is relatively cheap. Although its chemistry has been not
fully understood, it is generally accepted that the inter‐ and intramolecular cross‐linking
reaction occurs between the free amino groups of lysine (Lys) residues on the enzyme or
protein molecule and the carbonyl group of glutaraldehyde resulting in a Schiff base formation
[129].
3.1. Carrier‐free immobilization
The CLEA method is used for the dual purpose of combining both the purification and
immobilization of enzyme in one step [130]. The first step is enzyme precipitation with the
most suitable precipitating agent and the second step is enzyme cross‐linking with a cross‐
linking reagent. An example of CLEA preparation is presented in Figure 1, where the scheme
illustrates the preparation of CLEAs from horseradish peroxidase (HRP) [131]. Beside the
precipitating agent and cross‐linker, some other compounds are added to form the enzyme
clusters. The reason for their use is described below (Figure 6).
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Figure 6. Preparation of CLEAs from HRP [131].
As mentioned before, the first step of CLEA preparation is the precipitation of the enzyme
from the solution with the most suitable precipitating agent. Which precipitating agent is the
most suitable one for a certain enzyme? This question may be answered after a simple
experiment where the enzyme is precipitating with different precipitating agents and then
resuspended again. The precipitating agent that gives the highest residual activity of the
resuspended enzyme is the most suitable one. The most commonly used precipitating agents
are acetone, methanol, ethanol, propanol, 2‐propanol, and ammonium sulfate.
CLEAs are easily prepared from crude enzyme extracts, and the costs of (often expensive)
carriers are circumvented. Many studies employed purified or partially purified enzyme
samples for CLEA preparation [132–139]. On the contrary, it was successfully demonstrated
that the lipase from Penicillium expansum (PEL)‐CLEAs can be prepared directly from the fresh
fermentation broth or its lyophilizate [140]. They generally exhibit improved storage and
operational stability towards denaturation by heat, organic solvents, and autoproteolysis and
are stable towards leaching in aqueous media. Furthermore, they have high catalyst produc‐
tivities (kilogram product per kilogram biocatalyst) and are easy to recover and recycle. In
CLEAs, immobilized enzymes are much more resistant to shear and extreme pH values than
the soluble enzymes as well.
The particle size of CLEAs is usually between 5 and 50 μm, but it can be varied by changing
the preparation parameters, such as precipitating agent or cross‐linker concentration. Al‐
though with a smaller size of the clusters higher reaction rates are obtained, sometimes
applications dictate the formation of bigger clusters. It is obvious that bigger particle sizes
result in better filterability and smaller pressure drop in packed bed reactors. Table 1
represents particle size variations of CLEAs from cellulase (from 26 to 161 μm) in the depend‐
ence from the used precipitating agents.
Micro‐ and Nanocarriers for Immobilization of Enzymes
http://dx.doi.org/10.5772/63129
35







Table 1. Particle size deviation of CLEAs from cellulase.
However, the concentration of the cross‐linking agent must be carefully optimized to prevent
the enzyme activity loss. Namely, too big particle size of the enzyme preparation, which is
formed with high glutaraldehyde concentration, may affect the mass transfer of the substrates
to contact with the enzymes in the inner side. In this case, inner enzymes of the enzyme
preparation lose the opportunity to form complexes with the substrates, which results in the
apparent activity loss of the enzyme.
Scanning electron microscopy showed a uniform structure of the cross‐linked α‐amylase
aggregates. The diameter of CLEAs was about 250 nm with a small deviation (Figure 7). CLEAs
Figure 7. Scanning electron microscopy (SEM) image of CLEAs from α‐amylase.
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can form larger clusters that do have mass transfer limitations, especially in fast UV‐based
assays. One CLEA particle can contain up to 8 million enzyme molecules. The size of these
clusters can be up to 100 μm, making them visible with the bare eyes. The number of CLEAs
in a cluster is much less uniform than enzymes in an aggregate; it can vary from a few to many
hundred thousands [141].
A broad spectrum of enzymes for CLEA preparation has been used. The majority of CLEAs
that have been described involve enzymes, which belong to the class of hydrolases (proteases,
amidases, lipases and esterases, glycosidases), oxidoreductases (oxidase, peroxidase), or lyases
(nitril hydratase, hydroxinitril lyase), have been successfully immobilized as CLEAs [142]. The
reason is probably because they are the enzymes that have the most industrial applications
and are the simplest enzymes to work with.
With enzymes containing few or no accessible Lys residues, cross‐linking may be insuffi‐
cient and lead to CLEAs that are unstable towards leaching in aqueous media. One way to
overcome this problem is to add polyamines, such as polyethyleneimine, which are then
coimmobilized with the enzyme [143]. Problems can also be encountered in CLEA forma‐
tion when the protein concentration in the enzyme preparation is low. In such cases, CLEA
formation can be promoted by the addition of a second protein, such as bovine serum albu‐
min (BSA), as a so‐called proteic feeder [144]. A typical enzyme with low content of amine
residues is aminoacylase [145]. Therefore, the immobilization of aminoacylase was im‐
proved by adding BSA to yield coaggregates [146]. Using BSA as a proteic feeder is also a
solution in cases when the enzyme activity is vulnerable to high concentrations of glutaral‐
dehyde required to obtain aggregates [139,144]. Namely, a high concentration of glutaralde‐
hyde may reduce the activity of the obtained CLEAs, as free amino groups present in the
proteic structure may react with this cross‐linker [147] or it can bind amino acids associated
with the active site.
These drawbacks can be prevented by the use of molecules with a large amount of Lys residues
in the surface, such as BSA. With such a solution, the possibility of cluster formation, as in the
case of excess of glutaraldehyde, with mass transfer limitations, may be prevented. Shah et al.
prepared CLEAs of Pseudomonas cepacia lipase (PCL) with BSA addition. The recovered activity
relative to that of free enzyme was 100% in contrast with the same preparation without BSA,
which retained only 0.4% of activity [16]. More recently, the synthesis of CLEAs of lipase B
from Candida antarctica (CALB) showed difficulties in the cross‐linking step due to the low
content of surface Lys on CALB [18]. The addition of BSA as a feeder allowed an effective cross‐
linking step and permitted to greatly stabilize CLEAs.
To enhance the activity of CLEA used enzymes, it is possible to use a modification of the
CLEA synthesis protocol using proteic feeder. The enzyme could be added after cofeeder
aggregates are formed and cross‐linked. A slightly cross‐linked layer of the enzyme is
formed over the cofeeder cores, which might lead to enhanced enzyme‐substrate contact
(Figure 8). This approach was successfully demonstrated by Guauque Torres et al. [147] us‐
ing TLL. The layer methodology led to high increase in retained activity compared to non‐
layered TLL CLEAs.
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Figure 8. Nonlayered and layered structures of CLEAs: (a) nonlayered CLEAs, (b) one enzyme layer, and (c) three en‐
zyme layers.
3.2. CLEA formation using carriers
There may appear some difficulties using CLEAs in a reaction system, as it is difficult to isolate
and recover CLEAs from the reaction system only by centrifugation or filtration, especially
when the substrate particles are in the same size range as CLEAs [148]. Therefore, some new
reactor styles were designed [149–152]. Another way is to improve the operability and
mechanical stability of CLEAs. For that reason, CLEAs of papain were prepared in commercial
macroporous silica gel from simple adsorption, precipitation, and one‐step cross‐linking [148].
Another example was when CALB was adsorbed and cross‐linked on a polypropylene carrier
[153]. Such enzyme preparation maintained its activity when dispersed in ionic liquids, such
as [BMIm][NO3], which denatured the free enzyme. This is an important fact, as ionic liquids
are, to an increasing degree, being accepted as reaction solvents, including biocatalytic
transformations [154,155]. However, ionic liquids that contain strongly coordinating anions,
such as [BMIm] nitrate or acetate, interact sufficiently strong with CALB to dissolve the enzyme
but also cause its deactivation [156,157].
Laccase‐based CLEAs were stabilized through the formation of a surrounding polymeric
network made of chitosan and 3‐aminopropyltriethoxysilane (EPES‐lac). The average size of
EPES‐lac particles was about 100 μm and with a spherical shape. The thermoresistance of the
resulting enzyme polymer engineered structures of laccase CLEAs (EPES‐CLEA) were more
than 30 times higher than that of free laccase and CLEAs at pH 3 and 40°C. The formation of
a polymer network around laccase‐based CLEAs had a desirable effect on the biocatalysts
formed in regard to chemical and physical characteristics, stability under harsh conditions,
and kinetic parameters [158].
3.3. A broad spectrum of biotechnological reactions may be catalyzed with CLEAs
With CLEA of purified nitrilase from Escherichia coli harbouring gene of Pseudomonas putida,
the hydrolysis of (RS)‐mandelonitrile to (R)‐mandelic acid, a versatile chiral building block,
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was performed by Kumar et al. [130]. (R)‐mandelic acid is namely used as a chiral synthon for
the production of antitumor and antiobesity agents [159].
The industrial production of enantiopure L‐amino acids from N‐acyl DL‐amino acid can be
performed using L‐aminoacylase (N‐acyl amino acid amidohydrolase or acylase I; E.C.
3.5.1.14), which has excellent chiral specificity and is one of the top 10 enzymes used in
biotechnology [160]. This enzyme from Aspergillus sp. is useful for a broad spectrum of
reactions, such as enantioselective hydrolysis of amino acid esters and amides [161], regiose‐
lective alcoholysis of carboxylic acid esters [162–164], acylation of primary and secondary
alcohols [165–168], and acylation of amines [165–169]. Immobilization of L‐aminoacylase from
Aspergillus melleus using coaggregation with polyethyleneimine and subsequent cross‐linking
with glutaraldehyde resulted in stable aminoacylase‐polyethyleneimine CLEAs (AP‐CLEA)
with significantly higher temperature and storage stability of the enzyme without affecting its
enantioselectivity [170].
The enzymatic synthesis of β‐lactam antibiotics, such as ampicillin, is generally performed
under conditions, such as lower pH and temperature, which are far from the optimum of the
enzyme [171]. With the aim of achieving a high synthesis/hydrolysis ratio at high conversion
and a high productivity and space‐time yield, penicillin G acylase was immobilized in the form
of CLEAs using ammonium sulfate or tert‐butanol as precipitation agents [132].
For obtaining advanced intermediates of β‐lactam antibiotics such as desacetyl‐7‐ACA and
desacetyl cephalosporanic acid, a highly active CLEA of the purified rAXE from Bacillus
pumilus CECT5072 with strong operational stability was produced. The operational stability
of this CLEAs was with a half‐life of 45 cycles. Therefore, this new methodology should
decrease the industrial cost of CLEAs both in terms of biocatalyst production and reusability
[133].
Penicillin G acylase (penicillin amidohydrolase; E.C. 3.5.1.11) is widely used in the industrial
synthesis of 6‐aminopenicillanic acid (6‐APA) by the enzymatic deacylation of penicillin G
[172,173]. The free enzyme is known to have a limited thermal stability and a low tolerance
toward organic solvents [174] and this drawback could be circumvented by the immobiliza‐
tion of the enzyme. In the synthesis of ampicillin, CLEAs of penicillin G acylase were more
efficient catalysts than cross‐linked crystals (CLECs) of the same enzyme and maintained their
activity in organic solvents [175].
It is well known that lipases are the most commonly used enzymes in industrial scale.
Esterification reactions to produce industrially important products such as emulsifiers,
surfactants, wax esters, biopolymers, modified fats and oils, structured lipids, and flavores‐
ters [146], esters of short‐chain alcohols and short‐chain fatty acids, which are important aroma
compounds [170], esters of short‐chain alcohols and long‐chain fatty acids, which are valua‐
ble oleochemicals that may be used as lubricants, diesel fuel, and antistatic reagents [138], and
esters of long‐chain fatty acids and polyhydric alcohols such as glycerol, sorbitol, and other
carbohydrates, can be catalyzed by lipases. Therefore, there exist much interest in their
immobilization methods. CLEAs from Candida rugosa lipase (CrL) using glutaraldehyde as the
cross‐linker had some advantages, such as thermal stability, good reusability and enhanced
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stability, and better dispersibility in organic solvents, which were reflected in improved
operational performance compared to the free enzyme in the synthesis of esters from a variety
of alcohols and fatty acids [138].
The third generation of biodiesel from microalgae is interesting due to the advantages of easy
cultivation and fast reproduction, high oil content, no competition for water and land
resources, and being more ecofriendly [176]. PEL‐CLEAs catalyzed biodiesel production from
microalgal oil in the IL [BMIm][PF6] with a conversion of 85.7%, demonstrating that they can
be taken as a promising catalyst for this application [140].
CLEAs may be used in the environmental care as well. Mushroom tyrosinase was used for the
enzymatic treatment of phenolic wastewater. Catalyzed by the enzyme immobilized in the
form of CLEAs, phenolic compounds such as phenol, p‐cresol, p‐chlorophenol, and bisphe‐
nol A can be efficiently eliminated, with a complete conversion, superior to other processes
catalyzed by the same enzyme [177].
CLEAs of laccase are promising biocatalysts for the decolorization of synthetic dyes in aqueous
solution [178]. Namely, industrial applications of laccase for dye decolorization require large
amounts of readily available crude or purified laccase, enzyme stability under operational
conditions, and recyclability [1,128,179], which can be achieved by enzyme immobilization in
CLEA formation. The use of free laccases in such applications has disadvantages, such as their
relatively short lifetime and their instability under harsh environment (e.g., temperature,
organic solvents, and salts) [4].
In the case of removal of hydrogen peroxide residue from milk, production of gluconicacid,
phenyl pyruvic acid, and dihydroxyacetone phosphate catalase has been used in combina‐
tion with oxidases [180–184]. However, the single use and the instability of free catalase in
harsh reaction conditions are not economically viable. The reusability of catalase plays an
important role in the industrial applications and can be achieved by immobilization. Therefore,
bovine liver catalase was immobilized as cross‐linked catalase aggregates (CLEA‐CAT) via
precipitation with ammonium sulfate and then cross‐linking with glutaraldehyde. Finally,
BSA as the proteic feeder was used. Although the catalase had the low Vmax value after
immobilization process, the thermal and storage stabilities of CLEA‐CAT‐BSA derivative were
comparably higher than those of free CAT. CLEA‐CAT‐BSA derivative was reused for 400
cycles in the batch‐type reactor and the total amount of H2O2 decomposed was 1.2×104 mol
H2O2 throughout 400 consecutive uses [185].
There are also some unusual examples of CLEA use, such as biocatalytic synthesis of silver
nanoparticles from silver nitrate. For this biocatalytic synthesis, immobilized NADH‐depend‐
ent nitrate reductase as CLEAs was used based on the bioreduction ability of nitrate reduc‐
tase [186]. At the same time, immobilization improved the thermal stability of the enzyme.
Another advantage of this type of immobilized enzymes is the preparation of combined
CLEAs, so called combi‐CLEAs, which is the possibility to coimmobilize two or more different
enzymes in a single CLEA. In this case, CLEAs are capable to catalyze two or more biotrans‐
formations, independently or in sequence as catalytic cascade processes.
A good example is the bioconversion of sucrose to trehalose (Figure 9).
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Figure 9. Biotransformation of sucrose to trehalose using combi‐CLEAs in comparison to the use of individual en‐
zymes for each reaction step.
Combi‐CLEAs of amylosucrase (AS), maltooligosyltrehalose synthase (MTS), and maltooli‐
gosyltrehalose trehalohydrolase (MTH) were successfully established with acetone and
glutaraldehyde (GA) as a precipitant and a cross‐linker to achieve the one‐step bioconver‐
sion of sucrose to trehalose [187]. The stability of this enzyme preparation was quite good, as
reusability of about five cycles without any activity loss was obtained. This reaction is
important in the food, cosmetic, and pharmaceutical industries, because trehalose is known to
have high water‐holding activity and this characteristic makes it applicable to the develop‐
ment of additives, stabilizers, and sweeteners [188].
4. Conclusion
The stability of enzymes is important for biotechnological applications and can be achieved
via immobilization methods. Large amounts of research have been devoted into exploring the
synthesis and modification of magnetic nanoparticles. They have been proven to be a
successful tool for the immobilization of enzymes, proteins, drugs, and other biologically
active molecules because of their biocompatibility, biodegradability, colloidal stability, low
toxicity, and nanometer scale. Magnetic nanoparticles that are properly surface functional‐
ized can be applied into various fields of science, mostly benefiting in biomedicine and
biotechnology, improving targeted drug deliveries of active therapeutic agents, and explor‐
ing and developing new strategic applications to improve and increase our development in
the future. Another interesting possibility for enzyme immobilization is CLEA formation. With
their micrometer size and unique advantages, where there is no need for carriers and pure
enzymes, they are applicable in different kinds of bioreactors and biosensors.
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Abstract
Nanoparticle-based drug delivery systems have gained immense popularity due to their
ability to overcome biological  barriers,  effectively deliver drugs,  and preferentially
target  tissue.  In  this  chapter,  the  current  progresses  and  challenges,  especially
evaluation methods for nanodrugs in antitumor drug delivery systems, are summar‐
ized,  citing our works targeted at  cancer therapy.  It  includes four parts.  First,  the
principle,  advantages,  and significance of nanoparticle-based tumor targeting drug
delivery  system  are  presented.  Recent  developments  in  nanoparticle-based  tumor
targeting  drug  delivery  system  including  passive  targeting,  active  targeting,  and
stimuli-responsive systems/triggered release are introduced. Second, current formula‐
tions of nanoparticle-based drug delivery systems are described, including lipid-based,
polymeric and branched polymeric,  metal-based, magnetic,  and mesoporous silica.
Third, analytical techniques used for evaluating nanodrugs in vitro  and in vivo  are
emphatically described. Finally, disadvantages and challenges of nanodrug are also
discussed.
Keywords: nanoparticle, nanomicelle, tumor targeting, biological evaluation, nano‐
carrier, nanodrug, controlled-release, drug delivery system
1. Introduction
The last decade has witnessed enormous advances in the development and application of
nanotechnology in cancer detection, diagnosis, and therapy. A nanoparticle as per the National
Institutes of Health (NIH) guidelines is any material that is used in the formulation of a drug
resulting in a final product smaller than 1 micron in size. This chapter summarizes current
progresses and challenges, especially evaluation method for nanodrug in antitumor drug
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delivery systems, citing our works targeted at cancer therapy. This chapter mainly consists of
four parts. The first part presents the principle, advantages, and significance of nanoparticle-
based tumor targeting drug delivery system, including passive targeting, active targeting, and
stimuli-responsive systems/triggered release. The second part introduces the formulations of
nanocarriers, with emphases laid on lipid-based, polymeric and branched polymeric, metal-
based, and mesoporous silica. Some nanodrug carriers designed by us are introduced in this
part.  They  are  active  targeting  and  acid-responsible  nanoparticles,  novel  copolymers,
multifunctional acid-sensitive micelle,  and tumor microenvironment multiple responsible
nanodrug  release  system.  The  third  part  introduces  analytical  techniques  used  for  the
characterization of nanoparticles in vitro and in vivo, such as dynamic light scattering (DLS),
transmission electron microscope (TEM), scanning electronic microscopy (SEM), NMR, FTIR,
and UV-Vis were commonly used to characterize the nanodrugs. Techniques for cell biolo‐
gy, such as TEM, confocal microscopy, flow cytometry, Western blot, and immunohistochem‐
istry (IHC), were employed to evaluate target ability of nanodrugs in vitro. In vivo imaging
system, micro-CT, NMR, and drug biodistribution were used to assess the in vivo behavior
and  efficacy  of  nanodrugs.  Finally,  disadvantages  and  challenges  of  nanodrug  are  dis‐
cussed.  So far,  there  are  so  many papers  but  so  few nanodrugs in  cancer  therapy.  The
uncertainty and limitation of nanodrugs in pharmacology, toxicology, immunology, large-
scale  manufacturing,  quality  standard  setting,  and regulatory  issues  make  nanoparticle-
based tumor targeting delivery system have a long way to go.
2. Construction of nanoparticle-based tumor targeting drug delivery
systems and their targeting functionalities
2.1. Definition of nanoparticle-based drug delivery system and classification of targeting
functionalities
Increasing demand for and awareness of the applications of nanotechnology in medicine has
resulted in the emergence of a new fast-growing multidisciplinary area—nanomedicine.
Nanoparticles (NPs) serve as promising delivery system for various cargos such as drugs.
Drugs are incorporated in nanoparticles that have the ability to get through physiological
barriers and access the whole systemic circulation and thus are cleared less rapidly than free
drug.
Nanoparticle-based drug delivery system represents an opportunity to achieve sophisticated
targeting strategies and multi-functionality. They can increase the antitumor efficacy of
conventional chemo-therapeutics, decrease their systemic toxicity, prolong duration time in
systemic circulation, also present the following advantages, (1) help to overcome problems of
solubility and chemical stability of anti-cancer drugs; (2) protect anti-cancer drug from
biodegradation or excretion; (3) help to improve distribution of chemo therapeutics; (4)
designed to release their payload response to biological triggers; and (5) may decrease
resistance of tumors against anti-cancer drugs.
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Therefore, targeted delivery is of utmost importance in order to overcome current limitations
in cancer therapy. Recent developments in nanoparticle-based tumor targeting drug delivery
system could be concluded in four aspects, passive targeting, active targeting, and stimuli-
responsive systems/triggered release.
2.2. Passive targeting
Passive targeting is realized by specific porous loose structure of tumor vessels, which is easier
for nanoparticles to accumulate. This leaky cascularization is the so-called EPR effect (en‐
hanced permeability and retention effect), which allows migration of macromolecules up to
400 nm into tumor site [1–5]. For example, pegylated liposomal doxorubicin (Doxil®/Caelyx®)
and nab-paclitaxel (Abraxane®) are the first generation nanomedicine based on passive
targeting [6]. Numerous macromolecules and nanocarriers have shown to accumulate in tumor
via the passive targeting owing to the EPR effect [7, 8]. EPR-based chemotherapy is thus
becoming an important strategy to improve the delivery of therapeutic agents to tumors for
anticancer drug development, and macromolecular agents are potentially usefully for not only
cancer therapy, but for cancer diagnosis and imaging [9]. Although passive targeting ap‐
proaches form the basis of clinical therapy, they suffer from several limitations. Not all the
tumors exhibit EPR effects, and the permeability of vessels may not be the same throughout a
single tumor [10, 11]. For example, Kaposi sarcoma with fenestrated vasculature, nanomedi‐
cine therapeutics could passive target into tumors without any specific ligand attached to the
surface of the nanocarrier. However, heterogeneity of the tumor, such as different hypoxic
gradient, can severely impact on the efficacy of passive targeting delivery. Moreover, increased
interstitial fluid pressure (IFP) is another limitation of passive targeting, which reduces
convective transport, while the dense extracellular matrix hinders diffusion [12]. Finally,
though passive targeting could be used for delivering nanomedicine to certain solid tumor, it
does not prevent accumulation of nanocarriers in some organs with fenestrated endothelium,
for example, the liver and spleen [13].
Therefore, the development of nanomedicine drugs with active targeting functionalities is
certainly warranted. One way to increase the targeting efficacy of nanoparticle-based drug
delivery systems is to attach affinity ligands, such as antibodies [14], peptides [15], aptamers
[16] or small molecules such as folic acid and carbohydrates onto the surface.
2.3. Active targeting
Passive targeting allows for the efficient localization of nanoparticles within the tumor
microenvironment. Active targeting facilitates the active uptake of nanoparticles by the tumor
cells themselves. Nanoparticle-based drug delivery systems decorated with specific targeting
ligands will recognize and bind to target cells and then enter the cells through receptor
mediated endocytosis. In order to achieve high specificity, those receptors should be highly
expressed on tumor cells, but not on normal cells. In our previous studies, folic acid [17], LHRH
[18], HAb18 F(ab′)2 [19] and monoclonal antibody [14] have been conjugated on the nanopar‐
ticles surface to enhance their targeting efficacy. The active targeting nanoparticles first specific
bind to the receptor on the cell surface, then get internalized in small concave formed on the
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cell membrane. Small concave closed the opening to form endocytic vesicle, then early
endosome. The newly formed endosome is transferred to specific organelles, and drugs could
be released by acidic pH or enzymes [20–22]. This endocytosis procedure was also confirmed
in our recent research [14], which was illustrated by the schematic below (Figure 1).
Figure 1. Illustrative schematic representing the endocytosis procedure of the SiO2@AuNP delivery system after bind‐
ing to cell surface targets. Followed by escaping from the endosomes/lysosomes, the drugs were sequentially released
in cytoplasm to eliminate cancer cells. Confocal microscopy and TEM were introduced to testify the endocytosis and
endosomal escape procedure of SiO2@AuNP [14].
Among the potential targets for mAb-mediated nanoparticle delivery, human epidermal
growth factor receptor 2 (HER2) [23], epidermal growth factor receptor (EGFR) [24], transferrin
receptor (TfR) [25], and prostate-specific membrane antigen (PSMA) [26] have been extensively
investigated. Over the last several years, aptamers have quickly become a new class of
targeting ligands for drug delivery applications. Aptamer-based delivery systems of chemo‐
therapy drugs (e.g., doxorubicin, docetaxel, daunorubicin, and cisplatin), toxins (e.g., gelonin
and various photodynamic therapy agents), and a variety of small interfering RNAs were well
established during past years [27]. Small molecules such as folic acid were also been widely
used due to its inherent properties, which confer distinctive advantages and make it suitable
ligand for nanoparticle targeting [28].
Furthermore, active targeting of nanocarriers has shown the potential to suppress multidrug
resistance (MDR) via bypassing of P-glycoprotein-mediated drug efflux [29].
Although active targeting delivery systems looks promising, no one was currently approved
for clinical use. Moreover, nanodrugs currently under clinical development lack specific
targeting.
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2.4. Stimuli-responsive systems/triggered release
Although passive and active targeting has been widely investigated, it still cannot guarantee
sufficient high drug concentration in tumor site to achieve the complete eradication of tumors.
Sufficient and sustained therapy is on the demand of controlled and sustained release of
chemotherapeutics in tumor site. Therefore, it is highly desirable to design stimuli-responsive
controlled drug delivery systems (CDDSs), which could release drugs by responding to tumor
cell environmental changes, such as pH, temperature, glucose, adenosine-5′-triphosphate
(ATP), glutathione (GSH), and H2O2 [30].
Among these stimuli, change in acidity as an internal signal is particularly crucial for the
development of CDDSs that facilitate tumor targeting. Compared to the extracellular pH of
normal tissues at pH 7.4, the measured tumor extracellular pH (pHe) values of most solid
tumors range from pH 6.5 to 7.2. Moreover, changes in pH are also encountered once the
CDDSs enter cells via endocytosis where pH can drop as low as 5.0–6.0 in endosomes and 4.0–
5.0 in lysosomes. The pH gradient is caused by hypoxia that upregulates glycolysis, followed
by the production of lactate and protons in extracellular microenvironments [31]. pH-sensitive
CDDSs can be used for delivering anti-cancer drugs to specific cancer cells, enhancing cellular
internalization and rapid intracellular drug release. In order to increase the targeting activity,
ligand-modified pH-sensitive CDDSs have been used for tumor targeting [32, 33]. In our
previous study, many efforts have been made on several systems based on pH sensitive drug
release characteristics. For instance, (1) pyrrolidinedithiocarbamate (PDTC) and doxorubicin
Figure 2. Schematic of targeting approaches and drug release procedures of LHRH-PEG-PHIS-Dox/Dox-TAT mixed
micelles [18].
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(DOX) was codelivered by copolymer folate-chitosan (FA-CS) nanoparticles to achieve
targeted drug delivery, stimuli sensitive drug release, and to overcome multidrug resistance
(MDR). (2) A novel delivery system based on LHRH-PEG-PHIS-Dox/Dox-TAT acid-sensitive
micelles was developed, as shown in Figure 2. Such system could dissociate when responding
tumor extracellular pHe and release Dox-TAT. This system showed remarkable antitumor
efficacy and negligible systematic toxicity.
Higher concentration of GSH tripeptides is another important internal stimulus for rapid
destabilization of CDDSs inside cells to accomplish rapid intracellular release [34]. The
intracellular GSH concentration (1–10 mM) is substantially higher than extracellular levels
(2 μM in plasma), providing a mechanism for selective intracellular release [35]. Gold nano‐
particles were widely used for design GSH-triggered drug delivery systems. Its surface
monolayer is stable under most physiological conditions, thus providing a reservoir of
hydrophobic drugs, yet allowing controlled release by GSH though place exchange reactions
of thiols on gold nanoparticle surfaces. These Au nanoparticles systems, which are under
intensive study, display very intriguing properties, such as the precise control of intracellular
drug release triggered by GSH. However, despite their great potential, additional investiga‐
tions will be required to fully understand their pharmacokinetics, their interactions with the
immune system, and the extent of cytotoxicity due to the surface and the geometry of the gold
nanoparticles. Our research also focused on GSH-mediated drug release, such as siRNA [14]
(Figure 3) and miR-218 mimics [36] (Figure 4) release from AuCOOH. After endocytosis,
mediated by mAb198.3, the siRNA release process was illustrated by Figure 3. siRNA was
released by the place exchange of glutathione (GSH) [37], and different band shifts on the
denatured polyacrylamide gel page demonstrated the process of GSH-triggered siRNA
release. In the research based on FA-CS@AuCOOH nanoparticles, temozolomide was released
by diffusion due to FA-CS nanogel swelling, followed by miR-218 mimics was released by
place exchange of GSH in tumor cells, which was illustrated in Figure 4. The sequential release
of both chemo-drug and bio-drug exhibited significant synergistic effect against U87MG
glioblastoma cells.
Figure 3. siRNA release procedure of outer AuNP layer. Schematic illustration of siRNA release procedures via GSH
place exchange (A), confirmed by denatured SDS page (B) [14].
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Figure 4. Schematic of drug design and drug release schedule. GSH mediated miR-218 mimics release from AuNP was
emphasis by blue box [36].
Temperature is also a typical trigger at the tumor site, which could be exploited for drug
delivery systems design [37, 38]. Thermo-responsive drug delivery is among the most
investigated stimuli-responsive strategies. Usually, thermo-responsive nanocarriers were
governed by a nonlinear sharp change with temperature, following by the release of the drug
response to the temperature change. Ideally, thermo-responsive drug delivery systems should
stay stable at body temperature (37°C) and rapidly release the payload within a locally heated
tumor (40–42°C) to counteract rapid blood-passage time and washout from the tumor [38].
Poly(N-isopropyl acrylamide), PNIPAM was one of the most widely investigated thermo-
sensitive materials, which exhibit a lower critical solution temperature. When surrounding
temperature is above its LCST, the PNIPAM nanocarriers will shrink and push out the payload.
For liposomes, thermos responsiveness usually arises from a phase transition of the constituent
lipids and the associated conformational variations in the lipid bilayers [38, 39]. Thermo-
responsive nanoparticle drug delivery systems typically present a lower critical solution
temperature (LCST) at which they undergo coil-to-globule phase transitions. Thermo-sensitive
liposomes usually composed of polymers with low LCST, which attached to lipid membranes
due to hydrophobic interactions. The liposomes shrink to dehydrate and collapse, when the
temperature achieve LCST, promoting drug release. By adjusting monomers types and ratio,
polymer LCST can be tuned to different values, which could be used for controlling drug
release at different environments [39].
ATP is a new member of physiological triggers to achieve “on-demand” therapeutic delivery
with several merits, for example, high intracellular ATP concentration and sharp concentration
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contrast between intracellular and extracellular environment make ATP a robust trigger signal
to reduce premature drug release before cellular uptake and enhance intracellular accumula‐
tion of drugs [40]. ATP-triggered drug release system provides a more sophisticated drug
delivery system, which can differentiate ATP levels to facilitate the selective release of drugs.
Polymeric nanocarriers functionalized with an ATP-binding aptamer-incorporated DNA
motif can selectively release the intercalating doxorubicin via a conformational switch when
in an ATP-rich environment [41]. However, since the ATP binding modules are basically DNA
or protein, potential concerns for immunogenicity from the components need to be addressed
before clinical translations.
Glucose-responsive nanoparticles were widely investigated for insulin delivery [42]. Glucose
nanosensors are being incorporated to precise and accurate tracking blood glucose levels. Also,
they provide the guide for glucose-responsive nanoparticles which better mimic the body’s
demand for insulin. Besides, glucose-sensitive self-assembly is relevant for the application of
anticancer therapeutic drug delivery. Since cancer cells metabolize differently than normal
cells, glucose accumulate faster in tumor site than normal tissues and circulation [43–45].
Accumulation of glucose analogue 18fluoro-2-deoxy-d-glucose (18FDG) is 3.3–4.7 times greater
for tumor than normal liver [46, 47]. A novel approach for glucose-triggered anticancer drug
delivery from the self-assembly of neutral poly (vinyl alcohol) (PVA), and chitosan was been
investigated by Satish Patil research group. This system could release glucose controllable by
disintegration of layer by layer polymers. The capsules size and shape can be tuned because
of physically cross-linked PVA hydrogel inside the multilayer. Because of the presence of
borate in multilayer wall, the encapsulated drugs could be release programmable by different
glucose concentration. The borate mediated self-assembly of PVA hydrogel and chitosan
provide promising platform for intelligent anti-cancer drug delivery. The in vivo studies are
under going in their laboratory [48].
Reactive oxygen species (ROS) play important roles in a variety of physiological and patho‐
physiological processes [49]. Moreover, many types of cancer cells exhibit high level of ROS
stress [50]. An increase of H2O2 at cellular levels characteristic for cancer cells, which is a major
component of ROS and a common marker for oxidative stress, plays a key role in carcinogen‐
esis [51]. Thus, intracellular H2O2 in cancer cells was utilized as tumor site stimulus for drug
delivery in cancer therapy. Synergistic release of anticancer drugs and O2 can be achieved in
an H2O2-responsive nanocarrier incorporated with catalase. Such a system demonstrated
improved therapeutic efficacy against cisplatin resistant cell lines which often appear to be in
hypoxia [52]. However, the most challenging problem for engineering ROS-controlled-release
systems is to improve the responsive sensitivity to ROS species, because of low concentration
and very short half-lives in most cellular. Although there are increasing number of ROS-
controlled release systems have been reported, development of highly sensitive nanocarriers
which are specifically responsive to physiological levels of ROS are highly desired.
Till now, no optimized targeting drug delivery platform has been announced. Each has its own
advantages and flaws, even for those under preclinical or clinical testing. It might be possible
that the combination sequential drug delivery system design could be more effective to precise
drug delivery, paving the way for a more effective personalized therapy.
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3. Nanoparticlated formulation-based drug delivery systems
What is such drug delivery systems composed of? Currently, many formulations of nanocar‐
riers are utilized including lipid-based, polymeric and branched polymeric, metal-based, and
mesoporous silica.
3.1. Lipid-based nanocarriers
The formulation of lipid-based nanomedicines against cancer has been hypothesized to
improve drug localization into the tumor tissue and to increase the anticancer efficacy of
conventional drugs, while minimizing their systemic adverse effects [53]. An ideal multifunc‐
tional lipid-based nanoparticle drug delivery system with targeting and triggering drug
release functions should be composed of a matrix phospholipid, a destabilizing phospholipid,
conjugation lipid, ligand attached, and a cell death marker. Chemotherapeutics and imaging
agents were loaded in nanoparticles in aqueous phase [54]. Among various lipid-based
formulations, classical examples are “liposomes,” which primarily consist of phospholipids
(major components of biological membranes) and have been extensively studied [55]. Prof.
A.D. Bangham of the United Kingdom first published preparation of liposomes with entrap‐
ped solutes. Then, many scientists present a well-studied class of drug carriers generally
characterized by the presence of a lipid bilayer that is primarily composed of amphipathic
phospholipids [54].
3.2. Polymeric and branched polymeric nanocarriers
Polymer-based nanomedicine for improvement in efficacy of cancer therapeutics has been
widely explored, including polymeric nanoparticles, polymer micelles, dendrimers, polymer‐
somes, polyplexes, polymer-lipid hybrid systems, and polymer-drug/protein conjugates.
Polymeric nanoparticles are defined by their morphology and composition. The therapeutic
agent is either conjugated to the nanoparticles surface, or encapsulated and protected inside
the polymeric core [56]. These polymeric nanoparticles are capable of loading wide range of
drugs for a sustained or controlled release at tumor sites to provide enhanced antitumor
efficacy with minimal systemic side effects. Also, these nanoparticles protect drugs from their
rapid metabolism during systemic circulation and clearance by the liver, kidney, and reticu‐
loendothelial system, which further improves drug’s stability and target specificity [3, 57]. In
recent years, major branch of our research was based on multifunctional poly(β-L-malic acid)-
based nanoconjugates [18]. This nanoconjugate with a pH-dependent charge conversional
characteristic was developed for tumor-specific drug delivery. As shown in Figure 5, nano‐
conjugates minimize nonspecific interactions with serum components and change the surface
charge of nanoconjugates in response to the tumor acidity (pHe), leading to promoted cell
internalization by the combination of electrostatic absorptive endocytosis and receptor-
mediated endocytosis.
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Figure 5. Schematic illustration of the stealth property and promoted tumor cell uptake of nanoconjugates (A) and
DOX-loaded nanoconjugates (DOX/HDPEPM) (B). DMA, 2,3-dimethylmaleic anhydride; DOX, doxorubicin;
HDPEPM, nanoconjugate formed by covalent attachment of fragment HAb18 F(ab′)2 and 2,3-dimethylmaleic anhy‐
dride to polyethylenimine-modified poly(β-L-malic acid); PEI, polyethylenimine; PMLA, poly(β-L-malic acid) [19].
3.3. Metal-based nanocarriers
Metal-based inorganic nanoparticles with monodispersity have been extensively studied for
imaging using magnetic resonance and high-resolution superconducting quantum interfer‐
ence devices for cancer therapy [58]. Among all inorganic nanoparticles, gold nanoparticles
were mostly explored for anti-tumor therapeutics delivery, due to its surface properties, strong
affinity to thiol and amine functionalities and relative non-toxic nature [59]. Gold nanoparticles
have been used mostly as a probe for electron microscopy and as a delivery vehicle for
biomolecules. Also, super paramagnetic iron oxide nanoparticles (SPION) and gadolinium
chelates are gaining interest as MRI agents [60]. Magnetic nanoparticles (MNPs) are also
gaining clinical importance as MRI contrast materials, such as ferumoxides and ferumoxtran;
approved by the FDA for detecting solid tumors [61]. Gadolinium-conjugated TiO2-DNA
oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-
weighted contrast enhancement in magnetic resonance images. Moreover, the increased
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retention time, Gd accumulation, and intracellular delivery may find its use in Gd neutron-
capture cancer therapy [62]. Silver and platinum nanoparticles are also used for therapeutics
delivery applications. Scientists at UC Santa Barbara presented a class of AgNPs that are
exceptionally bright and photostable, carry peptides as model targeting ligands, can be etched
rapidly and with minimal toxicity in mice, and that show tumor uptake in vivo [63]. These
results illustrate how plasmonic nanoprobes based on etchable Ag cores will be a powerful
tool in studies of targeted uptake and trafficking from a subcellular to tissue level. Nanopar‐
ticles built from platinum cross-linker present a novel platform for anti-tumor drug delivery.
As novel cross-linker, platinum Pt (IV) diester derivative agglomerates PEG-based brush-arm
star polymers (BASPs) with tunable structures was used for delivery several kinds of antitumor
drug, such as doxorubicin, camptothecin, and cisplatin. The cross-linker disintegrates when
reduced by glutathione, which is abundant inside cells, to release the drugs bound covalently
to the star polymers. This process is well-controlled as the sizes and Pt-loading of the narrowly
dispersed stars is tunable by variables such as brush length and cross-linker loading. Further‐
more, in vitro and in vivo assays demonstrate an efficacy of anticancer activity and low off target
toxicity [64].
3.4. Mesoporous silica–based nanocarriers
Multifunctional mesoporous silica nanoparticles (MSNs) are widely used as universal
platform for drug delivery [65]. Highly attractive features, such as high internal surface area
and pore volume, tunable pore sizes, colloidal stability, and the possibility to specifically
functionalize the inner pore system and/or the external particle surface, make MSNs a
promising and widely applicable platform for diverse biomedical applications including
bioimaging for diagnostics [66], biosensing [67], biocatalysis [68], bone repair and scaffold
engineering [69], and drug delivery [70]. For applications of multifunctional MSNs as drug
delivery systems in future and further advanced in clinical trials, they should be designed with
two different ways. One approach is to build up systems which could release drug response
to stimuli already present in the organism, such as lower pH values and redox potential in
endosomes (for triggered release functions). The other approach would rely on the use of
external triggers (in combination with internal stimuli) to control the drug release behavior,
for example, to release payloads in certain location of tissues or in certain time. Recent studies
focus on the ultimate combination of diagnostic and therapeutic capabilities in the multifunc‐
tional mesoporous nanoparticles, such that the nanocarrier uses diagnostic information to
control or tune its therapeutic actions [65]. Stimuli-free programmable drug release for
combination chemo-therapy has been also investigated by Dr. Fan in our research group. In
her previous work, she demonstrated programmed delivery of both chemotherapeutics and
biodrug with tumor targeting efficacy by introducing SiO2-based self-decomposable nanopar‐
ticles. The programmable drug delivery is realized by adjusting drug loading ratios and
concentration with external stimuli-free characteristics [71]. The present system provides a
simple and feasible system for design targeting and combination chemotherapy with pro‐
grammed drug release (Figure 6).
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Figure 6. Schematic of the SiO2 NP delivery system, its targeting scheme, and sequential drug release process. (a) Drug
design of the mAb198.3-SiO2-Dox/MB NP, (b) Targeting scheme of the NP drug (c) Multi-drug release process in a se‐
quential manner [71].
4. Analytical techniques used for characterization of nanoparticles in
vitro and in vivo
When materials are reduced at nanoscale dimensions, they show unique properties that are
different from their massive counterparts. In order to characterize nanoparticles, their particle
size, size distribution, morphology, composition, surface chemistry, and reactivity are
important factors that need to be defined accurately. These properties make nanomaterials a
suitable carrier for unique sensing applications and, at the same time, they may also create
complications during the characterization process. Choosing the right method for the charac‐
terization of nanoparticles is a challenging task since one should be aware that each technique
has its own limitations. The characterization of nanoparticles is carried out through various
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techniques such as dynamic light scattering (DLS), scanning electron microscopy (SEM),
transmission electron microscopy (TEM), NMR, FTIR, UV-Vis spectroscopy [72]. Techniques
for cell biology, such as TEM, confocal laser scanning microscopy (CLSM), and flow cytometry,
were employed to evaluate target ability of nanodrugs in vitro. In vivo imaging system and
drug biodistribution were used to assess the in vivo behavior and efficacy of nanodrugs.
4.1. Dynamic light scattering (DLS) analysis
The size of nanoparticles is one of the key parameters that influence the interaction between
nanoparticles and cells, which influenced cellular uptake [73, 74]. DLS is the most suitable
technique to determine the particle size of nanoparticles (Figure 7).
Figure 7. Particle size and size distribution of nanoparticles.
DLS is a technique in physics that can be used to determine the size distribution profile of small
particles in suspension or polymers in solution, by measuring the random changes in the
intensity of light scattered based on dynamic Brownian motion of the suspended particle. This
technique is also called photon correlation spectroscopy (PCS) and quasi-elastic light scattering
(QELS). The latter terms are more common in older literature. Typical applications are
emulsions, micelles, polymers, proteins, nanoparticles or colloids. In general, the technique is
best used for submicron particles and can be used to measure particle with sizes less than a
nanometer. In this size regime (microns to nanometers) and for the size measurement (but not
thermodynamics), the distinction between a molecule (such as a protein or macromolecule)
and a particle and even a second liquid phase (such as in an emulsion) becomes blurred.
There are several advantages associated with DLS: simplicity; sensitivity and selectivity to
NPs; short time of measurement; and the fact that calibration is not needed. Therefore, this
technique is increasingly used for nanoparticle characterization in various science and
industry fields [75, 76]. However, some problems are encountered when measuring samples
with larger size distributions or multimodal distributions [77]. If the measured colloid is
monodispersed, the mean diameter of the nanoparticles can be determined using the DLS
technique. For polydispersed colloids, there is a risk during the DLS measurement, as small
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particles can be screened by bigger particles, since bigger particles have more scattering
property .
Some DLS instrument can measure not only particle size, but also Zeta potential at the same
time [78]. Zeta potential is the surface charge of nanoparticles in solution (colloids). Nanopar‐
ticles have a surface charge that attracts a thin layer of ions of opposite charge to the nano‐
particles surface. This double layer of ions travels with the nanoparticle as it diffuses
throughout the solution. The electric potential at the boundary of the double layer is known
as the Zeta potential of the particles and has values that typically range from +100 mV to
−100 mV. Zeta potential is an important tool for understanding the state of the nanoparticle
surface and predicting the long-term stability of the nanoparticle (Figure 8).
Figure 8. Zeta potential of different DOX-loaded nanoconjugates at (A) pH 7.4 and (B) pH 6.8 (n = 5). At pH 7.4, no
charge-conversional behaviors were observed. When the pH was decreased from 7.4 to 6.8, both DOX/DPEPM and
DOX/HDPEPM nanoconjugates showed a significant charge conversion [19].
4.2. Transmission electron microscope (TEM) and scanning electronic microscopy (SEM)
Particle morphology is another important parameter for the characterization of nanoparticles,
and this is achieved with the help of microscopic techniques such as SEM and TEM. Both
techniques produce a resolution that is a thousand times greater than the optical diffraction
limit. SEM uses a beam of high-energy electrons to produce a variety of signals that contain
information about the sample’s surface composition, topography, and other properties such
as electrical conductivity. We can analyze the sample at various times because X-rays generated
by SEM do not lead to a loss of volume of the sample. However, electron microscopy creates
a risk of radiation damage that is caused by the electron beam, which leads to the generation
of free radicals. The diffusion of free radicals and the loss of mass may cause physical damage
to the sample [78]. Also, TEM suffers from the limitations of poor contrast, especially in the
event of peptide/protein nanoparticles and their conjugates. Besides particle morphology,
TEM and SEM could also be used to study the physical size of nanoparticles (Figure 9).
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However, there are some disadvantages associated with TEM and SEM: time consuming, high
operator fatigue, few particles examined.
Figure 9. TEM and SEM micrographs of blank and drug-loaded nanoparticles (a) TEM of blank nanoparticles; (b) TEM
of drug-loaded nanoparticles; (c) SEM of blank nanoparticles; (d) SEM of drug-loaded nanoparticles [79].
4.3. NMR, FTIR, and UV-Vis spectroscopy
NMR, FTIR, and UV-Vis spectroscopies are primary methods for determining the structure of
compounds. They are also used in analyzing the structure of nanoparticles, especially to
confirm the modification of polymer carriers. These are simply done and rapid. They can be
combined to give overlapping information. NMR spectroscopy is one of the most nondestruc‐
tive techniques in elucidating molecular structure as well as understanding the molecular
dynamics of organic, organometallic, inorganic, polymeric, and biological molecules (Figure
10). It can be also used in nanoparticle size determination and nanoparticle surface study [80,
81]. IR spectra can be used to provide information on the functional groups as well as the
structure of a molecule as a whole. UV-Vis spectra have broad features that could provide only
limited information of structure but very useful for quantitative measurements.
Figure 10. 1H NMR spectra of (a) PMLA, (b) PEI-PMLA (PEPM), (c) DOX/PEPM, and (d)DOX/DPEPM. DMSO was
used as the solvent [19].
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The ability to enter target cell efficiently is a key character of nanoparticles. Techniques for cell
biology, such as confocal microscopy, flow cytometry, were employed to evaluate target ability
of nanodrugs in vitro.
4.4. Confocal laser scanning microscopy (CLSM)
CLSM is a technique for obtaining high-resolution optical images with depth selectivity. The
key feature of CLSM is its ability to acquire the in-focus images from selected depths, a process
known as optical sectioning. It could be used to observe the cellular uptake of fluorescence
labeled nanoparticles, as well as nanoparticles-cell interaction (Figure 11).
Figure 11. Confocal images of Colo 205 cells incubated with AuCOOH(Cy5)_isotype (negative control) and Au‐
COOH(Cy5)_mAb198.3 and nucleus stained with DAPI. Incubated time: 15 min, 30 min and 4 h. (Blue fluorescence is
associated with DAPI, and red fluorescence is associated with Cy5). Scale bar at 20 μm [36].
4.5. Flow cytometry
Flow cytometry is a laser-based, biophysical technology employed in cell counting, cell sorting,
biomarker detection, and protein engineering, by suspending cells in a stream of fluid and
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passing them by an electronic detection apparatus. It is extensively used in research for the
cell apoptosis and fluorescence quantitative analysis of nanoparticles to evaluate its targeting
efficacy (Figure 12).
Figure 12. FACS analysis of A2780/DoxR cells incubated for 1 h at 37°C with untreated cell as control (A, E), LHRH-
PEG-PHIS-Dox/Dox-TAT (B, F), LHRH-PEG-PHIS-Dox/Dox (C, G) and LHRH-PEG-PHIS-Dox (D, H) at pH 7.4 or pH
6.8, respectively [18].
4.6. In vivo imaging system
The ability of nanoparticles to achieve high, local concentrations of drugs at a target site
provides the opportunity for improved system performance and patient outcomes along with
reduced systemic dosing. Current technologies for tumor imaging, such as in vivo imaging
system, are able to yield high-resolution images for the assessment of nanoparticles uptake in
tumors at the microscopic level; a microscopic visual representation of a biological component
inside the body [82]. The imaging procedure often utilizes a variety of diagnostic tools to
provide insight regarding disease states, molecular characterization, and biological processes
(Figure 13).
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Figure 13. In vivo imaging of Colo 205 tumor bearing mice. Fluorescent signal captured by IVIS Lumina Imaging Sys‐
tem in tumor bearing mice after injection with AuCOOH(Cy5)_ mAb198.3 (a), AuCOOH(Cy5)_ isotype (b), and
mAb198.3_Cy5 (c) for 24 h. Luminescent image of resected organs from Colo 205 tumor-bearing mouse injected with
AuCOOH(Cy5)_ mAb198.3 (d), AuCOOH(Cy5)_ isotype (e), and mAb198.3_Cy5 (f) for 24 h [36].
4.7. Drug biodistribution analysis
Another method to assess the in vivo behavior and efficacy of nanodrugs is drug biodistribution
analysis. This is a method of tracking where drugs of interest travel in an experimental animal
or human subject by the determination of drug concentration in targeted site and other organs.
5. Disadvantages and challenges of nanodrug
Nanodrug since its emergence has proved to be promising novel drug delivery system. In
recent years, great progress was achieved in making drugs owning the characteristics of
targeted and controlled release via nanotechnologies. However, there are some challenges in
the use of large size materials in drug delivery. Some of these challenges are poor targeting
and therapeutic effects, sustained and targeted delivery to site of action, poor bioavailability,
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generalized side effects, in vivo stability, intestinal absorption, and plasma fluctuations of drugs
[83]. Taking the active targeting strategy as an example, it is not always as effective as expected.
The main mechanism behind active targeting is the recognition of the ligand by its target
substrate. But because of the heterogeneity of tumor cells, receptors on the surface of tumor
cells are different from cell to cell. Therefore, the interaction between cell receptors and ligands
linked to nanoparticles becomes unreliable, which the nanoparticles was relied on to enter into
the cell. This results in poor targeting and therapeutic effects in some cases [84]. Besides,
distribution through the tumor is severely limited by its relatively large size which slows
diffusion and may become trapped in the ECM. Other obstacles with nanocarriers that must
be concerned include complicated synthesis, in vivo aggregation and recognition by the
reticuloendothelial system leading to high clearance. This is further complicated when the
therapeutic is covalently attached to the drug carrier as in the case of many polymers. Finally,
most studies are at the basic research stage at present. Since it was unknown about environ‐
mental influence and genetic effect of novel nanomaterials, much works and a long process
for acceptance by public were needed for more nanodrugs to be used in clinic.
To reach the promise of nanodrugs, it is necessary to take a step back and look at the problems
facing drug delivery as a whole rather than designing around only one or two obstacles.
Incremental designs may not be sufficient to accomplish the task of treating cancer effectively.
Instead, a revolution in concept is needed. Nanodrug delivery system with simple synthesis
routes and high targeting/therapeutic efficacy may point the way out.
So far, there are so many publications but so few nanodrugs in cancer therapy [85]. The
uncertainty and limitation of nanodrugs in pharmacology, toxicology, immunology, large-
scale manufacturing, and regulatory issues make it become an important research field in
nanoparticle-based tumor targeting delivery system. And how we can overcome these
difficulties, it is a long way to go.
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Abstract
Vaccination, one of the most effective strategies to prevent infectious diseases, is the
administration of antigenic materials to stimulate an individual’s immune system to
develop adaptive immunity to a specific pathogen. Though it is so advantageous for
diseases control and prevention, vaccines still have some limitations. Nanotechnology is
an approach to prepare a novel biomedicine vaccine with the vaccine consumption and
side effects significantly decreased. Regulation is the most important criterion for the
development of nanovaccines. All marketing products have to meet the requirement of
regulation. The fast-track designation potentially aids in the development and expe‐
dites the review of nanovaccines that show promises in an unmet medical need. Here,
some successful nanovaccine products are introduced—Inflexal® V, Epaxal®, GardasilTM,
and CervarixTM have been widely used for the clinical applications, which are delivered
either in the form of virosomes or virus-like particles. Vaccines based on nanotechnolo‐
gy may overcome their original disadvantages and lead to the development of painless,
safer, and more effective products.
Keywords: biomedicine, clinical application, fast track, nanotechnology, vaccine
1. Introduction
The terms vaccine and vaccination, derived from Variolae vaccinae (smallpox of the cow), were
devised by Edward Jenner to denote cowpox. Edward Jenner was an English doctor and
scientist who was the pioneer of smallpox vaccine, the first vaccine in the world. In 1796, Jenner
took pus from the hand of a milkmaid with cowpox and scratched it into the arm of an 8-year-
old boy. Six weeks later, he inoculated the boy with smallpox, afterwards observing that he
did not catch smallpox and no diseases followed [1, 2]. The boy was further challenged with
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
various materials and again showed no signs and symptoms. In 1798, Jenner extended his
studies and reported that his vaccine was safe and could be transferred from arm-to-arm to
reduce dependence on uncertain supplies from infected cows [3]. In the 1880s, the second
generation of vaccines was introduced by Louis Pasteur who developed vaccines for chick‐
en cholera and anthrax [4]. In 1881, to honor Jenner, Louis Pasteur proposed that the terms
should be extended to cover the new protective inoculations then being developed [4]. From
the late nineteenth century,  vaccines were considered a matter  of  national  prestige,  and
vaccination is a compulsory policy in many countries [5]. In the twentieth century, several
successful vaccines were introduced such as those against diphtheria, measles, mumps, and
Type Definition Example
Inactivated Virulent microbes are previously
destroyed with chemicals, heat,
radiation, or antibiotics
Influenza vaccine, whole cell pertussis
vaccine, cholera vaccine, hepatitis A vaccine,
rabies vaccine, plague vaccine, inactivated
polio vaccine (IPV)
Attenuated Live microbes are cultivated under
conditions to disable their virulence,
or closely related but less dangerous
microbes are used to induce broad
immune responses
Yellow fever vaccine, shingles vaccine,
measles, mumps and rubella (MMR) vaccine, (1)typhoid
(Ty21a) vaccine, BCG vaccine, rotavirus vaccine,
live attenuated influenza vaccine (LAIV),
oral polio vaccine (OPV)
Toxoid Vaccines are made from inactivated
toxic compounds that cause illness
rather than microbes
Tetanus toxoid, diphtheria toxoid
Subunit Protein-based vaccine: A fragment of
protein creates an immune response,
rather than introducing inactivated
or attenuated microbes to an immune
system.




is covalently attached to a






pathogens have poorly immunogenic
polysaccharide outer coats. The
immune system recognizes the
polysaccharide as if it were a
protein antigen by linking
these outer coats to proteins
Haemophilus influenzae
type b (Hib) vaccine, (3)pneumococcus
vaccine, (4)meningococcus vaccine
Table 1. The major types of vaccines in the clinical application represent different strategies used to reduce the risk of
illness, while retaining the ability to induce beneficial immune responses.
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rubella.  During  this  period,  the  development  of  the  polio  vaccine  in  the  1950s  and the
eradication of smallpox around 1960s–1970s are great achievements. As vaccines had already
become more common, many people began taking them for granted.
A vaccine, an antigenic material, is a biological preparation that provides adaptive immuni‐
ty to a specific disease. The agent triggers immune responses to recognize the disease-causing
agent to destroy and remember it, so that the immune system can immediately recognize and
destroy the foreign agent once it invades into the body later. Inactivated microbes live
attenuated microbes, toxoids, subunits, or conjugates have been manufactured as vaccines and
employed to stimulate adaptive immune responses (Table 1). A monovalent (univalent)
vaccine is designed to immunize against a single antigen or microorganism such as measles
vaccine, while a multivalent (polyvalent) vaccine is designed to immunize against more than
one strain of the same microorganism or against more than one microorganism such as oral
polio vaccine (OPV), three in one (e.g., diphtheria-tetanus-pertussis, DTP) vaccine, etc.
Heterologous vaccines are pathogens of other animals that do not cause diseases or only cause
mild diseases in the organism being treated, such as the cowpox vaccine and the Bacillus
Calmette-Guérin (BCG) vaccine.
(1) Two types of typhoid vaccines are available: typhoid (Ty21a) vaccine (a live, attenuated
vaccine given by mouth) and typhoid (Vi) vaccine (a subunit vaccine given by injection). (2)
Current hepatitis B vaccine and human papillomavirus (HPV) vaccine may be produced by
recombinant DNA technology; therefore, they are sometimes called recombinant vaccines. (3)
Two types of pneumococcus vaccines given by injection are available: pneumococcal polysac‐
charide vaccine (PPSV) and pneumococcal conjugate vaccine (PCV). (4) Two types of menin‐
gococcus vaccines given by injection are available: meningococcal polysaccharide vaccine
(MPSV) and meningococcal conjugate vaccine (MCV).
It is well-known that prevention is better than cure for diseases control. Vaccination is the best
approach to prevent infectious diseases ahead of the incidence of diseases. Vaccination can
prevent or ameliorate morbidity from infection and result in herd immunity when a high
percentage of population has been vaccinated. For the past centuries, some diseases are
globally eradicated such as smallpox; some diseases are significantly controlled in much of the
world such as polio, measles, and tetanus through vaccines distribution. The effectiveness of
vaccination has been widely studied and verified such as the influenza vaccine [6], HPV
(Human papillomavirus) vaccine [7], and the shingles (chicken pox) vaccine [8], etc. In 2012,
the World Health Organization (WHO) reports that licensed vaccines are currently available
to contribute to the prevention and control of 25 infections. From the discovery of the related
pathogens, 25 infection have been effectively prevented using licensed vaccines; however,
vaccines remain elusive for many important diseases, such as the infections of Zika viruses,
cytomegaloviruses (CMV), hepatitis C viruses (HCV), Human immunodeficiency viruses
(HIV), severe acute respiratory syndrome (SARS) viruses, Ebola viruses, respiratory syncy‐
tial viruses (RSV), and malaria parasites Plasmodium, etc. (Figure 1). A vaccine is not only
conventionally prophylactic, hinting to prevent or alleviate the effects of a future infection, but
also may be therapeutic, vaccines against cancers are being investigated in recent research such
Nanotechnologies Applied in Biomedical Vaccines
http://dx.doi.org/10.5772/63453
87
as the HPV vaccine for cervical cancer, the BCG vaccine for bladder cancer [9] and colorectal
cancer [10].
Figure 1. Time line for the development of vaccines: 25 infections (  yellow column) have been reported by WHO
being prevented using licensed vaccines. However, some infections under research have no effective vaccines available
yet (  blank arrow column). *Varicella and herpes zoster: Varicella (chicken pox) and herpes zoster (shingles) are
diseases caused by varicella-zoster viruses (VZV) (one of the eight herpesviruses known to infect humans and verte‐
brates). **Influenza: A new version of the influenza vaccine is usually developed twice a year, because influenza virus‐
es mutate rapidly. ***Tuberculosis (TB): The Bacillus Calmette-Guérin (BCG) vaccine was originally developed from
Mycobacterium bovis found in cows; therefore, its efficacy against pulmonary TB appears to be variable in humans.
Abbreviations: Hepatitis (Hep.); Human papillomavirus (HPV); Human immunodeficiency virus (HIV); Japanese en‐
cephalitis (JE); Severe acute respiratory syndrome (SARS); Yellow fever (YF).
Vaccines have not only successfully reduced the incidence rate of many devastating diseases
to be always low but also prevented many infectious diseases from persistently bursting out.
At present, only few people have ever experienced the detrimental effects of many illnesses.
The two main advantages of vaccination are noted as follows:
1. Prevention in advance
Vaccination can result in lower morbidity and mortality rate as well as faster recovery
even though a partial, late, or weak immunity may only alleviate an infection. The early
protective efficacy of vaccination is primarily conferred by the induction of antigen-
specific antibodies. Vaccination can trigger adaptive immunity before contacting with the
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pathogen. Should a pathogen infect the body, there is no illness in that the immune
responses stimulated by vaccines continuously guard against the disease. The quality of
such antibody responses (avidity: a measure of the overall strength of an antigen–antibody
complex) has been identified as a determining factor of vaccines efficacy. However, there
is more to antibody-mediated protection than the peak of vaccine-induced antibody titers.
Vaccination stimulates both humoral and cell-mediated immunity of one’s own through‐
out the body. This kind of defensive response is usually safer, more effective and with
fewer side effects (e.g., inflammation, muscle aches, allergy, etc.) due to the active,
acquired and specific immunity is established. Through vaccination, humans can
eliminate or alleviate the attack of pathogens beforehand to avoid the suffering of diseases.
2. Immunity for long term
Vaccination stimulates adaptive immunity to create immunological memory that can
maintain in the body for a long period of time. Therefore, people will be protected from
the attack of diseases as long as these specific memory cells are still in the body. The disease
control or elimination requires the induction of protective immunity in a sufficient
proportion of the population. This is best achieved by vaccination programs capable of
inducing the long term protection (adaptive immunity) that contrasts to the quick but
short-lasting immune responses (innate immunity). Long-term immunity is conferred by
the maintenance of antigen-specific immune effectors and/or by the induction of im‐
mune memory cells that may be efficiently and rapidly reactivated upon subsequent
microbial exposure.
In spite of vaccines’ advantages for diseases control and prevention, three major limitations
related to vaccines are noted as follows:
1. Complex vaccination schedules
The potency of vaccines may not be high enough in receiving immunization only once.
Though the body develops antibodies, protection sometimes is not adequate due to the
development of immunity might be too slow to be effective in time. Furthermore, the
antibodies might not disable the pathogen completely, or there might be multiple strains
of the pathogen, not all of which are equally susceptible to the immune responses. In order
to provide the best protection, additional “booster” shots are often required to achieve
full immunity. Vaccine schedules are usually regulated by the competent authority or
physician groups to achieve maximum effectiveness. A vaccination schedule is a series of
vaccinations, including the timing of all doses, which may be either recommended or
compulsory. Many vaccines require multiple doses for maximum effectiveness, either to
produce sufficient initial immune responses or to boost responses that fade over time.
Over the past two decades, the recommended vaccination schedule has grown rapidly
and become more complex as many new vaccines have been developed.
2. Strict requirements for storage and shipment
Vaccines are temperature sensitive and their storage and shipment are usually restrict‐
ed to cold temperature [11]. Potency can be negatively affected by exposing to extended
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or multiple temperature excursions (out-of-range temperatures). It is essential to have a
label on the storage unit to indicate that vaccines should be stored in the freezer (−20 or
−80°C) or in the refrigerator (2–8°C). Correct cold-chain (a temperature-controlled supply
chain) procedures must be followed during production, warehousing, and transporta‐
tion, that is, vaccines have to be stored properly from the time that they are manufac‐
tured, distributed until administered to the people. Most live, attenuated vaccines tolerate
freezing temperatures, but deteriorate rapidly after being removed from cold tempera‐
ture. Inactivated vaccines will be damaged by exposing to temperature fluctuations. Cold-
chain failure has to be evaluated in addition to routine tests such as potency, sterility,
toxicity, safety, chemical, visual, and pyrogen test.
3. Restricted routes of administration
Most vaccine products are administered by injection such as intramuscular (IM), subcu‐
taneous (SC), and intradermal (ID) injection, though some can be given by oral adminis‐
tration or intranasal spray. IM injection administers the vaccine into the muscle mass.
Vaccines containing adjuvants should be injected into muscle to reduce adverse local
effects. SC injection administers the vaccine into the subcutaneous layer above the muscle
and below the skin. ID injection administers the vaccine in the topmost (dermis) layer of
the skin. BCG is the known vaccine with ID injection; this route reduces the risk of
neurovascular injury. The professional person’s assistance is usually required for the
injection administration. Oral administration vaccines (e.g., OPV and rotavirus vaccine)
make immunization easier by self-administration and eliminating the need of an injec‐
tor. The intranasal spray vaccine (e.g., influenza vaccine live) also offers a needle-free
approach through the nasal mucosa. Percutaneous administration, such as a multiple
puncture device (4–5 cm length, with 9 short needles) used for BCG vaccination in Japan,
indicates that any medical procedure is done via needle puncture of the skin, rather than
using an “open” approach where inner organs or tissues are exposed.
In the new era of subunit vaccines, to against both infectious diseases and cancers effectively,
subunits made of proteins, peptides, DNA antigens, or potent adjuvants may provide a good
choice to enhance immunogenicity. Subunit vaccines are not generally immunogenic in
humans because of size, degradation, destruction, nonspecific targeting, lack of cross-
presentation, and others [12]. This reveals that it is necessary to develop a new approach to
package and present antigens to the immune system. Nanomedicine is an area of research that
combines nanotechnology and medicine and provides new hopes for therapeutic strategies
and diseases control.
Advances in nanotechnology have shown to be beneficial for therapeutic strategies such as
drug discovery, drug delivery, and gene/protein delivery. Through nanotechnology, drug
consumption and side effects can be significantly decreased by locating the active agent at the
desired site. Nanotechnology is the study and application of extremely small things and
capable of being used in many science fields, such as biology, chemistry, physics, materials
science, and engineering. It is referred to the particular technology with a goal to precisely
manipulate atoms and molecules for fabrication of nanoscale products, which size below 100
nm (or sometimes up to 200–300 nm) [12] (Figure 2). Advances in nanotechnology in biome‐
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dicines have proved to be beneficial in vaccines development. The efficacy of vaccines can be
improved and side effects also can be significantly decreased. For the past decades, a nano‐
vaccine has become a novel approach for vaccination.
Adjuvants may be added to vaccines to modify the immune response by boosting it to give
more antibodies and longer-lasting protection. Adjuvants have been an important compo‐
nent of vaccine formulations since aluminum salt (Alum) was approved in the 1920s [13] and
adjuvant system 04 (AS04) was approved in 2009 in the United States, respectively. AS04 is a
trade name for combination of adjuvants used in vaccine products by GlaxoSmithKline (GSK),
which consists of aluminum hydroxide (Al (OH) 3) and 3-O-desacyl-4-monophosphoryl lipid
A (MPLA). The toll-like receptor (TLR) agonist and MPLA are being intensively investigated
as part of a new class of biological adjuvants [14]. In Europe, a few other adjuvants based on
oil in water emulsions such as adjuvant system 03 (AS03) and liposomes (made of lipid vesicles)
have been approved for using as adjuvants in humans by the European Medicines Agency
(EMA) since the 1990s [15]. AS03 is a trade name for a squalene-based immunologic adju‐
vant used in vaccine products by GSK, which contains squalene, DL-α-tocopherol and
polysorbate 80. For a great need for potent adjuvants in the vaccine clinical applications, we
believe that nanotechnology could be well positioned to take on such a challenge. Conse‐
quently, we focus on the vaccine products based on nanotechnology. In this chapter, we review
the regulation related to the development of nanovaccines, already marketed products based
on nanotechnology and the perspective of developing highly effective, stable, and economic
vaccines using micro-/nanoparticles.
Figure 2. Size comparison of biological substances: The size range of nanomaterials used in nanotechnology relative to
the size of various biological system. Abbreviation: virus-like particle (VLP).




In accordance with the guidelines of WHO, US Food and Drug Administration (FDA) and
EMA, vaccines belong to a heterogeneous class of agent; each has suitable, individual, and
specific standards of evaluation. The major quality concerns in a vaccine human clinical trial
are as follows:
1. Theoretical values and expected values of the trial: In preclinical studies stage, potency,
and immunogenicity should be tested in addition to toxicity and safety. A suitable animal
challenging model should be established; otherwise, an alternative method must be
proposed. The contribution and clinical significance of vaccine should be explained, and
a declaration of interest is usually needed.
2. Protection of the testers: The right and interest of testers should be emphasized either in
the placebo control group (e.g., use insert placebos) or the active control group (e.g., use
already licensed vaccines).
3. Selection of testing population group: Random health volunteers are tested in phase I, but
the representation of testers’ population should be considered in phase II and III. The
related factors include testers’ population, social economics, and the epidemiology of
target disease, etc.
4. Condition of inclusion and exclusion for testing population group: Tester should be in
good health condition and meet the criteria of examination, some people would be
excluded such as allergy, cardiovascular disease, immunodeficiency, and neuropathy
sicks.
5. Dosage, administration route, and schedule: Dose-response data should be achieved in
the dose-finding study. The schedule of vaccination depends on the traits of antigens, the
characteristics of testing population, and the pharmacokinetics induced by vaccines.
Tolerance, safety, dosage, and administration routes should be evaluated in phase I. The
optimal dose and schedule of vaccination should be defined in phase II and would be a
reference in phase III.
6. Safety evaluation of testers: The adverse events should be recorded and evaluated in all
phases of the clinical trial. Post-marketing surveillance for side effects in phase IV is
usually required.
7. Limitation of concomitant administration: The interaction between drugs and vaccines is
rare, but it is necessary to record the consequence while concomitant administering them.
8. Efficacy and effectiveness of vaccines: Vaccine efficacy is the measure of the reduced
disease incidence after vaccination, compared with the unvaccinated group. Vaccine
effectiveness is the measure of vaccine induced protection (not population related
protection), which is influenced with many factors such as the protection coverage of
vaccination, the immunological state of testers, and the epidemiology of target disease.
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9. Lot-to-lot consistency study: It is necessary to evaluate the consistency of vaccine
production and performance by comparing the different lots of vaccine products by the
predefined standard (usually various parameters in immunology).
Vaccines, as all medicinal products regulated by national regulatory authorities (NRA) and
national control laboratories (NCL), undergo a rigorous review of laboratory and clinical data
to ensure their safety, efficacy, purity, and potency. In the stages of discovery and develop‐
ment of vaccines, the manufacturer has to comply with the related regulation, including
nonclinical work, consultation, preclinical trials, and human clinical trials. Furthermore,
vaccines approved for marketing may also be required to perform additional studies to give
further evaluation and often address specific questions such as safety, efficacy or possible side
effects and contraindications for post-marketing surveillance (Figure 3).
Lot release is an independent assessment of each lot of a licensed vaccine or biologic prior to
it is released onto the market. General practices for lot release involve the review of manufac‐
Figure 3. Frame work of vaccine research and development: The research, development, surveillance, and application
of vaccines involve several practices performance and regulation requirements. (A) Stage: Vaccines discovery, devel‐
opment, and postmarked surveillance are three stages for the application of new vaccines. (B) Studies: There is much
research work to do at every stage. (C) Phase: Each stage can be divided into different phases. (D) Regulation: Various
regulations or guidelines are required for every stage. (E) Special procedure: fast track and communication. Abbrevia‐
tions: Good Laboratory Practice (GLP); Good Clinical Practice (GCP); Good Distribution Practice (GDP); Investigation‐
al New Drug (IND), Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme/
Good Manufacturing Practice (PIC/S GMP).
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turers’ production data and quality control test results by NRA and NCL. These practices can
be performed by an agency or a contracted laboratory for the NRA. It may be supplemented
by other documents such as the release certificate from the responsible NRA/NCL and in some
circumstances, by tests in the other laboratory which is independent of the manufacturers’
quality control testing.
Fast-track procedures can be implemented under special circumstances, such as disease
outbreaks or an acute shortage in global vaccine supply. It is a process designed to facilitate
the development and expedite the review of drugs that show promise in treating a serious or
life-threatening disease and address an unmet medical need as follows:
1. Serious condition: To determine if the drug will have an impact on such factors as survival,
day-to-day functioning or the disease will progress more serious if left untreated such as
acquired immune deficiency syndrome (AIDS), Alzheimer’s disease, heart failure, cancer,
epilepsy, depression, and diabetes.
2. Unmet medical need: The drug must be developed to treat or prevent a disease that does
not have a current therapy. If there are available therapies, a fast-track drug must show
some advantage over available therapy such as showing of superior effectiveness,
avoidance of serious side effects, improvement of the diagnosis, decrease of clinically
significant toxicity, and the need of emerging or anticipated public health.
The purpose of a fast-track designation is to get important new drugs to the patient earlier
through the consultation system. Once a drug receives fast-track designation, early and
frequent communication between the NRA and a drug manufacturer is encouraged through‐
out the entire development and review process of drugs. The communication ensures that all
questions and issues can be solved quickly, often leading to earlier drug approval and access
by patients. For example, US FDA is able to offer accelerated approval or priority review if the
requisite criteria are met. Priority review rapids the review process for a new drug from 6 to
10 months even can have US FDA make a final decision within 60 days.
In the application of nanoparticles as vaccines, some obstacles need to be overcome such as
stability during manufacturing and storage, sterilization by nonthermal methods, and
reproducibility of formulation during large-scale production [16]. Reproducibility of formu‐
lation during manufacturing is one of the major hurdles [17]; for instance, size-dependent
immunogenicity has been reported [18] and it is observed that nanomaterials may change
toxicity only by changing size and shape but not composition [19]. If the nanoparticles are
cleared slowly over a long period of time, they may induce toxic effect. In addition, large
counterparts may accumulate in vital organs to cause toxicity, even though small nanoparti‐
cles can be removed quickly from the body. Because of the toxic concerns of nanomaterials,
the potential effects on the human body, public health, and environment pollution should be
taken into account. It is necessary to evaluate the effects on DNA damage, gene expression,
cell death, and growth in the body when different types of cells are exposed to nanoparticles.
The safety surveillance and quality control of nanovaccines are as central as the evaluation of
their efficacy. Regulatory policies are based mainly on the purity and safety of the vaccine. For
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risk management, some special regulations or guidelines for nanotechnology application in
vaccines are as follows.
1. The approach to nanotechnology products
A. Product-focused and science-based regulatory policy
B. Attention to nanomaterials being incorporated into standing procedures
C. In legal standards for different product-classes
2. The regulation of pharmacopoeia (European Pharmacopeia 7.0 and 8.0; EP7.0, 8.0)
A. General provisions of products: The production method is validated to demon‐
strate that the product would comply with the test for abnormal toxicity for immu‐
nosera and vaccine for human use. Additionally, this method has to yield consistent
vaccines comparable with the vaccine of proven clinical efficacy and safety in
humans.
B. Preparation of nanoparticles (virosomes): Inactivated influenza virions are solubi‐
lized using a suitable detergent and purified by high-speed centrifugation to obtain
supernatants containing mainly influenza antigens. After the addition of suitable
phospholipids, virosomes are formed by removal of the detergent either by adsorp‐
tion chromatography or another suitable technique.
C. Tests of final products: residual infectious virus, pH, phospholipids, ratio of hemag‐
glutinin to phospholipids, antimicrobial preservative, free formaldehyde, ovalbu‐
min, total protein, sterility, virosome size, and bacterial endotoxin
3. Preclinical efficacy and toxicity testing of nanoparticles
A. Physicochemical characterization: size measurement, topology, molecular weight,
aggregation, purity, chemical composition, surface characteristics, functionality, zeta
potential, stability, and solubility test
B. In vitro characterization: sterility, targeting, drug release, in vitro immunology, and
toxicity test
C. In vivo characterization: efficacy and repeated-dose toxicity test
3. Products in the clinical application using micro/nanoparticles
Inflexal® V, Epaxal®, GardasilTM, and CervarixTM, marketed in many countries for over 10
years, are four common vaccine products based on micro/nanotechnologies. They use
nanoparticles-virosomes (special liposomes) or virus-like particles (VLPs) as a delivery and
adjuvant system, and all should be administered by IM and stored at 2–8°C (Table 2).
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Product Inflexal® V Epaxal® (1)GardasilTM and (2)CervarixTM
Indication Influenza Hepatitis A Cervical cancer








of Al(OH)3 and MPLA
Nanoparticle Virosome Virosome VLP
Size in diameter 150 nm (100–300 nm) 150 nm (100–300 nm) 20–60 nm
Abbreviations: adjuvant system 04 (AS04); amorphous aluminum hydroxyphosphate sulfate (AAHS); aluminum
hydroxide (Al(OH)3); immunopotentiating reconstituted influenza virosomes (IRIV); 3-O-desacyl-4-monophosphoryl
lipid A (MPLA); virus-like particle (VLP).
Table 2. Comparison of different vaccine products based on nanotechnology.
A virosome is a kind of vaccine delivery tool with a typical size in diameter about 150 nm. It
consists of a phospholipid membrane vesicle incorporating viral-derived proteins and tends
to form a pure fusion-active vesicle. Virosomes are only able to fuse with target cells without
replicating inside their hosts. In contrast to liposomes, virosomes contain functional viral
envelope glycoproteins: influenza virus hemagglutinin (HA) and neuraminidase (NA)
intercalated in the phospholipid bilayer membrane. Virosomes represent an innovative,
extensively applicable adjuvant and carrier system and are used in areas beyond convention‐
al vaccines.
Virus-like particles (VLPs), derived from viruses and having no genetic materials, are self-
assembling nanoparticles (20–60 nm in diameter) that expose multiple epitopes on their surface
and resemble native virions [20, 21]. VLPs can differentiate themselves from soluble recombi‐
nant antigens, and their structure is capable of inducing stronger immune responses. They also
can express one or several viral structural proteins in a recombinant heterologous system [22],
for example, the recombinant baculovirus system results in the expression of massive and
various virus proteins. It is possible to engineer vaccines with multiple viral epitopes to elicit
protective immunity due to the availability of viral three-dimensional structures [23]. VLPs
co-administered with oil, mutant E. coli heat-labile toxins in calves [24] and with bluetongue
viruses in sheep [25] have provided protection against the related viruses. The immunogenic‐
ity of VLPs may be induced because of their interaction with dendritic cells (DCs) and has been
a useful approach for immunity against viruses in animals [16].
3.1. Inflexal® V
Influenza is an important respiratory infection of humans, responsible for many deaths
worldwide every year. The influenza viruses are genetic variable due to continuous and
gradual mutation as well as rearranged genome segments between viruses [26]. Frequent
mutations of the surface glycoproteins HA and NA result in the gradual evolution of viral
strains (antigenic drift). Consequently, it is required to develop a version of new influenza
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hydroxide (Al(OH)3); immunopotentiating reconstituted influenza virosomes (IRIV); 3-O-desacyl-4-monophosphoryl
lipid A (MPLA); virus-like particle (VLP).
Table 2. Comparison of different vaccine products based on nanotechnology.
A virosome is a kind of vaccine delivery tool with a typical size in diameter about 150 nm. It
consists of a phospholipid membrane vesicle incorporating viral-derived proteins and tends
to form a pure fusion-active vesicle. Virosomes are only able to fuse with target cells without
replicating inside their hosts. In contrast to liposomes, virosomes contain functional viral
envelope glycoproteins: influenza virus hemagglutinin (HA) and neuraminidase (NA)
intercalated in the phospholipid bilayer membrane. Virosomes represent an innovative,
extensively applicable adjuvant and carrier system and are used in areas beyond convention‐
al vaccines.
Virus-like particles (VLPs), derived from viruses and having no genetic materials, are self-
assembling nanoparticles (20–60 nm in diameter) that expose multiple epitopes on their surface
and resemble native virions [20, 21]. VLPs can differentiate themselves from soluble recombi‐
nant antigens, and their structure is capable of inducing stronger immune responses. They also
can express one or several viral structural proteins in a recombinant heterologous system [22],
for example, the recombinant baculovirus system results in the expression of massive and
various virus proteins. It is possible to engineer vaccines with multiple viral epitopes to elicit
protective immunity due to the availability of viral three-dimensional structures [23]. VLPs
co-administered with oil, mutant E. coli heat-labile toxins in calves [24] and with bluetongue
viruses in sheep [25] have provided protection against the related viruses. The immunogenic‐
ity of VLPs may be induced because of their interaction with dendritic cells (DCs) and has been
a useful approach for immunity against viruses in animals [16].
3.1. Inflexal® V
Influenza is an important respiratory infection of humans, responsible for many deaths
worldwide every year. The influenza viruses are genetic variable due to continuous and
gradual mutation as well as rearranged genome segments between viruses [26]. Frequent
mutations of the surface glycoproteins HA and NA result in the gradual evolution of viral
strains (antigenic drift). Consequently, it is required to develop a version of new influenza
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vaccine almost every year in that infectious viruses can no longer be neutralized effectively by
the antibodies raised against previously circulating strains.
Inflexal® V, an influenza vaccine, is composed of a mixture of three monovalent virosome
pools, each formed with specific glycoproteins HA and NA of one influenza virus strain. The
vaccine is completely biodegradable and contains no thiomersal, formaldehyde, and very low
levels of ovalbumin. Virosomes, reconstituted by nanotechnology, can deliver influenza
antigens to stimulate a strong immune response; thus, this product is highly efficacious by
mimicking natural viral infection [22]. The product has been approved by many countries and
is the only adjuvanted influenza vaccine licensed for all age groups.
3.2. Epaxal®
Hepatitis A is an acute infectious disease of the liver caused by the hepatitis A virus (HAV),
which symptoms include nausea, vomiting, diarrhea, jaundice, fever, and abdominal pain.
Around 10–15% of people experience a recurrence of symptoms during the six months after
the initial infection. Acute liver failure may rarely occur with this being more common in the
elderly.
Epaxal®, a hepatitis A vaccine, is adjuvanted with immunopotentiating reconstituted
influenza virosomes (IRIV). This vaccine is based on formalin inactivated HAV adsorbed to
the surface of virosomes that replace the adjuvant-aluminum hydroxide with phospholipids.
A single injection of virosomal HAV vaccine is well tolerated and highly immunogenic, with
88–97% of seroprotection 2 weeks after the first dose (reinforcing immunization: one dose at
6–12 months after the first dose).
3.3. GardasilTM and CervarixTM
HPV is a sexually transmitted infection and results in serious illness including genital warts
and cervical cancers. Cervical cancer is the second most common cause of cancer deaths in
females worldwide, only next to breast cancer [27]. HPV causes many cervical cancer cases
every year, of all the cases, type 16 and 18 are responsible for about 70%.
GardasilTM and CervarixTM are subunit vaccines containing VLPs assembled from the major
capsid protein (L1 protein) of HPV type 6, 11, 16, and 18 (GardasilTM) and type 16 and18
(CervarixTM) [21]. Vaccination with these two products has been shown to protect women
against a high proportion of precursor lesions of cervical cancer caused by HPV.
GardasilTM is a sterile liquid suspension prepared from the highly purified VLPs composed of
L1 proteins of HPV types 6, 11, 16, and 18. The L1 proteins of these HPV types (6, 11, 16, and
18) are produced by separate fermentations in the recombinant Saccharomyces cerevisiae and
self-assembled into VLPs. The VLPs for each type are purified and adsorbed on a aluminum-
containing adjuvant formulation-amorphous aluminum hydroxyphosphate sulfate (AAHS).
CervarixTM is a preparation of purified VLPs composed of L1 proteins of HPV type 16 and 18,
which is formulated in AS04 adjuvant-containing aluminum hydroxide and 3-O-desacyl-4-
monophosphoryl lipid A (MPLA) [28]. The MPLA immunostimulant is a detoxified deriva‐
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tive of the lipopolysaccharide of the bacterium Salmonella minnesota strain. The L1 proteins of
these HPV types (16 and 18) are separately produced using a recombinant baculovirus
expression system and the insect cell line derived from the moth-cabbage looper (Trichoplu‐
sia ni). After the expression of L1 proteins and further purification, L1 proteins are assem‐
bled separately as VLPs. It is the first vaccine licensed by the US FDA that includes MPLA as
an adjuvant. The adjuvant AS04 acts as a substance incorporated into a vaccine that enhan‐
ces or directs the immune response of the vaccinated individual.
The advantages that nanotechnology-based vaccines may over conventional vaccines are as
follows:
1. Substitution for traditional adjuvants: Nanovaccines demonstrated immunogenicity
similar to conventional vaccines without the presence of traditional adjuvant (Alum)
which is found to cause irritation.
2. Extended history of safety and shelf life: Nanoparticles as vaccine delivery systems avoid
the use of toxic substances such as thimerosal and formaldehyde and potentially extend
the stability of vaccines on the shelf.
3. Less frequency of administration for boost: Nanovaccines can be administered for
reinforcement immunization less frequently than conventional vaccines, which are
usually multi-injection or multi-dose delivery systems.
4. Perspective
Nanotechnology may provide us a new choice for safe and effective vaccines. However,
frequency of boost, refrigeration of vaccines, and routes of administration are still challenges
for vaccines distribution in small areas or villages of some countries. Nanovaccines are
expected to be more effective, convenient, and economic than conventional vaccines (Figure
4). We will have a great future ahead in nanovaccines if the following three aims are achieved.
1. Controlled release at specific location
Biodegradable polymers are superior to nondegradable polymers because the former may
not need additional removal procedures. For reliability and reproducibility, synthetic
biodegradable polymers are the best choice for antigen encapsulation in single-dose
vaccine production. Biodegradable polymer microsphere such as poly-1-lactic acid (PLA)
and poly lactic-co-glycolic acid (PLGA) has been used to control the time and rate of
vaccine antigen release due to their safety and ability to provide long-term controlled
vaccine antigen release [29]. Sustained release and pulsatile release are two possible types
of vaccine antigen release with biodegradable PLGA microspheres. Sustained release,
continued vaccine antigen diffusion after the initial release, mimics the administration of
several small boosters. Pulsatile release, second vaccine antigen diffusion distinct from
the first release, mimics the current vaccination schedule [30]. PLA and PLGA allow
encapsulation within a hydrophobic core or adsorption to the hydrophilic shell, which
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can manipulate to encapsulate vaccine within the interior [31, 32]. For example, tetanus
toxoid (TT) can be used to prevent tetanus which is caused by the bacterium Clostridium
tetani. A pattern of constant release with a decreasing release rate after the initial burst of
TT has been identified. Small-sized TT-PLA microspheres with rapid release kinetics
induced an earlier release compared with larger TT-PLGA 50:50 microspheres with slow
release kinetics [33]. A continuously increasing release rate after the initial burst was
observed with low molecular weight TT-PLGA microspheres [34].
Nanoscale carriers can enhance the potency of vaccines to develop safer and more effective
vaccine formulations. A nanoparticle-based strategy was demonstrated to safely deliver
and detain intact toxins to mount a potent anti-toxin immune response. A biomimetic
nanoparticle cloaked in biological membranes was used to sequester membrane-active
toxins. As the event of contacting with the nanoparticles, the toxins will retrained and lose
toxicity in that they are prevented from interacting with cellular targets. The resulting
particles and toxin complex adopts a nanoparticulate morphology that facilitates the
intracellular delivery of toxins. This technique assists to design a novel toxoid vaccine that
promises more effective anti-toxin immune responses. The potent nanotoxoid formula‐
tions provide a viable anti-virulence approach to combat with microorganisms that
contain membrane damaging toxins such as Staphylococcus aureus and Group A strepto‐
coccal infections [35].
2. Stable at room temperature
The common adjuvant -alum is known to cause irritation if it is used in the convention‐
al hepatitis B vaccine. However, the use of needle-free nasal immunization with a
combination of nanoemulsion and hepatitis B antigen was found to be tolerable, effec‐
tive, and safe without side effects [36]. The solvent extraction or evaporation from a water-
in-oil-in water (W/O/W) emulsion is usually used to prepare the antigen-encapsulated
nanoparticles [37]. Interestingly, refrigeration was not required for this nanoemulsion, as
it was effective at 25°C for one month and at 40°C for 6 weeks, respectively [16].
To make an effort to develop nanoparticles from biodegradable and biocompatible
polymers (e.g., PLA, PLGA) as vaccine delivery systems can induce both humoral and
cell-mediated immunity. These biodegradable polymers may make nanovaccines have
extended history of safety and proven biocompatibility at room temperature. The
additional advantage is their property to control the time and rate of polymer degrada‐
tion and antigen release [38].
3. Replaceable routes of administration
In addition to injection (IM, SC or ID), mouths and nostrils are two successful alterna‐
tive routes for administration. The vaccine can be given by these two routes without the
help of trained health workers and the equipment of sterile injection. These two meth‐
ods are relatively effective, inexpensive, and convenient, compared with injection. For
example, Sabin vaccine (OPV) and FluMist® are administered by oral administration and
intranasal spray, respectively, in contrast to Salk vaccine (IPV) and influenza vaccine
(flu shots), which are both given by injection.
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A. Sabin vaccine: An OPV is indicated for the prevention of poliomyelitis, which trivalent
contains a mixture of attenuated strains of three poliovirus types. The live polioviruses vaccine
produces antibodies to all types of poliovirus and triggers a local immune response in the
mucous membrane of the intestines. Once infected with wild polioviruses, these antibodies
protect against paralysis by restricting the viral replication inside the intestine to avoid
invading to the nervous system. Later, the live attenuated vaccine virus would be excreted in
Figure 4. Nanotechnologies applied in biomedicines’ vaccine (a cartoon figure for the perspective): Nanoparticles used
in the vaccine production potentially overcome the disadvantages of conventional vaccines. (A) Vaccines encapsulated
in nanoparticles which are polymers in solid form may be assistance in the stabilization at room temperature, elonga‐
tion of storage time, exploration of alternative administration routes, and facilitation of controlled release. (B) Nano‐
vaccines may only need to be boosted once; however, conventional vaccines usually need to be boosted many times.
(C) Soluble antigens released from nanovaccines may induce both humoral immunity (B cell responses) and cell-medi‐
ated immunity (helper and cytotoxic T cell responses). *Ab (antibody): serum immunoglobulin G (IgG), mucosal IgG
and mucosal IgA. Abbreviations: antigen (Ag); antibody (Ab); antigen presenting cell (APC); antibody forming cell
(AFC); antibody-dependent cytotoxic cell (ADCC); cytotoxic T cell (Tc); granulocyte (GC); helper T cell (Th); macro‐
phage (MAC); memory cell (MC); natural killer cell (NKC).
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the faces and spreaded to others in close contact. This means that OPV may result in the passive
immunization of unvaccinated people, so that OPV can rapidly stop person-to-person
transmission of wild poliovirus in areas where there is poor public health.
B. FluMist®: An intranasal spray attenuated vaccine is indicated for the prevention of influenza
which quadrivalent contains four virus strains (a type A/H1N1, a type A/H3N2, and two type
B strains). The live, attenuated influenza vaccine (LAIV) contains neither thimerosal nor
preservatives and is sprayed into the nostrils. LAIV produces a significantly stronger im‐
mune response than inactivated vaccines, because it is delivered via the natural site of entry
of the influenza virus [39–41]. In addition, this intranasal spray vaccine can prevent more 50%
cases than the flu shots given by IM in younger children [42].
The skin is also an attractive organ for vaccine delivery because of its large surface area that
is easily accessible for administration, and dermal delivery is almost pain-free [43, 44].
Furthermore, the skin contains many antigen presenting cells (e.g., Langerhans cells and
dermal dendritic cells) and is available for the induction of immune responses [44–46]. Besides,
the delivery via the skin circumvents the problem of swallowing, the first-pass effect of the
liver, and the absorption and stability of vaccines in the gastrointestinal tract. However, the
stratum corneum (the outermost layer of the epidermis) barrier may form significant resist‐
ance for vaccines to permeate into the body. To overcome the stratum corneum barrier,
percutaneous administration such as microneedle arrays (needle-like structures with a length
of less than 1 mm) [43–46] is one of the most promising delivery systems.
Microparticles or nanoparticles (e.g., PLA, PLGA) have been proved to be capable of making
an inactive Vibrio cholera whole-cell vaccine given by oral administration and demonstrating
in vitro release in mice [47]. This is an approach using nanoparticles as an oral delivery system
to improve bioavailability of vaccine and elated efficacy in therapy. Nanoparticulate materi‐
al makes it possible that vaccines can be given without invasion through oral, nasal spray, and
percutaneous administration such as diffusion patches, multiple puncture devices, and
microneedle arrays, thus allowing painless and efficient delivery without the involvement of
the professional.
5. Conclusion
Nanotechnology has extensively been utilized in the drug preparation and delivery for clinical
applications. Nanomedicine has already been an attractive research area and the develop‐
ment of nanovaccines is one of the most promising enterprises. A variety of nanoparticles in
vaccines have been employed as a delivery tool or immunity booster, inducing not only the
highest efficacy but also the least side effects. The significance of nanovaccine development is
to make it practical to have a perfect vaccination system including refrigeration-free, single-
dose, and painless administration. Indeed, we might have effective, safe, convenient, and
cheap vaccines through nanotechnology in the near future.
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Abstract
The  use  of  nanoparticles  has  increased  in  consumer  products  in  recent  decades;
however, concerns regarding their safety remain. Zinc oxide is used in sunblocking
and  may  generate  free  radicals  in  response  to  UV  illumination,  leading  to  DNA
damage and an immunological response. With high‐resolution, high‐contrast imaging
in biological tissue, multiphoton microscopy is able to separate nanoparticles signals
from endogenous  fluorophores.  It  has  been  proven  to  be  very  useful  in  imaging
penetration  of  zinc  oxide  nanoparticles  in  skin  and  in  combination  with  fluores‐
cence lifetime imaging microscopy study cellular function as well. This chapter aims
to review the use of these imaging techniques in studying the uptake and distribu‐
tion  of  nanoparticles  in  skin  and  liver.  Due  to  the  questionable  clinical  use  and
possible  toxicity  of  nanoparticles,  it  is  important  to  study their  pharmacokinetics.
Some nanomaterials  have been identified as relatively toxic  to humans and a few
metal  nanoparticles  have  been  reported  to  penetrate  and  be  detected  in  blood.
Multiphoton microscopy has high resolution and is able to visualize nanoparticles,
due to their optical properties, in vivo. The addition of fluorescence lifetime imaging
makes it possible to measure the physiochemical environment, with outputs that can
be statistically  analyzed,  posing an advantage over  fluorescence intensity  imaging
only.
Keywords: multiphoton microscopy, fluorescence lifetime imaging microscopy, nano‐
particles, skin, liver
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1. Introduction
Nanoparticles (NPs) are particles ranging from 1 to 100 nm in size and are a promising
pharmaceutical tool for drug delivery and functionalized cosmetic products like sunscreens.
There are growing public and regulatory concerns of topical application of NPs, due to the
increasing manufacturing of NPs in commercial products as well as continuing discovery of
new applications. NPs are available in several different shapes, such as sphere, rod, cylinder,
and cube. Furthermore, they can be soft or hard, aggregated or dispersed. NPs present in
commercial products are often made from metals such as gold and silver or metal oxides like
zinc oxide and titanium oxide, but also include quantum dots (QDs),  carbon nanotubes,
fullerenes, and lipid‐based materials. From an environmental and occupational health and safety
point of view, it is important to investigate NPs interaction with organs following unintended
exposure. On the other hand, it is very necessary to study their properties in active drug delivery
and clearance without adverse effects for therapeutic and cosmetic applications. Properties,
such as particle size and shape, surface charge, pH, formulation, are important factors in
determining the penetration of NPs in the skin. Toxicity of NPs is mainly of concern for the
smaller particles. The skin may be more susceptible to NPs penetration if it is diseased, hot,
damaged, inflamed, hydrated, dry, or moisturized. Positively charged NPs are most prefer‐
red for skin penetration [1].
Determining the presence or absence as well as concentration of NPs in biological tissue has
been enabled by multiphoton microscopy (MPM), especially in investigating interactions of
NPs with human skin [2].
Most knowledge in the biological world has been gathered from studying images [3]. Thus, a
growing interest for live‐tissue imaging has evolved. In conventional confocal microscopy, the
intensity from the beam is approximately uniform above and below the focal plane, which
results in the specimen generating fluorescence out of the focal plane that is rejected by the
pinhole. This leads to the specimen being subjected to photobleaching and photodamage,
affecting image quality, and tissue health [4]. MPM avoids this because a much smaller area
of the specimen is being stimulated by the excitation light source and no out of focus light is
generated, which leads to photobleaching being restricted to the focal point only [4, 5]. At an
excitation wavelength in the near infrared range (NIR, ∼ 700–1000 nm), the photon penetration
depth of the incident light is maximized, and the tissue scattering and absorption are mini‐
mized [6, 7].
In confocal microscopy (single photon), fluorescence occurs when a photon is absorbed by a
fluorescent molecule and raises an electron to an excited energy state (Figure 1). When the
electron returns to the ground state, it converts the absorbed energy to heat, by transferring
the energy to another molecule emitting a lower energy photon [8, 9], producing an image. In
MPM, two (or more) photons of the same energy from a pulsed laser (usually femtosecond
laser) interact with a molecule to produce excitation equivalent to the absorption of a single
photon possessing twice (or multiple) the energy (Figure 1). If the excited molecule is fluores‐
cent, it can emit a single photon [8–10].
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Figure 1. Jablonski energy diagram (adapted from Refs. [8–11]). Imagine a fluorescent molecule with single absorption
and emission at 450 and 500 nm, respectively. In order to excite electron(s) from this molecule, light from a laser is
needed. The electron(s) is then raised into a higher excited state, where it decays rapidly into the ground vibrational
state within the electronically excited state. From there the electron can return to the electronically ground state by
emitting light, which can yield in fluorescence. The emitted light has lower energy (higher wavelength) than the absor‐
bed light. The emission spectrum of fluorescence excited by MPM is usually similar to the one excited with single pho‐
ton excitation. To excite the molecule with two‐photon, two photons of equal wavelengths, which together meet the
energy gap between the ground and excited states, are needed (here 900 nm).
An important application of MPM is to image the physiology, morphology, and cell‐cell
interactions in intact tissue of live animals with high resolution. However, one limitation is
that it cannot quantitatively study cellular function on a molecular level [12]. MPM in combi‐
nation with fluorescence lifetime imaging microscopy (FLIM), however, can identify fluoro‐
phores with overlapping spectral properties. Furthermore, it enables insights into their
biological function by being sensitive to the binding site and the environmental surrounding
[13]. The fluorescence lifetime is proportional to the reciprocal Einstein coefficient of the
spontaneous emission, that is, to the sum of the rate constants of all possible return paths for
the electron from the excited state to the ground state that is not stimulated emission [14]. This
is determined by both intramolecular and intermolecular events [4]. FLIM has been described
as a direct approach to monitor energy transfers between fluorophore and the environment,
for example, DNA binding, which change the fluorescence lifetime of that fluorophore [15].
FLIM is particularly important when identifying fluorophores with overlapping spectral
properties [13]. One application for FLIM in liver imaging is to study levels of the autofluor‐
escent NADH, as a direct measure for the redox state as a metabolic marker of the cells [8].
The principle of FLIM is illustrated in Figure 2. Imagine a sample with two regions, each with
equal intensity, but two different fluorescence lifetimes, one shorter (τ1) and one longer (τ2).
τ2 could be due to binding to other molecules, change in pH, cation concentration, oxygen
concentration, or polarity. The intensity image itself can not reveal these environmental
differences (Figure 2a), but the FLIM image can (Figure 2b and c). The fluorescence lifetimes
within a FLIM image can be presented on a grey (Figure 2b) or colour scale (Figure 2c) or as
three‐dimensional (3D) surface where the height represents the local decay times (Figure 2d)
[16].
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Figure 2. Principles of fluorescence lifetime imaging (FLIM). (a) Intensity (I) cannot reveal any difference in the sur‐
rounding environment; (b) FLIM enables distinguishing the two components with different fluorescence lifetime and
can give insights into biological function (grey scale represents fluorescence lifetimes, where τ2 > τ1). (c) Fluorescence
lifetimes can also be colour coded or; (d) displayed as third coordinate, resulting in a 3D image (adapted from Ref.
[Lakowitz et al., Fluorescence lifetime imaging of free and protein-bound NADH. Proceedings of the National Academy of
Sciences 1992 89(4): 1271-1275).
MPM can be used to image fluorescent and sometimes even nonfluorescent NPs in living cells,
tissue, and organs in vivo. Nonfluorescent NPs can have nonlinear optical properties so that
they can become visible for MPM (e.g., zinc oxide (ZnO) NPs, gold (Au) NPs, and silver (Ag)
NPs) [17]. One physical phenomenon is second harmonic generation (SHG). It is based on
elastic scattering. The wavelength of the SHG signal is at the double frequency of the incident
excitation light of the femtosecond laser. The optical response is quasi‐instantaneous and
therefore can easily be identified by FLIM. A second process is the so‐called localized surface
plasmon resonance (LSPR) [18]. The LSPR signal can be tailored by modifying the size or the
shape of the NPs. This signal can be very broadband (inelastic phenomenon) and strong but
is also characterized by a very rapid optical response in the femtosecond range so that it also
can easily be identified by FLIM technique [19].
MPM has proven to be very useful in imaging the uptake of metal NPs, such as ZnO‐NPs, Au‐
NPs and Ag‐NPs in the skin. Additionally, NAD(P)H (NADH+NADPH) can be imaged
simultaneously without the need for additional dyes using FLIM. This can help to understand
how NPs affect the viable skin condition. The additional time‐resolved measurements with
FLIM can be used to differentiate NP signals from endogenous tissue [2]. This chapter aims to
critically review the use of these imaging techniques in studying the penetration of NPs and
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quantum dots (QDs) into skin, how to facilitate intentional uptake, as well as the uptake and
distribution in the liver.
2. Topical application of zinc oxide nanoparticles
Zinc oxide NPs (ZnO NPs) are incorporated into a plethora of commercially available formu‐
lations including sunscreens, cosmetics such as mineral‐based make‐up, and nappy rash
ointments. Though ZnO NPs are considered to be safe after topical application [20], there have
been concerns raised about the lack of assessment of toxicity under “in‐use” conditions [21].
ZnO NPs are transparent and affords the viable epidermis broad spectrum protection from
harmful UV radiation. Irradiation of ZnO NPs, however, can result in the production of
reactive oxygen species (ROS) that are harmful if exposed to the keratinocytes within the viable
epidermis [22]. It is therefore of importance to delineate the deposition of ZnO NPs after topical
application to comprehensively assessing whether ZnO NPs can penetrate the stratum
corneum and reach the viable epidermis. A ZnO NP suspension was applied to human skin
in vivo at 10% wt for 6 hours and then occluded to simulate clothing covering the skin with the
applied sunscreen. It was found that occlusion, and thus, skin hydration does not aid the
penetration of ZnO NPs into human skin and no localized toxicity was observed within the
viable epidermis using metabolic lifetime imaging [23]. In this study, the photoluminescence
of ZnO NPs was spectrally resolved from that of the endogenous fluorophores, and thus, the
deposition was mapped after application to the volunteers’ forearms. The fluorescence lifetime
amplitude, α1%, of ZnO NPs (multiphoton‐excited photoluminescence) was found to be
distinct from that of the autofluorescence. This enabled the authors’ to map the distribution of
ZnO NPs after application to viable skin in vivo. Further, using MPM–FLIM, the free‐to‐bound
ratio of endogenous NAD(P)H was determined to elucidate any effect ZnO NP application
had on the redox state of the viable epidermis.
Other studies conducted include the in vivo application of ZnO NPs with massage and arm
flexing in which the conclusions were that again no ZnO NP penetration as observed with the
exception of ZnO NPs within the sebaceous gland of one volunteer and no localized toxicity
was observed by metabolic imaging [23]. An in vivo study was also conducted to assess any
ZnO penetration after repeated exposure [25] as the cancer council advises the public to
reapply sunscreen every 2 hours [24]. In this study, once again no ZnO NP penetration or
localized toxicity within the viable epidermis was observed even after repeated liberal
application to volunteers’ forearm [25]. Lin et al. applied ZnO NPs to intact human skin and
also skin that was tape‐stripped (20×), or had psoriatic and atopic dermatitis lesions. The study
showed that the ZnO NP photoluminescence signal was most intense at the skin surface after
application to impaired lesioned skin compared to intact skin in vivo. In this study, no
penetration of ZnO NP was observed within the viable epidermis after application of ZnO NPs
in caprylic capric triglyceride (CCT) [26].
As NPs have a high surface‐to‐volume ratio, the reactivity and dissolution of constituent ions
increases with decreasing diameter of the NP. Zinc ion release and percutaneous absorption
has been observed after topical ZnO NP application to human skin both in vivo [27–29] and in
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vitro [30]. Further, NPs are known to accumulate within the hair follicles and undulations of
human skin for up to 10 days [31] whereby they may act as a reservoir undergoing dissolution
into constituent solubilized species within these reduced environments. To increase stability,
reduce dissolution and production of ROS, coated ZnO NPs have been employed within
formulations. Leite‐Silva et al. [23] investigated the deposition of ZnO NPs after application
to in vivo human skin within various formulations. MPM–FLIM was used once again to
simultaneously map ZnO NP deposition whilst also determining the NAD(P)H free‐to‐bound
ratio of the underlying viable epidermis after application of both coated and uncoated ZnO
NPs in (a) CCT suspension, (b) a gel formulation, (c) oil‐in‐water emulsion, and (d) water‐in‐
oil emulsion. The study reported the deposition of the ZnO NPs only within the superficial
layers of the stratum corneum and within the furrows as reported previously after application
in a water‐in‐oil emulsion (Roberts MS, Roberts MJ, Robertson TA, Sanchez W, Thorling CA,
Zou Y, Zhao X, Becker W and Zvyagin AV. In vitro and in vivo imaging of xenobiotic transport
in human skin and in the rat liver. Journal of Biophotonics 1(6): 478-493, 2008). The exception
was minimal ZnO NP penetration was observed within isolated areas in parallel to the furrow
within the stratum granulosum after application of coated ZnO NPs in a water‐in‐oil emulsion
observed in Figure 3 [23]. This, however, did not result in a change in redox state within the
stratum granulosum; therefore, the penetrated ZnO NPs did not cause toxicity [23].
Figure 3. Pseudocoloured MPM–FLIM images of human skin treated with ZnO NPs in vivo. ZnO NPs were dispersed
in three types of formulations, gel, emulsion E1 o/w, and emulsion E2 w/o in coated or uncoated form. Control images
do not contain any NPs. The green colour corresponds to skin autofluorescence (α1% 45‐85), whereas the orange‐red
colour corresponds to ZnO‐NPs photoluminescence (α1% 90–100). Scale bar is 20 μm. The colour scale bar represents
α1% 0–100.
3. Topical application of gold nanoparticles
Gold NPs (Au NPs) are being increasingly investigated for topical drug delivery due to their
monodispersed controllable size, the ability to functionalize the surface of the Au NPs and due
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to their low reactivity potential. Recently, Au NPs have been investigated as a drug delivery
platform in the treatment of psoriasis [32] and as contrast agents in skin cancer imaging [33].
The Au NP (6–15 nm in diameter) penetration study showed 15 nm AuNP in aqueous solution
was also observed by MPM–FLIM to aggregate within furrows of skin after treated on excised
viable skin sample and also showed penetration of 6 nm Au NP suspended in toluene within
the stratum spinosum of the viable epidermis [34]. No change in the redox state of the viable
epidermis was observed when Au NPs were applied to the skin in an aqueous vehicle though
a change in redox state was observed when Au NPs were applied in toluene [34]. The authors’
further investigated the penetration of Au NPs into skin using dimethyl sulfoxide (DMSO), a
known chemical penetration enhancer, and found that DMSO enhanced the penetration of Au
NPs into skin [35]. A study also showed that Au NP skin penetration was found to be size
dependent with 6 nm Au NPs penetrating to higher degree than 15 nm Au NPs [35]. Fernandes
et al. found that the skin penetration on Au NPs could be tailored depending on the surface
chemistry and shape of the NP [36]. Larese Filon et al. also concluded that Au NPs can penetrate
into both intact and impaired human skin in vitro [37]. Conversely, Lin et al. found no
Figure 4. En face MPM–FLIM images of treated human viable skin. FLIM images showing the different layers of ex‐
cised full‐thickness skin (stratum corneum, granulosum, spinosum, and basale) after 24‐hour treatment with Au NPs
suspended in sodium citrate. Images are pseudocoloured based on α1% signal (skin autofluorescence 0–95% and
AuNPs 95–100% signal). No Au NP signal was detected in the saline control (a)–(d) and detected in the sodium citrate
control (e)–(h). The AuNP‐treated groups, 10 nm (i)–(l), 30 nm (m)–(p), and 60nm (q)–(t), resulted in signal throughout
the stratum corneum. Scale bar indicates 20 μm. Colour bar, blue to red indicates α1% 0–100%.
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penetration of Au NPs after topical application to human skin in vivo (as shown in Figure 4).
In this study, Au NPs of increasing diameter 10, 30, and 60 nm were applied to viable ex vivo
human skin and MPM–FLIM was used to assess any percutaneous absorption of Au NPs. No
penetration of Au NPs was observed past the stratum corneum and no change in the redox
state of the viable epidermis was observed indicating no localized toxicity [38]. The scientific
community has yet to reach a consensus on whether inorganic NPs can penetrate human skin
as exhibited by conflicting results within the literature.
4. Topical application of other nanoparticles
SECosomes are flexible nanovesicles constituted from surfactant, ethanol, and cholesterol,
hence the name SECosomes. MPM–FLIM was used to observe the penetration of SECosomes
into viable ex vivo human skin as deep at 40 μm within the viable epidermis, which resulted
in a shift of lifetime for NAD(P)H [39]. Silver NPs (Ag NPs) are found within a wide variety
of personal care products including deodorants’, antibacterial under garments, and wound
dressings. To determine whether Ag NPs penetrate human skin in vivo, Ag NPs were applied
to intact or tape stripped skin. No statistically significant difference in metabolic rate
measuring the inverse ratio of free‐to‐bound NAD(P)H (α1/α2) was observed within the viable
epidermis [40]. In a more recent study, the shape dependence of Ag NPs and their penetration
into human skin was determined on ex vivo human skin [19]. No Ag NPs either cube, sphere,
or truncated plates were observed within the viable epidermis in intact skin but Ag NP plates
were found within the wound bed of burned human skin. In this study, Ag NPs penetration
into both intact and burned human skin was assessed through detection of both the second
harmonic generation (SHG) signal and the localized surface plasmon resonance (LSPR) of the
NPs. Using MPM–FLIM, the detected nonlinear optical characteristics (SHG and LSPR) found
that the Ag NPs accumulated within the furrows of the skin, and in particular, the truncated
Ag NP plates showed great substantivity within the superficial layers of the stratum corneum
but that no penetration into the viable epidermis was observed for intact skin [19]. The authors’
also observed that Ag NP spheres accumulated within and around the hair follicle shafts after
topical application. This was also supported by the work of Zhu et al. [41] as they too did not
observe any penetration of Ag NPs into the viable epidermis of intact porcine skin but did
image Ag NPs within the hair follicles using MPM–FLIM and Raman scattering microscopy.
QDs are 2–10 nm fluorescent semiconductor nanomaterials with a larger excitor Bohr radius
than the NP radius, making these nanomaterials to undergo quantum confinement. As a result,
QDs have characteristic excitation states and larger bandgap values than bulk materials.
Emission wavelengths is dependent on size, bandgap increases as the radius decreases (i.e.,
for smaller QDs). They have greater resistance to photobleaching and have higher quantum
yield than conventional fluorophores [42]. Here, they characterized water‐soluble cadmium
selenide–zinc sulphide quantum dots for MPM imaging in live animals. They visualized QDs
dynamically through mice skin in capillaries hundreds of micrometres deep [43].
The advantages that MPM‐FLIM provides over other imaging techniques as outlined in the
Introduction section have enabled numerous researchers to map the deposition and potential
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percutaneous absorption of a wide variety of NPs into skin. Further elucidation is required,
however, to determine whether NPs can penetrate human skin due to conflicting conclusions
within the literature and with the nanotechnology sector rapidly increasing the risk of dermal
exposure to NPs will increase.
4.1. How do we improve penetration of nanoparticles for drug delivery?
The penetration of NPs can be improved by penetration enhancers, such as oleic acid, urea,
sodium lauryl sulphate, polysorbate, and DMSO. MPM was used to visualize the penetration
of a fluorescent NP with the assistance of oleic acid. The results showed that oleic acid was
effective in facilitating transdermal delivery of NPs [44]. Au NPs penetration was studied with
the chemical enhancers, urea, sodium lauryl sulphate, polysorbate, and DMSO, and it was
evident that the penetration was induced by DMSO [35]. Similarly, chemical enhancers can
increase penetration of ZnO NPs, by increasing lipid fluidity or by extracting noncovalently
bound amphiphilic lipid in the stratum corneum [26].
Another way of increasing penetration of NPs is by using microneedles, which can create pores
in the stratum corneum layer, which enables delivery of NPs to the deeper layers of the skin.
Gantrez R_AN‐139 microneedle successfully did this [45]. Two‐photon polymerization of an
acrylate‐based polymer was used to fabricate microneedle devices for transdermal drug
delivery and MPM visualized QDs penetration in porcine skin by a microneedle device [42].
5. Nanoparticles disposition in the liver
NPs are increasingly being used for the detection and treatment of human diseases, in
applications such as drug and gene delivery, imaging, and diagnostics [46, 47]. However their
short in vivo half‐lives limit their clinical utility and can lead to hepatotoxicity [46]. It is
important to monitor the biodistribution of NPs after intravenous administration in order to
evaluate their efficacy and possible side effects. The physiochemical properties of NPs, such
as size, shape, surface charge are important in determining the biodistribution [2–5]. For
example, hydrophobic NPs are rapidly removed by reticuloendothelial system (RES), mainly
by the liver and spleen [46]. Additionally, intravital imaging showed that positively charged
NPs where taken up by the hepatocytes (liver cells), whereas negatively charged NPs were
found to be taken up by Kupffer cells, liver macrophages, instead [46]. The positively charged
NPs have the potential to be cleared via hepatobiliary excretion; however, the negatively
charged NPs portends significant hepatotoxicity due to their accumulation in Kupffer cells
[46]. If NPs are taken up by hepatocytes, this would be through receptor‐mediated endocytotic
processes [48]. This is in contrast to smaller molecules, such as RH123 and fluorescein, which
are taken up by diffusion and transporter proteins in the liver membranes [49].
In a recent study, a multimodal nonlinear label‐free imaging technique to pinpoint polymeric
NPs within the intestine and liver was done. Encapsulation of active substances within
nanoscale particles can enhance bioavailability and biocompatibility, resulting in targeted
drug delivery, solubility, and bioactivity and reducing toxicity. They used MPM to show
Multiphoton and Fluorescence Lifetime Imaging Microscopy in Studying Nanoparticle Pharmacokinetics in Skin and
Liver
9115
cellular structures, SHG to visualize collagen and CARS to generate chemical‐specific images
of polymer‐based NPs with contrast derived from the molecular vibration of carbon–deuteri‐
um bonds within the polymer's palmitic acid chains. These modalities combined give accurate
location of the NPs in relation to the cellular structure in the liver, gall bladder, and intestine
[50].
The use of MPM to visualize the delivery of Cy5‐siRNA with lipid NPs vehicles to hepatocytes
was shown by Chen et al. They analysed the diffusion of Cy5‐siRNA into the hepatocytes by
computation of the percentage signal strength in the region of interest over time [51].
Quantum dots (QDs) are nanomaterials recognized as promising diagnostic and imaging
agents. QDs are the most effective semiconductor materials for applications in the field of
bioimaging, since they have unique optical and photophysical properties, with high quantum
yield and strong fluorescence at both visible and NIR wavelengths. QDs are also stable and
retain their fluorescence for a long period of time. QDs have been found to be retained in the
organs of the RES for over 22 days after injection, suggesting that they are consumed by
mononuclear phagocytes [52]. QDs are particularly well suited for the detection of low
abundance antigens, such as hepatitis C virus (HCV), because they are less prone to photo‐
bleaching. MPM has been used in combination with QDs to visualize the distribution of HCV‐
infected cells within the liver [53].
In a previous study, our group applied MPM–FLIM to investigate the in vivo subcellular,
spatiotemporal disposition of negatively charged QDs in rat liver. The cellular behaviour of
QDs was found to be very different from traditional fluorescent molecules, rhodamine 123
(RH123) and fluorescein (Figure 5). Results showed that QDs were quickly detected in the liver
sinusoids immediately after injection and were not taken up by hepatocytes, but the fluores‐
cence stayed in the sinusoids and started to decrease after about 60 min. The QDs were found
to be taken up by Kupffer cells and liver sinusoidal endothelial cells (LSECs).
Figure 5. False‐coloured images of QDs, RH123, and fluorescein distribution in the rat liver at 5 min after injection
(adapted from Ref. [49]) using high (×40) and low (×10) magnification objectives. Red colour represents autofluores‐
cence of the liver excited at 740 nm. Green colour represents the fluorophores, QDs, RH123, and fluorescein, excited at
900 and 920 nm. Scale bar is 20 μm, H = hepatocyte, S = sinusoid, arrow points to bile ducts.
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The distribution of these QDs was similar to the distribution of rhodamine B isothiocyanate/
dextran 7000, which is a fluorescent marker for labelling the sinusoids of the liver. Addition‐
ally, this is in accordance to another study where they found no uptake of negatively charged
fluorescein isothiocyanate‐labelled mesoporous silica NPs [16]. Both RH123 and fluorescein
are excreted through the bile, and hence, the fluorescence signal in the liver declined rapidly,
but since these QDs were not excreted through the bile, the fluorescence declined much slower.
The fluorescence lifetime of the sinusoids increased after QDs injection, which was due to the
long lifetime of QD [49].
Fast and reliable ratiometric FLIM (rmFLIM) approach is described to analyse the distribution
of protein‐ligand complexes in the cellular context. In combination with Forster resonance
energy transfer (FRET), FLIM can be used to map protein–protein interactions on the nano‐
meter‐scale in living cells. Organic fluorophores label the ligands in the case of membrane
receptors or intracellular proteins that bind extracellular ligands. Imaging based on fluores‐
cence intensity is often used to localize cellular sites where the ligand binds to its cognate
receptor, but these techniques may be biased by unspecific binding and distribution of the
ligand in various subcellular compartments. FLIM is sensitive to the physiochemical environ‐
ment, posing an advantage over fluorescence intensity measurements. In this study, they show
a fast and reliable FLIM‐based method for the localization of target molecules and their
discrimination against the fluorescent background of cell membranes and tissue. FRET relies
on the shortening of the donor lifetime due to the less energy transfer of radiation to the
acceptor. Physiochemical environment can also affect the fluorescence lifetime, for example,
quenching. The shortening of fluorescein's fluorescence lifetime when it binds to Cys316 in the
opsin molecule results from additional dynamic interaction of the bound dye with the
surrounding protein matrix, which functions as a quencher. A ratiometric FLIM (rmFLIM)
relies on the specific multiexponential lifetime signature of a protein–ligand complex that is
unique compared to the fluorescence lifetime distribution of the background. Only one
fluorophore is needed. rmFLIM was used to analyse the fate of a polymer‐based nanocarrier
for drug delivery in the metabolic clearance process. They used a polyanionic, dendritic
polyglycerolsulfate (dPGS) labelled with a fluorescent indocarbocyanine dye (ICC, spectrally
analogue to Cy3). In solution, this nanocarrier had 2 fluorescence lifetimes of 0.27 and 1.1 ns.
Paraffin‐embedded liver section from rats, previously injected with dPGS‐ICC, was used for
FLIM measurements [54].
6. Conclusions and future directions
In this chapter, we review the use of MPM and FLIM to visualize the disposition of NPs and
QDs in the skin and liver. Nanotechnology and its applications in dermatology and drug
delivery have received a growing interest over the past years. Increased applications of NPs
have led to an enhanced unintentional skin exposure of NPs and it is therefore important to
study when and how NPs penetrate skin. Some conclusions of NP penetrations into skin are
as follows: (1) The SC forms an effective barrier to NPs penetration, but smaller‐sized NPs are
more likely to penetrate. (2) Hair follicles are an important collection site for NPs, and
Multiphoton and Fluorescence Lifetime Imaging Microscopy in Studying Nanoparticle Pharmacokinetics in Skin and
Liver
111 7
increasingly so when the skin is massaged or flexed. (3) The surface charge and formulation
of NPs can affect its penetration.
Negatively charged QDs were found to distribute immediately after injection in the sinusoids
of mice livers and accumulated in Kupffer cells and LSECs. Positively charged NPs, however,
can be taken up by hepatocytes and subsequently be subjected to biliary excretion. It is
important to know where NPs are localized after intravenous injection as these cells are
emerging as significant targets for therapies in many liver diseases.
Author details
Camilla A. Thorling1*, Amy Holmes2, Hauke Studier2, David Liu1, Xiaowen Liang1 and
Michael S. Roberts1,2
*Address all correspondence to: c.thorling@uq.edu.au
1 Therapeutics Research Centre, Translational Research Institute, School of Medicine, The
University of Queensland, Brisbane, Australia
2 School of Pharmacy and Medical Sciences, The University of South Australia, Adelaide,
Australia
References
[1] Liang XW, Xu ZP, Grice J, Zvyagin AV, Roberts MS, Liu X. Penetration of nanoparticles
into human skin. Current Pharmaceutical Design. 2013;19(35):6353–66.
[2] Prow TW, Monteiro‐Riviere NA, Inman AO, Grice JE, Chen X, Zhao X, et al. Quantum
dot penetration into viable human skin. Nanotoxicology. 2012;6(2):173–85.
[3] Eliceiri KW, Rueden C. Tools for visualizing multidimensional images from living
specimens. Photochemistry and Photobiology. 2005;81(5):1116–22.
[4] Emptage NJ. Fluorescent imaging in living systems. Current Opinion in Pharmacology.
2001;1(5):521–5.
[5] Stutzmann GE, Parker I. Dynamic multiphoton imaging: a live view from cells to
systems. Physiology. 2005;20(1):15–21.
[6] Masters BR, So PT. Confocal microscopy and multi‐photon excitation microscopy of
human skin in vivo. Optics Express. 2001;8(1):2–10.
[7] Hoover EE, Squier JA. Advances in multiphoton microscopy technology. Nature
Photonics. 2013;7(2):93–101.
Micro and Nanotechnologies for Biotechnology1218
increasingly so when the skin is massaged or flexed. (3) The surface charge and formulation
of NPs can affect its penetration.
Negatively charged QDs were found to distribute immediately after injection in the sinusoids
of mice livers and accumulated in Kupffer cells and LSECs. Positively charged NPs, however,
can be taken up by hepatocytes and subsequently be subjected to biliary excretion. It is
important to know where NPs are localized after intravenous injection as these cells are
emerging as significant targets for therapies in many liver diseases.
Author details
Camilla A. Thorling1*, Amy Holmes2, Hauke Studier2, David Liu1, Xiaowen Liang1 and
Michael S. Roberts1,2
*Address all correspondence to: c.thorling@uq.edu.au
1 Therapeutics Research Centre, Translational Research Institute, School of Medicine, The
University of Queensland, Brisbane, Australia
2 School of Pharmacy and Medical Sciences, The University of South Australia, Adelaide,
Australia
References
[1] Liang XW, Xu ZP, Grice J, Zvyagin AV, Roberts MS, Liu X. Penetration of nanoparticles
into human skin. Current Pharmaceutical Design. 2013;19(35):6353–66.
[2] Prow TW, Monteiro‐Riviere NA, Inman AO, Grice JE, Chen X, Zhao X, et al. Quantum
dot penetration into viable human skin. Nanotoxicology. 2012;6(2):173–85.
[3] Eliceiri KW, Rueden C. Tools for visualizing multidimensional images from living
specimens. Photochemistry and Photobiology. 2005;81(5):1116–22.
[4] Emptage NJ. Fluorescent imaging in living systems. Current Opinion in Pharmacology.
2001;1(5):521–5.
[5] Stutzmann GE, Parker I. Dynamic multiphoton imaging: a live view from cells to
systems. Physiology. 2005;20(1):15–21.
[6] Masters BR, So PT. Confocal microscopy and multi‐photon excitation microscopy of
human skin in vivo. Optics Express. 2001;8(1):2–10.
[7] Hoover EE, Squier JA. Advances in multiphoton microscopy technology. Nature
Photonics. 2013;7(2):93–101.
Micro and Nanotechnologies for Biotechnology1218
[8] Roberts MS, Dancik Y, Prow TW, Thorling CA, Lin LL, Grice JE, et al. Non‐invasive
imaging of skin physiology and percutaneous penetration using fluorescence spectral
and lifetime imaging with multiphoton and confocal microscopy. European Journal of
Pharmaceutics and Biopharmaceutics. 2011;77(3):469–88.
[9] Oheim M, Michael DJ, Geisbauer M, Madsen D, Chow RH. Principles of two‐photon
excitation fluorescence microscopy and other nonlinear imaging approaches. Ad‐
vanced Drug Delivery Reviews. 2006;58(7):788–808.
[10] Helmchen F, Denk W. Deep tissue two‐photon microscopy. Nature Methods.
2005;2(12):932–40.
[11] Campagnola PJ, Clark HA, Mohler WA, Lewis A, Loew LM. Second‐harmonic imaging
microscopy of living cells. Journal of Biomedical Optics. 2001;6(3):277–86.
[12] Niesner RA, Andresen V, Gunzer M. Intravital two-photon microscopy: focus on speed
and time resolved imaging modalities. Immunological Reviews. 2008;221(1):7–25.
[13] Yan L, Rueden CT, White JG, Eliceiri KW. Applications of combined spectral lifetime
microscopy for biology. Biotechniques. 2006;41(3):249.
[14] Becker W. Fluorescence lifetime imaging–techniques and applications. Journal of
Microscopy. 2012;247(2):119–36.
[15] Errington RJ, Ameer‐Beg S, Vojnovic B, Patterson LH, Zloh M, Smith PJ. Advanced
microscopy solutions for monitoring the kinetics and dynamics of drug–DNA targeting
in living cells. Advanced Drug Delivery Reviews. 2005;57(1):153–67.
[16] Lakowicz JR, Szmacinski H, Nowaczyk K, Johnson ML. Fluorescence lifetime imaging
of free and protein‐bound NADH. Proceedings of the National Academy of Sciences.
1992;89(4):1271–5.
[17] Podlipensky A, Lange J, Seifert G, Graener H, Cravetchi I. Second‐harmonic generation
from ellipsoidal silver nanoparticles embedded in silica glass. Optics Letters.
2003;28(9):716–8.
[18] Mock J, Barbic M, Smith D, Schultz D, Schultz S. Shape effects in plasmon resonance of
individual colloidal silver nanoparticles. The Journal of Chemical Physics. 2002;116(15):
6755–9.
[19] Holmes A M, Lim J, Studier H, S RM. Varying the morphology of silver nanoparticles
results in differential toxicity against micro?organisms, human keratinocytes and
affects skin deposition. 2016 (unpublished data).
[20] Scientific Committee on Consumer Safety OPINION ON Zinc oxide (Nano Form); 2012,
SCCS/1489/12. Available from: http://ec.europa.eu/health/scientific_committees/
consumer_safety/docs/sccs_o_137.pdf
Multiphoton and Fluorescence Lifetime Imaging Microscopy in Studying Nanoparticle Pharmacokinetics in Skin and
Liver
131 9
[21] Miller G, Sales L. Nano ingredients in sunscreen: the need to regulation. Friends of the
Earth 2012. Available from: http://emergingtech.foe.org.au/resources/nano‐ingredi‐
ents‐in‐sunscreen‐the‐need‐for‐regulation/
[22] Graf BW, Chaney EJ, Marjanovic M, De Lisio M, Valero MC, Boppart MD, et al. In vivo
imaging of immune cell dynamics in skin in response to zinc‐oxide nanoparticle
exposure. Biomedical Optics Express. 2013;4(10):1817–28.
[23] Leite‐Silva VR, Le Lamer M, Sanchez WY, Liu DC, Sanchez WH, Morrow I, et al. The
effect of formulation on the penetration of coated and uncoated zinc oxide nanoparti‐
cles into the viable epidermis of human skin in vivo. European Journal of Pharmaceutics
and Biopharmaceutics. 2013;84(2):297–308.
[24] Cancer Council Australia. Available from: www.cancer.org.au.
[25] Mohammed Y, Sanchez W, Haridass IN, Pilorget C, Penloup AL, Studier H, Chandra‐
sekaran N, et al. Does repeated topical application of zinc oxide nanoparticles over 5
days result in penetration into human skin in vivo? (unpublished work) 2016.
[26] Lin LL, Grice JE, Butler MK, Zvyagin AV, Becker W, Robertson TA, et al. Time‐
correlated single photon counting for simultaneous monitoring of zinc oxide nanopar‐
ticles and NAD (P) H in intact and barrier‐disrupted volunteer skin. Pharmaceutical
Research. 2011;28(11):2920–30.
[27] Gulson B, Wong H, Korsch M, Gomez L, Casey P, McCall M, et al. Comparison of
dermal absorption of zinc from different sunscreen formulations and differing UV
exposure based on stable isotope tracing. Science of the Total Environment.
2012;420:313–8.
[28] Gulson B, McCall M, Korsch M, Gomez L, Casey P, Oytam Y, et al. Small amounts of
zinc from zinc oxide particles in sunscreens applied outdoors are absorbed through
human skin. Toxicological Sciences. 2010, 118, 140–149.
[29] Ågren M. Percutaneous absorption of zinc from zinc oxide applied topically to intact
skin in man. Dermatology. 1990;180(1):36–9.
[30] Holmes AM, Song Z, Moghimi HR, Roberts MS. Relative penetration of zinc oxide and
zinc ions into human skin after application of different zinc oxide formulations. ACS
Nano, 2016, 10 (2), pp 1810–1819.
[31] Lademann J, Richter H, Teichmann A, Otberg N, Blume‐Peytavi U, Luengo J, et al.
Nanoparticles – an efficient carrier for drug delivery into the hair follicles. European
Journal of Pharmaceutics and Biopharmaceutics. 2007;66(2):159–64.
[32] Bessar H, Venditti I, Fratoddi I, Benassi L, Vaschieri C, Azzoni P, et al. Functionalized
gold nanoparticles for topical delivery of Methotrexate for the possible treatment of
psoriasis. Colloids and Surfaces B: Biointerfaces. 2016, 141, 141–147.
Micro and Nanotechnologies for Biotechnology1420
[21] Miller G, Sales L. Nano ingredients in sunscreen: the need to regulation. Friends of the
Earth 2012. Available from: http://emergingtech.foe.org.au/resources/nano‐ingredi‐
ents‐in‐sunscreen‐the‐need‐for‐regulation/
[22] Graf BW, Chaney EJ, Marjanovic M, De Lisio M, Valero MC, Boppart MD, et al. In vivo
imaging of immune cell dynamics in skin in response to zinc‐oxide nanoparticle
exposure. Biomedical Optics Express. 2013;4(10):1817–28.
[23] Leite‐Silva VR, Le Lamer M, Sanchez WY, Liu DC, Sanchez WH, Morrow I, et al. The
effect of formulation on the penetration of coated and uncoated zinc oxide nanoparti‐
cles into the viable epidermis of human skin in vivo. European Journal of Pharmaceutics
and Biopharmaceutics. 2013;84(2):297–308.
[24] Cancer Council Australia. Available from: www.cancer.org.au.
[25] Mohammed Y, Sanchez W, Haridass IN, Pilorget C, Penloup AL, Studier H, Chandra‐
sekaran N, et al. Does repeated topical application of zinc oxide nanoparticles over 5
days result in penetration into human skin in vivo? (unpublished work) 2016.
[26] Lin LL, Grice JE, Butler MK, Zvyagin AV, Becker W, Robertson TA, et al. Time‐
correlated single photon counting for simultaneous monitoring of zinc oxide nanopar‐
ticles and NAD (P) H in intact and barrier‐disrupted volunteer skin. Pharmaceutical
Research. 2011;28(11):2920–30.
[27] Gulson B, Wong H, Korsch M, Gomez L, Casey P, McCall M, et al. Comparison of
dermal absorption of zinc from different sunscreen formulations and differing UV
exposure based on stable isotope tracing. Science of the Total Environment.
2012;420:313–8.
[28] Gulson B, McCall M, Korsch M, Gomez L, Casey P, Oytam Y, et al. Small amounts of
zinc from zinc oxide particles in sunscreens applied outdoors are absorbed through
human skin. Toxicological Sciences. 2010, 118, 140–149.
[29] Ågren M. Percutaneous absorption of zinc from zinc oxide applied topically to intact
skin in man. Dermatology. 1990;180(1):36–9.
[30] Holmes AM, Song Z, Moghimi HR, Roberts MS. Relative penetration of zinc oxide and
zinc ions into human skin after application of different zinc oxide formulations. ACS
Nano, 2016, 10 (2), pp 1810–1819.
[31] Lademann J, Richter H, Teichmann A, Otberg N, Blume‐Peytavi U, Luengo J, et al.
Nanoparticles – an efficient carrier for drug delivery into the hair follicles. European
Journal of Pharmaceutics and Biopharmaceutics. 2007;66(2):159–64.
[32] Bessar H, Venditti I, Fratoddi I, Benassi L, Vaschieri C, Azzoni P, et al. Functionalized
gold nanoparticles for topical delivery of Methotrexate for the possible treatment of
psoriasis. Colloids and Surfaces B: Biointerfaces. 2016, 141, 141–147.
Micro and Nanotechnologies for Biotechnology1420
[33] Zhang Q, Iwakuma N, Sharma P, Moudgil B, Wu C, McNeill J, et al. Gold nanoparticles
as a contrast agent for in vivo tumor imaging with photoacoustic tomography.
Nanotechnology. 2009;20(39):395102.
[34] Labouta HI, Liu DC, Lin LL, Butler MK, Grice JE, Raphael AP, et al. Gold nanoparticle
penetration and reduced metabolism in human skin by toluene. Pharmaceutical
Research. 2011;28(11):2931–44.
[35] Labouta H, El‐Khordagui L, Schneider M. Could chemical enhancement of gold
nanoparticle penetration be extrapolated from established approaches for drug
permeation? Skin Pharmacology and Physiology. 2012;25(4):208–18.
[36] Fernandes R, Smyth NR, Muskens OL, Nitti S, Heuer-Jungemann A, Ardern-Jones MR,
et al. Interactions of skin with gold nanoparticles of different surface charge, shape, and
functionality. Small. 2015;11(6):713–21.
[37] Larese Filon F, Crosera M, Adami G, Bovenzi M, Rossi F, Maina G. Human skin
penetration of gold nanoparticles through intact and damaged skin. Nanotoxicology.
2011;5(4):493–501.
[38] Liu DC, Raphael AP, Sundh D, Grice JE, Soyer HP, Roberts MS, et al. The human
stratum corneum prevents small gold nanoparticle penetration and their potential toxic
metabolic consequences. Journal of Nanomaterials. 2012;2012:7.
[39] Geusens B, Van Gele M, Braat S, De Smedt SC, Stuart MC, Prow TW, et al. Flexible
nanosomes (SECosomes) enable efficient siRNA delivery in cultured primary skin cells
and in the viable epidermis of ex vivo human skin. Advanced Functional Materials.
2010;20(23):4077–90.
[40] Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, et al. Nanoparticles and
microparticles for skin drug delivery. Advanced Drug Delivery Reviews. 2011;63(6):
470–91.
[41] Zhu Y, Choe C‐S, Ahlberg S, Meinke MC, Alexiev U, Lademann J, et al. Penetration of
silver nanoparticles into porcine skin ex vivo using fluorescence lifetime imaging
microscopy, Raman microscopy, and surface‐enhanced Raman scattering microscopy.
Journal of Biomedical Optics. 2015;20(5):051006.
[42] Gittard SD, Miller PR, Boehm RD, Ovsianikov A, Chichkov BN, Heiser J, et al. Multi‐
photon microscopy of transdermal quantum dot delivery using two photon polymer‐
ization‐fabricated polymer microneedles. Faraday Discussions. 2011;149:171–85.
[43] Larson DR, Zipfel WR, Williams RM, Clark SW, Bruchez MP, Wise FW, et al. Water‐
soluble quantum dots for multiphoton fluorescence imaging in vivo. Science.
2003;300(5624):1434–6.
[44] Lo W, Ghazaryan A, Tso C‐H, Hu P‐S, Chen W‐L, Kuo T‐R, et al. Oleic acid‐enhanced
transdermal delivery pathways of fluorescent nanoparticles. Applied Physics Letters.
2012;100(21):213701.
Multiphoton and Fluorescence Lifetime Imaging Microscopy in Studying Nanoparticle Pharmacokinetics in Skin and
Liver
15121
[45] Boehm R, Miller P, Hayes S, Monteiro‐Riviere N, Narayan R. Modification of micro‐
needles using inkjet printing. AIP Advances. 2011;1(2):022139.
[46] Cheng S‐H, Li F‐C, Souris JS, Yang C‐S, Tseng F‐G, Lee H‐S, et al. Visualizing dynamics
of sub‐hepatic distribution of nanoparticles using intravital multiphoton fluorescence
microscopy. ACS Nano. 2012;6(5):4122–31.
[47] Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, et al. In vivo
evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery
systems. Nanomedicine: Nanotechnology, Biology and Medicine. 2010;6(5):662–71.
[48] Johnston HJ, Semmler‐Behnke M, Brown DM, Kreyling W, Tran L, Stone V. Evaluating
the uptake and intracellular fate of polystyrene nanoparticles by primary and hepato‐
cyte cell lines in vitro. Toxicology and Applied Pharmacology. 2010;242(1):66–78.
[49] Liang X, Grice JE, Zhu Y, Liu D, Sanchez WY, Li Z, et al. Intravital multiphoton imaging
of the selective uptake of water-dispersible quantum dots into sinusoidal liver cells.
Small. 2015;11(14):1711–20.
[50] Garrett NL, Lalatsa A, Uchegbu I, Schätzlein A, Moger J. Exploring uptake mechanisms
of oral nanomedicines using multimodal nonlinear optical microscopy. Journal of
Biophotonics. 2012;5(5–6):458–68.
[51] Chen A, Dogdas B, Mehta S, Haskell K, Ng B, Keough E, et al., editors. Quantification
of Cy‐5 siRNA signal in the intra‐vital multi‐photon microscopy images. Engineering
in Medicine and Biology Society (EMBC), 2012 Annual International Conference of the
IEEE; 2012, San Diego, CA, USA.
[52] Loginova YF, Kazachkina NI, Zherdeva VV, Rusanov AL, Shirmanova MV, Zagaynova
EV, et al. Biodistribution of intact fluorescent CdSe/CdS/ZnS quantum dots coated by
mercaptopropionic acid after intravenous injection into mice. Journal of Biophotonics.
2012;5(11–12):848–59.
[53] Liang Y, Shilagard T, Xiao SY, Snyder N, Lau D, Cicalese L, et al. Visualizing hepatitis
C virus infections in human liver by two‐photon microscopy. Gastroenterology.
2009;137(4):1448–58.
[54] Boreham A, Kim T‐Y, Spahn V, Stein C, Mundhenk L, Gruber A, et al. Exploiting
fluorescence lifetime plasticity in FLIM: target molecule localization in cells and tissues.
ACS Medicinal Chemistry Letters. 2011;2(10):724–8.
Micro and Nanotechnologies for Biotechnology1622
[45] Boehm R, Miller P, Hayes S, Monteiro‐Riviere N, Narayan R. Modification of micro‐
needles using inkjet printing. AIP Advances. 2011;1(2):022139.
[46] Cheng S‐H, Li F‐C, Souris JS, Yang C‐S, Tseng F‐G, Lee H‐S, et al. Visualizing dynamics
of sub‐hepatic distribution of nanoparticles using intravital multiphoton fluorescence
microscopy. ACS Nano. 2012;6(5):4122–31.
[47] Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, et al. In vivo
evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery
systems. Nanomedicine: Nanotechnology, Biology and Medicine. 2010;6(5):662–71.
[48] Johnston HJ, Semmler‐Behnke M, Brown DM, Kreyling W, Tran L, Stone V. Evaluating
the uptake and intracellular fate of polystyrene nanoparticles by primary and hepato‐
cyte cell lines in vitro. Toxicology and Applied Pharmacology. 2010;242(1):66–78.
[49] Liang X, Grice JE, Zhu Y, Liu D, Sanchez WY, Li Z, et al. Intravital multiphoton imaging
of the selective uptake of water-dispersible quantum dots into sinusoidal liver cells.
Small. 2015;11(14):1711–20.
[50] Garrett NL, Lalatsa A, Uchegbu I, Schätzlein A, Moger J. Exploring uptake mechanisms
of oral nanomedicines using multimodal nonlinear optical microscopy. Journal of
Biophotonics. 2012;5(5–6):458–68.
[51] Chen A, Dogdas B, Mehta S, Haskell K, Ng B, Keough E, et al., editors. Quantification
of Cy‐5 siRNA signal in the intra‐vital multi‐photon microscopy images. Engineering
in Medicine and Biology Society (EMBC), 2012 Annual International Conference of the
IEEE; 2012, San Diego, CA, USA.
[52] Loginova YF, Kazachkina NI, Zherdeva VV, Rusanov AL, Shirmanova MV, Zagaynova
EV, et al. Biodistribution of intact fluorescent CdSe/CdS/ZnS quantum dots coated by
mercaptopropionic acid after intravenous injection into mice. Journal of Biophotonics.
2012;5(11–12):848–59.
[53] Liang Y, Shilagard T, Xiao SY, Snyder N, Lau D, Cicalese L, et al. Visualizing hepatitis
C virus infections in human liver by two‐photon microscopy. Gastroenterology.
2009;137(4):1448–58.
[54] Boreham A, Kim T‐Y, Spahn V, Stein C, Mundhenk L, Gruber A, et al. Exploiting
fluorescence lifetime plasticity in FLIM: target molecule localization in cells and tissues.
ACS Medicinal Chemistry Letters. 2011;2(10):724–8.
Micro and Nanotechnologies for Biotechnology1622
Chapter 6
Investigations on Dental Alloys Using Metallographic
Observation, Scanning Electron Microscopy, and Energy-
Dispersive X-Ray Spectroscopy
Lavinia Ardelean, Lucien Reclaru,
Cristina-Maria Bortun and Laura-Cristina Rusu
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64291
Abstract
Alloys are used in various areas of dentistry, but mainly in prosthetics. Their proper‐
ties, behavior, and corrosion resistance are of great importance for the success of the
prosthetic treatment. Among the investigations used for assessing dental alloys, in this
chapter, we focus on metallographic observation, scanning electron microscopy, and
energy-dispersive X-ray spectroscopy and present the ways we investigated several
types of dental alloys.  We obtained important data concerning their structure and
corrosion potential that could explain certain shortcomings which appeared after luting
of the fixed partial dentures.
Keywords: dental alloys, metallographic observation, scanning electron microscopy,
energy-dispersive X-ray spectroscopy, corrosion
1. Introduction
Alloys are used in various areas of dentistry, but mainly in prosthetics. Noble-metal alloys and
base-metal alloys are used for manufacturing different prosthetic pieces: crowns, inlays, fixed
partial dentures, and metallic frames of removable partial dentures. The field of dental alloys
is a very extensive one, in constant development, encompassing both the materials them‐
selves and the manufacturing methods [1].
In the past, the use of high-nobility alloys, with a high content of gold or noble metals, generally
ensured quality for fixed partial dentures. However, later, the use of low-nobility alloys gained
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
interest due to economic pressures. As a consequence of this trend, problems regarding
chemical stability of this type of alloys have emerged. Accordingly, more attention was paid
to the quantification of the chemical stability of dental alloys in terms of their corrosion
behavior.
In time, the necessity to introduce a large number of alternative casting alloys of low cost has
become more obvious. Base alloys containing nickel, chromium, cobalt, etc., and non-noble
metals, also had to be accompanied by the continuous check of corrosion resistance to assure
a long-term durability and good aesthetic result [2]. Classes of dental alloys used for dental
applications are listed in Table 1.
Class Type and area of use
A High-gold-content alloys for the metalo-ceramic technique
B High precious metals content alloys for the metalo-ceramic technique
C Pd-based alloys for the metalo-ceramic technique
D High-gold-content alloys for the conventional technique
E Low-gold-content alloys for the conventional technique
F Ag-Pd-based alloys for the conventional technique
1 Co-Cr base alloys for the metalo-ceramic technique
2 Ni-Cr base alloys for the metalo-ceramic technique
3 Fe-Ni-Cr base alloys for the conventional technique
4 Co-Cr base alloys for cast partial denture frameworks
5 Ti 4th grade for implants and the metalo-ceramic technique
6 Ti-6Al-4V for implantology pieces
7 Ti-Ni alloys for wires and endodontic use
Table 1. Classes of dental alloys.
The alloy’s microstructure is influenced by heat treatments. Varying the solidification rate and
post-solidification anneals leads to the modification of the grain size. The homogenization
anneals, alloy composition, and casting conditions influence the degree of segregation in a
casting. Furthermore, the particularity of low-gold alloys is that they exhibit both precipitation
and ordering reactions that affect their chemical stability. However, the desirable features of
low-gold-content alloys are large grains, a minimum of segregation, and the absence of
precipitates and ordered phases.
Cobalt-based alloys are often used to manufacture different types of devices implanted in the
body. In dentistry [3, 4], cobalt-chromium alloys are mainly used for manufacturing removable
partial dentures and metal ceramic fixed partial dentures, and also in fine framework con‐
structions. These alloys are characterized by excellent corrosion resistance and superior
mechanical properties [5]. Dental Co-Cr alloys have diversified over time, aiming at creating
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both new products and new technologies to process them [6], including attempts to combine
them with precious metals or to manufacture them by sintering instead of casting.
The alloy performance when processing is an important factor affecting its selection. Properties
such as castability, surface roughness, and deformation resistance affect the usability of an
alloy [7].
At present, there is no perfect dental alloy. Alloys are mixtures of two or more metals. Metals,
when cooling after melting, usually result in a solid solution with higher values of hardness,
resistance, and flexibility than the initial components. Due to their grain-type structure, alloys
are predisposed to corrosion. The oral cavity provides an ideal environment for conducting
electrochemical corrosion phenomena, which takes place in the presence of moisture. Other
shortcomings involve the manufacturing technology, which, in case of casting, is quite
laborious. Incorrect manufacturing technology or improper finishing may also contribute to
corrosion debut.
Corrosion results in a visible alteration of the material and also affects the metallic device’s
function, so the major goal for any alloy used in the oral cavity is to have a good corrosion
resistance.
The degree of corrosion damage on the prosthetic restoration depends on different factors such
as the type of alloy, the presence of soft or hard deposits on its surface, the relation with the
oral tissues, existing fractures of the veneering material, the age of the restoration, and the
composition of saliva [7]. Alloy-related internal factors include composition, structure,
impurities, and surface condition, and the external factors being electrolyte related (composi‐
tion, concentration, temperature, oxygen content, pH, heterogeneity, etc.) [8]. Parameters
related to topography (surface ratio of the two materials, geometric distribution, etc.) may also
play a role in developing corrosion.
Grain size and structural heterogeneity influence corrosion; impurities between grains and
large grains are favourizing factors. The tendency to corrode is lower in case of a more
homogeneous distribution of metallic atoms in the alloy. That is the reason why most alloys
are submitted to a homogenizing heat treatment, to minimize the possibility of electrochemical
corrosion.
The surface condition depends on the polishing degree, surface properties, and absence of
pores or cracks in the primary protective layers [9].
The correlation between pH and corrosion may be summarized as follows: low in a neutral
environment, generally high in an acidic environment, and variable in a basic environment.
The increase of the electrode potential is frequently the consequence of an increased electrode
potential [10]. The temperature’s effect is an important but indirect one. Concentration of the
metal’s specific ions, in the vicinity of the electrode surface, is influenced by the movement of
the solution and may cause variations. The process depends on the duration of exposure.
To assess the quality of a fixed partial denture and its corrosion potential, investigations such
as metallographic observation, scanning electron microscopy (SEM), and energy-dispersive
X-ray spectroscopy (EDX) are of much effectiveness.
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Metallography is essentially the study of the structural characteristics or constitution of a metal
or an alloy in relation to its physical and mechanical properties. Besides the crystallographic
nature of a material, imperfections inside a material have an even greater influence on the
mechanical properties, that is, tensile, fatigue, creep, fracture toughness, and impact proper‐
ties. Some defects such as missing atoms and dislocations cannot be observed optically except
by their effects, that is, strain, etch pits, and slip lines.
Scanning electron microscopy, an electron microscopy technique based on the principle of
electron-matter interactions, enabled us to produce high-resolution images of the sample’s
surface.
Energy-dispersive X-ray spectroscopy permitted us to do the elemental analysis or chemical
characterization of the samples. Its characterization capabilities are due in large part to the
fundamental principle that each element has a unique atomic structure, allowing unique set
of peaks on its X-ray emission spectrum.
2. Metallographic observation, scanning electron microscopy and energy-
dispersive X-ray spectroscopy in corrosion behavior investigation of
different types of dental alloys
2.1. Low-gold-content alloy
In case of a fixed prosthetic restoration (Figure 1), made of a low-gold-content conventional
class E alloy (Au, Ag, Pd, Cu, Zn), a severe color change and the loss of the metallic shine
occurred only a few months after luting, dark and shiny appearances or areas being present
at the surface. Removing was decided in order to analyze the causes that lead to its failure.
Figure 1. The deteriorated surface of the prosthetic restoration.
After removing it, we prepared two samples, one was used to analyze the damaged surface
using SEM and EDX, without any surface alteration, and the other one was used to observe
the superficial structure of the alloy, after transversally sectioning it.
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Figure 2. Surface image using retro diffused electrons (chemical contrast) of the sample.
Figure 3. (a) EDX spectrum of area 1 (without sulfur). (b) EDX spectrum of area 2 (rich in copper and sulfur). (c) EDX
spectrum of area 3 (rich in silver and sulfur).
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Figure 4. Retro diffused electron analysis (chemical contrast) of area 2 and allocation of the elements (Au, O, Cu, S, and
Ag).
The surface analysis with retro-diffused electrons (Figure 2) and EDX (Figure 3a–c) were
performed. They indicate the correlation between coloration and a non-homogeneous surface
composition. The presence of areas without sulfur (area 1, Figure 3a), areas rich in copper and
sulfur (area 2, Figure 3b), and areas rich in silver and sulfur (area 3, Figure 3c) are shown.
Retro-diffused electron analysis and the location of the elements (Au, O, Cu, S, and Ag)
(Figure 4) show that the shine loss in area 2 is related to the presence of high amount of sulfur
and copper. The presence of oxygen is related to copper localization.
SEM section analysis using secondary electrons (Figure 5a) reveals an important millimetric
internal porosity, localized in the external part, in some areas merging into the surface.
Figure 5b reveals a dendritic non-homogeneous structure in the vicinity of the surface (SEM
analysis with retro-diffused electrons).
Figure 5. SEM analysis with (a) secondary electrons (topographic contrast) and (b) retro diffused electrons (chemical
contrast) of the sample.
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Au, Ag, and Cu (main alloy elements) are positioned close to the surface and in the vicinity of
the porous areas, in a non-homogeneous way. This non-homogeneity is more important in the
sub-superficial darkened areas than in the sub-superficial shiny areas. The porosities are
colored in black and are characterized by the presence of tiny inclusions very rich in Cu
(Figure 6).
Figure 6. Observation of the sub-superficial layer of the dark area with retro diffused electrons (chemical contrast) and
element allocation (Au, Ag, and Cu).
The differences between the nominal chemical composition of the analyzed areas (areas I, II,
III, and IV) are shown in Table 2. The four areas where the relative chemical composition in
Au, Ag, and Cu was measured are as follows: I and II, internal composition of the matrix and
external composition of the inclusions; III, inclusions rich in Au and Ag (Figure 4); and IV,
inclusions rich in Cu (Figure 7). The corrosion resistance is negatively affected by any change
in the alloy’s composition (decreasing or increasing with one or more elements) [11], the
corrosion being accelerated by the unstable phases in the alloy structure. In our case, the shine
loss represents the result of selective corrosion subsequent to the appearance of a galvanic cell
between these unstable phases and the alloy matrix [2]. Composition analysis reveals the
presence of sulfur and oxygen. The presence of a high amount of copper or silver in the
darkened areas is explained by their reaction with the sulfurous compounds in the saliva.
Formation of insoluble chemical products (sulfides, copper, and silver) is involved in the
selective corrosion process [12].
Au* Ag* Cu*
I 560 243 197
II 574 237 189
III 611 354 35
IV 253 123 624
* % weight
Table 2. Relative chemical compositions of the four areas.
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Figure 7. Observation of the sub-superficial layer of the shiny area with retro diffused electrons (chemical contrast)
and the element allocation (Au, Ag, and Cu).
The failure is subsequent to the incorrect alloy melting. This caused the internal porosities and
areas with very different superficial compositions. Furthermore, the surface was not properly
polished, causing surface porosity. The porous and chemically non-homogeneous surface, led
to decreased corrosion resistance and subsequent degradation of the prosthetic restoration, in
a short time after luting.
2.2. High-gold-content alloy
For determining corrosion causes of a fixed prosthetic restoration made of noble alloys with
high content of gold, shortly after luting, we used SEM and EDX, applied to the restoration
surface and in section. The fixed prosthetic restoration consisted of a cast part and a metal-
ceramic part [13].
When superficially analyzing the cast part (Figure 8) using SEM, three different areas ap‐
peared.
• Areas with no deposits and free from corrosion deposits. EDX reveals a normal nominal
alloy composition.
• Areas in bluish-black color, without deposits. In these areas, the surface analysis by laser
ionization revealed the formation of copper and silver sulfides, concentration decreasing
rapidly in the depth.
• Areas characterized by whitish deposits. In these areas, sulfur, sodium, and potassium
chlorides are present, as well as calcium phosphates. A high concentration of copper was
also noticed, compared to that measured at the nominal composition.
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Figure 8. SEM observation (500× magnification) of the corroded crown surface.
Section analysis by EDX shows that the segregations are nodules of copper and zinc oxide.
Metallographic observation of a section through the cast part reveals no defects in the internal
structure of the alloy. On the other hand, SEM, with a 5000× magnification, shows an important
segregation in the cast part (Figure 9).
Figure 9. SEM observation (5000× magnification) of the cast part.
The nodules observed originate from the internal oxidation of the less noble alloy elements
[12]. Our conclusion is that, in this case, we are dealing with localized corrosion in which the
less noble parts of the surface consist of copper and zinc oxide nodules.
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Thus, a mixed potential (corrosion potential) has been created on the same surface due to the
areas of different chemical composition [14], the anodic parts being areas consisting of copper
and zinc oxide nodules. Corrosion was caused by the appearance of a mixed potential on the
surface of the cast part as a consequence of incorrect manufacturing.
2.3. Cobalt-chromium alloys doped with precious metals
To improve corrosion resistance, a new generation of cobalt-chromium alloys doped with
precious metals (Au, Pt, and Ru) was created [15]. We used EDX to determine the microstruc‐
ture of this new generation of alloys by testing four different products in order to determine
if they have improved corrosion resistance compared to classic Co-Cr alloys. The alloys were
also micrographically and electrochemically tested. The compositions of the four tested alloys
and of a classic Co-Cr alloy are listed in Table 3.
Element Co-Cr 1 2 3 4
Co 63.7 63.5 52.0 50.6 59.3
Cr 28.9 21.0 25.0 18.5 25.0
Mo 5.3 4.5 3.0 5.0
Ga 4.5 6.0 2.5
In Trace 5.0 1.2
Au 2.0 2.0 2.0
Pt Trace 2.0 15.0
Ru 10.0
Sn 1.0
Mn 0.8 6.5 0.5 1.0
Si 2.0 0.75





Table 3. Chemical composition of the tested alloys (wt %).
The alloys were micrographically analyzed, analysis of phases by EDX was carried out, and
hardness properties were also tested [15–17].
Metallographic structures of the tested alloys are shown in Figures 10–13. Phase compositions
are listed in Tables 4–7.
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if they have improved corrosion resistance compared to classic Co-Cr alloys. The alloys were
also micrographically and electrochemically tested. The compositions of the four tested alloys
and of a classic Co-Cr alloy are listed in Table 3.
Element Co-Cr 1 2 3 4
Co 63.7 63.5 52.0 50.6 59.3
Cr 28.9 21.0 25.0 18.5 25.0
Mo 5.3 4.5 3.0 5.0
Ga 4.5 6.0 2.5
In Trace 5.0 1.2
Au 2.0 2.0 2.0
Pt Trace 2.0 15.0
Ru 10.0
Sn 1.0
Mn 0.8 6.5 0.5 1.0
Si 2.0 0.75





Table 3. Chemical composition of the tested alloys (wt %).
The alloys were micrographically analyzed, analysis of phases by EDX was carried out, and
hardness properties were also tested [15–17].
Metallographic structures of the tested alloys are shown in Figures 10–13. Phase compositions
are listed in Tables 4–7.
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Figure 10. Microstructure of alloy 1.
Figure 11. Microstructure of alloy 2.
Figure 12. Microstructure of alloy 3.
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Figure 13. Microstructure of alloy 4.
Co Cr Mo Si Mn Ga In Fe Pt Au
1 60.15 28.42 4.39 1.06 0.50 4.89 - 0.58 - -
2 1.30 0.62 - - - - 42.77 - 28.31 27.01
Table 4. Phase composition (wt %) of alloy 1.
Co Cr Mo Si Ti W Ga In Pt Au
1 63.48 25.71 3.55 - - 4.85 2.41 - - -
2 28.46 32.83 22.98 1.74 0.95 11.31 - - 1.73 -
Table 5. Phase composition (wt %) of alloy 2.
Co Cr Mo Si Mn W Ti Nb Pt Ru
1 48.96 17.48 3.44 1.02 0.70 1.25 - - 16.44 10.72
2 42.75 19.51 11.76 4.36 0.88 1.56 - - 8.25 10.93
Table 6. Phase composition (wt %) of alloy 3.
Co Cr Mo Si Ga In Pt Au
1 59.61 28.04 5.37 0.63 6.35 - - -
2 1.44 0.76 - - - 51.17 28.87 17.77
Table 7. Phase composition (wt %) of alloy 4.
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The microstructures of alloys 1 and 4 are characterized by round inclusions. The diameter of
these inclusions is up to 0.1 mm. The chemical analysis of these zones showed In (between 42
and 51%), Pt (around 28%), and Au (between 18 and 27%). The Vickers tests of the zones with
inclusions for alloy 4 showed a mean hardness value of 147 HV. Compared to the overall
hardness value of the alloy (326 HV) this is more than twice lower [15–17]. The hardness values
are given in Table 8.
Alloys 1 overall 2 overall 3 overall 4 overall 4 zone 2
HV 0.2 333 435 338 326 147
Table 8. Vickers hardness of the tested alloys (n = 5).
For electrochemical measurements, artificial saliva of the Fusayama type was used, with the
rotating electrode technique. The cathodic and anodic potentiodynamic polarization curves
were measured from 1000 mV to + 1250 mV vs. saturated calomel electrode and showed
important differences in the behavior of all the four studied alloys, compared to the classic Co-
Cr alloy. The worst behavior was shown by the alloys 1 and 4 that contain only gold. This
confirms the existing results which state that Au is not miscible to Co and Cr [18].
Alloys 1 and 4 are characterized by a very complex microstructure. The round inclusions with
a diameter up to 0.1 mm are in part non-miscible phases with a very low corrosion resistance.
The classic Co-Cr alloy has the best corrosion behavior, followed by alloys 2 and 3 (addition
of, respectively, 4% and 25% precious metals). Alloys 1 and 4 (with only addition of 2% Au)
have the worst behavior. Adding of precious metals deteriorates the corrosion behavior of Co-
Cr alloys in a significant way. Gold doping, in particular, produces heterogeneous micro‐
structures that are vulnerable to corrosive attack [15, 16, 19].
In conclusion, Co-Cr dental alloys doped with precious metals do not make sense, due to their
poor behavior; using them as an alternative to conventional Co-Cr alloys is not justified [15–
17, 19].
2.4. Laser-sintered cobalt-chromium prosthetic elements
Co-Cr alloys are traditionally manufactured by casting. Alternative modern technologies
include the CAD/CAM systems. In this case, a ring-shaped material is used and most of the
alloy is therefore lost, only a limited part of the material being actually used [20, 21]. Another
alternative modern technique that does not have the disadvantage of losing material is the
laser sintering.
By means of a laser, using a well-established energy/local surface unit, a fine alloy powder is
locally sintered to form the prosthetic element (Figures 14 and 15) [22, 23].
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Figure 14. Co-Cr powder for sintering.
Figure 15. Selectively laser fusing the metal powder.
The topography of the respective restorations is designed by numerical monitoring after
having scanned the devised objects. Several objects are numerically programmed on the tray.
Subsequently, a computer-based program orders the laser beam. The laser is programmed in
a way that it only becomes active at the site where the elements should be achieved. The alloy
particles will consequently be sintered by the laser energy (Figure 16) [22, 23].
The programmed objects, virtually presented, are obtained by superposing several layers, a
process during which, after each period of laser exposure, the tray is raised by 60–80 μm and
is subjected to another laser exposure after the application of each additional layer of powder.
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Thus, the whole reconstruction process is achieved layer by layer. This results in a fast
prototype making process (Figure 17) [22, 23].
Figure 16. The bridge, immediately after separation from the tray, on the model.
Figure 17. Co-Cr sintered frameworks.
The powder has to be as spherical as possible and its granulometry has to be below 20–30 μm,
which represents the space between the sintered layers. The composition of the alloy used by
us is 64–67% Co, 28–30% Cr, and 5–6% Mo.
After sintering, the prosthetic elements are cut down from the tray. The result is clinical
satisfactory, with a precision of 25 μm (Figure 16). The surface has a stratified structure
matching the granulometry of the basic powder (Figure 18). From the mechanic point of view,
the breaking limits of the sintered metalo-ceramic elements are comparable to casted metalo-
ceramic elements, the average hardness being 395 HV.
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Figure 18. The internal surface of two crowns, immediately after sintering.
The metallographic observation (50× magnification) shows a slight porosity in the horizontal
sample (compared to the sintering plane) (Figure 19), while in vertical sample, the pore lines
are uninterrupted (Figure 20).
Figure 19. Metallographic observation of a horizontal sample, without chemical attack.
Figure 20. Metallographic observation of a vertical sample.
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sample (compared to the sintering plane) (Figure 19), while in vertical sample, the pore lines
are uninterrupted (Figure 20).
Figure 19. Metallographic observation of a horizontal sample, without chemical attack.
Figure 20. Metallographic observation of a vertical sample.
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The chemical attack shows (50× magnification), similar to the surface, a very fine layered
structure roughly corresponding to the original granular structure of the base powder
(Figure 21).
Figure 21. Metallographic observation of a horizontal sample, after chemical attack.
The local chemical composition is characterized by a high regularity: Co between 62.6 and
64.1%, Cr between 29.3 and 30.5%, and Mo between 4.9 and 6.4%. Mn and Si are less than 1%.
Our conclusion was that the laser sintering technique makes possible the manufacture of
extremely accurate prosthetic elements with mechanical properties that correspond to any
clinical requirement, but it seems to be a rather significant risk of internal porosity that might
lead to fracture, cracking, or corrosion [22, 23].
3. Conclusions
The biocompatibility of dental casting alloys is of great importance because these alloys are in
long-term intimate contact with oral tissues [24].
Alloys used for fixed prosthetic restorations must have an appropriate corrosion resistance to
avoid the release of cytotoxic or sensitizing elements into the biological milieu [25]. The
manufacturing conditions are of great importance as well as the environmental ones. The
corrosion of dental alloys may be significantly increased by improper processing (formation
of pits and crevices). Good corrosion resistance is an important criterion for alloy selection.
Corrosion influences other properties of an alloy, such as esthetics and strength.
Electrochemical corrosion of alloys involves the ionization of elements that are released into
the environment, for example, saliva [26], initially uncharged elements loose electrons and
become positively charged ions as they are released into solution. The released elements may
or may not cause problems [27]. One of the main factors that influence element release is the
alloy’s composition. Elemental release and corrosion occurs regardless of type or composition
of the alloy. The elements with higher tendencies to be released include copper, zinc, and
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nickel. Gold and palladium show a low release tendency [27]. Element lability is also influ‐
enced by the phase structure of the alloy. If multiple phases are present, the risk of element
release is greater because of the potential electrochemical corrosion among the phases [28].
The element release is also influenced by the surface characteristics of the alloy as roughness
and the presence of oxides. Surface roughness increases elemental release because it exposes
more atoms to the external environment. The oral environment also plays a role in corrosion.
Low pH increases corrosion, especially when nickel-based alloys are involved. Corrosion is
also particularly high in retentive areas such as crevices, pits, gingival, and sulcus [29].
The surface composition of the alloy may vary from the composition of the bulk of the alloy
[30]. The surface composition may have a direct influence on which elements are released [31,
32]. Base dental alloys (Co-Cr) have an inferior corrosion resistance than the noble alloys.
To determine the degree of internal porosity, in case of a major surface porosity we used
metallographic observation. Failure due to incorrect alloy usage may occur when the alloy’s
normal melting conditions are not respected. This incorrect melting may be the cause for the
internal porosities and for the areas with very different superficial compositions. A not
properly polished surface, porous and chemically non-homogeneous, may be a result of
incorrect melting and surface treatment, and leads to decreased corrosion resistance and
subsequent degradation, after luting.
We also used it to determine the quality of laser-sintered Co-Cr prosthetic elements, in
horizontal and vertical samples, with and without chemical attack. Our conclusion was that
there seems to be a rather significant risk of internal porosity which might lead to fracture,
cracking, or corrosion.
For determining the corrosion causes of a fixed prosthetic restoration made of noble alloys,
with high content or low content of gold, shortly after luting, we used scanning electron
microscopy and energy-dispersive X-ray spectroscopy, applied to the restoration surface and
in section. Using SEM we were capable of producing high-resolution images of the surface of
a sample. SEM limits itself to solid samples of certain size, but this was not an issue in our case.
In case of EDX, the accuracy of the spectrum can be affected by various factors, including the
nature of the sample, but generally has a statistical precision of ±1%.
EDX enabled us to do the elemental analysis or chemical characterization of the samples and
was also used to determine the microstructure of the new generation of cobalt-chromium alloys
doped with precious metals (Au, Pt, Ru) by testing four different such alloys to determine if
they have improved corrosion resistance compared to classic Co-Cr alloys. We concluded that
attempts to obtain alloys with better properties by doping Co-Cr alloys with precious metals
were not successful. Some cheaper alloys such as copper, aluminum, and bronze, also
developed to substitute gold dental alloys, proved to be a great failure.
For minimal biological risks, dentists should consider alloys with low corrosion potential,
mainly high-noble metal or noble alloys with single-phase microstructures. The alloy should
be selected for each patient using corrosion and biologic data from the manufacturer [27].
Success or failure of a prosthetic restoration depends on many factors: the producer, the proper
manufacture, and some related to the patient itself.
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